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General introduction
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Rheumatoid arthritis (RA) is a common autoimmune dis-
ease, mainly characterized by chronic inﬂammation of the 
joints. The persistent joint inﬂammation leads to pain, joint 
swelling and can eventually cause severe joint destruction. 
The disease afﬂicts about 1% of the population in all parts 
of the world and is approximately 3 fold more common in 
women than in men. The onset is most frequent in the third 
or fourth decade of life, but the prevalence increases until 
70 years of age. The ﬁrst symptoms of the disease usually 
are present in the small joints of the hands and feet. Later 
on in the disease, the inﬂammation spreads to the larger 
joints and may simultaneously affect multiple joints on 
both sides of the body (symmetric polyarthritis). The etiol-
ogy and historical origin of RA are still obscure. 
Historical considerations
It has been debated if RA existed in the Old World, 
because the ﬁrst precise descriptions of RA date from the 
end of the eighteenth century. In 1782, Jón Pétursson (1733-
1801) from Iceland described a common, chronic, symmet-
ric, destructive, inﬂammatory polyarthritis that is different 
from osteoarthritis and is sometimes accompanied by sys-
temic manifestations [1]. The disease predominantly affects 
females with a peak incidence around the age of forty. Eigh-
teen years later, a young Parisian doctor named Augustin 
Jacob Landré-Beavais (1772-1840) wrote the last sentence 
of his MD thesis: “… il faut admettre une nouvelle espèce 
de GOUTTE sous la dénomination de GOUTTE ASTHÈ-
NIQUE PRIMITIVE.” (“…we must recognize the existence 
of a new form of gout under the designation primary asthenic 
gout.”) [2]. Landré-Beavais described how this pathology 
differs from classical gout by its presentation as a remit-
tent polyarticular chronic disease in women associated 
with asthenia. Furthermore, the progressive deformation 
of the joints and the absence of tophi (mineral deposits in 
the joint) and suppuration (the formation and discharge of 
pus) were noteworthy [2]. This report is often considered 
the ﬁrst unambiguous description of RA [3]. Nevertheless, 
the name rheumatoid arthritis was only given to the dis-
ease in 1859 by Sir Alfred Baring Garrod (1819-1907) who 
demonstrated that the blood of patients suffering from gout 
contained elevated levels of uric acid, whereas there was no 
R
 heumatoid arthritis, Pathol. A chronic disease marked by signs and symptoms 
of inﬂammation of the joints, frequently accompanied by marked deformities, 
and ordinarily associated with manifestations of a general, or systemic, 
afﬂiction.
Webster’s encyclopedic unabridged dictionary of the English language(1994), Dilithium Press, Ltd., 
New Jersey, USA
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such increase in patients with RA or in healthy individuals 
[4].
Although these reports contain the ﬁrst precise descrip-
tions of RA patients, paleontological and pictorial evidence 
suggests that RA may be an ancient disease (reviewed 
in [5,6]). This evidence includes the discovery of skel-
etal remains of American Indians that lived in the Late 
Archaic period (3,000 to 5,000 years ago) in Alabama. In 
some of these skeletons, symmetrically distributed joint 
erosions that are characteristic of RA could be observed 
[3]. It has also been suggested that the Byzantine emperor 
Constantine IX (circa 980-1055) suffered from severe RA 
as described by his biographer Michael Psellus (in Chro-
nographia [7]): “I myself saw his ﬁngers, once so beautifully 
formed, completely altered from their natural shape, warped 
and twisted with hollows here and projections there, so that 
they were incapable of grasping anything at all. His feet were 
bent and his knees, crooked like the point of a man’s elbow, 
were swollen, making it impossible for him to walk steadily, 
or to stand upright for any length of time. Mostly he lay on 
his bed, and whenever he wished to give audience, others had 
to prop him up and make him comfortable.” There is also 
pictorial evidence of the existence of RA in Europe before 
the eighteenth century, including The Temptation of St. 
Anthony (Museu Nacional de Arte Antiga, Lisbon, Portugal) 
by Hieronymus Bosch (circa 1450-1516), in which a beggar 
is shown with RA-like deformities of his hands and wrists. 
Also, some paintings of Peter Paul Rubens (1577-1640), who 
himself was believed to suffer from a chronic polyarthritis 
affecting his limbs [6], show hand deformities that are at 
least compatible with RA (for example The Three Graces; 
Museo del Prado, Madrid, Spain).
Etiology of RA
Although there has been progress in unveiling the 
etiology of RA, it is still obscure what causes this dis-
ease. Some researchers claim that the disease is caused 
by a virus (discussed in [8]), but the cause is probably 
much more complex and the unfortunate sum of multiple 
factors. Several of these risk factors have already been 
identiﬁed and they include genetic and environmental 
variables (reviewed in [9,10]). The best known (genetic) 
Figure 1. Electron micro-
graph of healthy synovial 
membrane. Several macro-
phage-like type A cells, rich 
in vacuoles, occupy the su-
perﬁcial layer of the intimal 
lining. Several ﬁbroblast-
like type B synoviocytes, 
with highly developed 
endoplasmic reticulum are 
located further from the 
joint cavity [15]. Kindly 
provided by Dr. Iwanaga, 
Sapporo, Japan. Original 
magniﬁcation 6400x. 
Figure 2. Scanning elec-
tron micrograph of healthy 
synoviocytes. A. Aggre-
gated type A cells, equiped 
with microplicae and mi-
crovilli on their surface. B. 
Type B cells extend several 
thick cytoplasmic processes 
towards the intimal surface. 
[15]. Kindly provided by Dr. 
Iwanaga, Sapporo, Japan. 
Original magniﬁcation 
3400x (A); 2500x (B).
A B
B
B
joint cavity
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risk factor for the development of RA is sex, as women 
are more often affected than men. Furthermore, it has 
been demonstrated that a genetic predisposition resides 
in certain genes of the Human Leukocyte Antigen (HLA) 
system (e.g. HLA-DR4; discussed in Chapter 9). The 
total genetic contribution to the disease has been calcu-
lated from twin studies to be greater than 50% [11,12]. 
The environmental risk factors that have been identiﬁed 
include the use of oral contraceptives, microbial infec-
tions and smoking [8,10].
Joints and synovitis
Diarthrodial joints are movable joints in which the 
opposing bony surfaces are covered with a layer of car-
tilage. There is a joint cavity, which is lined with syno-
vial membrane: a thin cellular surface layer or intima 
and a deeper vascular underlying layer or subintima. 
The intimal lining layer consists of type A and type B 
synoviocytes (Figures 1 and 2). The type A cells are 
macrophage-like cells that originate in the bone marrow 
and migrate to the synovium as monocytes, where they 
complete their ﬁnal differentiation. These cells consti-
tute approximately 20-30% of the cell population in 
healthy synovium (Figure 3, left panel) [13,14]. The type 
B synoviocytes are locally proliferating ﬁbroblast-like 
cells. The main function of the type B cells is to pro-
duce the synovial ﬂuid that ﬁlls the joint cavity and acts 
as a lubricant. The type A synoviocytes are important 
in the maintenance of the synovial ﬂuid by removing 
unwanted substances by phagocytosis [13-15].
The inﬂamed synovial membrane in the joint of an RA 
patient differs in many ways from the healthy synovium 
(Figure 3, compare left and right panels). Most notice-
able is the synovial hyperplasia, which is believed to be 
mainly the result of massive inﬁltration by leukocytes 
from the periphery, although increased proliferation of 
resident ﬁbroblasts may also contribute to the hyper-
cellularity [13,14]. Macrophage-like synoviocytes are the 
most abundant cell type in the inﬂamed synovium, con-
stituting 80% or more of the total cell population [14]. 
The cells are activated as they show upregulated HLA 
class II expression and express inﬂammatory cytokines 
(reviewed in [16,17]). Besides activated macrophages, also 
activated T cells [18], B cells [19], plasma cells and den-
dritic cells [20,21] accumulate in the inﬂamed synovium. 
The result is a hyperthrophic synovium that forms 
numerous villi that extrude into the synovial cavity. The 
ﬁnger-like protrusions of the aggressive synovial mem-
brane are called pannus and creep over the surface of 
the articular cartilage. The activated inﬂammatory cells 
in the pannus produce a variety of degrading enzymes 
that degrade the cartilage and subchondral bone. This 
process eventually destroys the joint.
Figure  3. Schematic com-
parison of a healthy joint 
(left panel) and the joint 
of an rheumatoid arthritis 
patient (RA, right panel). 
Due to severe hyperpla-
sia, the inﬂamed synovial 
membrane is increased in 
size, which in combina-
tion with an increased 
production of synovial ﬂuid 
causes swelling of the joint. 
Activated macrophage-like 
synoviocytes (type A cells) 
are abundantly present, but 
also activated T cells, B 
cells, plasma cells, and den-
dritic cells accumulate in 
the inﬂamed synovium. This 
results in the formation of 
an aggressive tissue, called 
pannus, that invades the 
cartilage and subchondral 
bone eventually destroying 
the joint.
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Diagnosis of RA
The destruction of the joints in RA is irreversible, but 
with current therapies (reviewed in [22]) it can be pre-
vented or at least slowed down. Because it is crucial to start 
treatment before the onset of joint erosions [23-25], early 
and accurate diagnosis of RA is very important. The 1987 
ACR (American College of Rheumatology) criteria for the 
classiﬁcation of RA (Table 1, [26]) are commonly used in 
the diagnosis of RA. These criteria are, however, not very 
well suited for early diagnosis of the disease [27-29] as they 
rely heavily on the presence of clinical symptoms of RA 
and these are often not all clearly present in early RA. The 
ACR criteria include one serological parameter: the pres-
ence of IgM rheumatoid factor (RF). Although RF can be 
detected in the very early stages of the disease [30,31], it 
is not very speciﬁc for RA because it occurs frequently in 
other inﬂammatory conditions, including other forms of 
joint disease that mimic RA in their early stages (discussed 
in Chapter 2). This limits the use of RF as a diagnostic 
criterion. Fortunately, antibodies that are very speciﬁc for 
RA exist as well: the family of anti-citrullinated protein 
antibodies. These antibodies meet all the requirements of 
accurate diagnostic markers for RA.
Outline of this thesis
The goals of the research described in this thesis were 
to investigate the presence and nature of citrullinated 
proteins in the synovium and to investigate the expres-
sion and regulation of relevant citrullinating enzymes 
(PAD enzymes, peptidylarginine deiminase).
Chapter 2 provides an extensive review of literature 
on anti-citrullinated protein antibodies. The clinical util-
ity of these antibodies as diagnostic and prognostic mark-
ers in RA is discussed. Furthermore, it is hypothesized 
what the possible role of the anti-CCP antibodies and 
their antigens in the disease could be and what mecha-
nisms might be involved in the generation of citrulli-
nated autoantigens. The actual presence of citrullinated 
autoantigens in the rheumatoid synovium is investigated 
in Chapter 3. We show that the citrullinated proteins 
are detectable not only in RA synovium, but also in syno-
vial tissue of patients with other arthropathies. The local 
presence of these antigens at the site of inﬂammation is 
thus not speciﬁc for RA. The high speciﬁcity of the anti-
citrullinated protein autoantibodies is, therefore, most 
likely the result of an abnormal, RA-speciﬁc humoral 
response.
Criterion Deﬁnition
1. Morning stiffness Morning stiffness in and around the joints, lasting at least 
1 hour before maximal improvement
2. Arthritis of 3 or more joint areas At least 3 joint areas simultaneously have had soft tissue 
swelling or ﬂuid (not bony overgrowth alone) observed by 
a physician. The 14 possible areas are right or left PIP, MCP, 
wrist, elbow, knee, ankle, and MTP joints
3. Arthritis of hand joints At least 1 are swollen (as described in 2) in a wrist, MCP, or 
PIP joint
4. Symmetric arthritis Simultaneous involvement of the same joint areas (as deﬁed 
in 2) on both sides of the body
5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or exterior 
surfaces, or in juxtaarticular regions, observed by a physi-
cian
6. Serum rheumatoid factor Demonstration of abnormal amounts of serum rheumatoid 
factor by any method for which the results has been posi-
tive in  less than 5% of normal control subjects
7. Radiographic changes Radiographic changes typical of RA on posteroanterior 
hand and wrist radiographs, which must include erosion 
or unequivocal bony decalciﬁcation localized in or most 
marked adjacent to the involved joints (osteoarthritis 
chanes alone do not qualify)
Table 1. The 1987 revised 
criteria for the classiﬁca-
tion of RA. A patient can 
be classiﬁed as having RA, 
when at least 4 of these 
7 criteria are satisﬁed. 
Criteria 1 through 4 must 
have been present for at 
least 6 weeks. Obtained 
from ref. [26]. PIP = distal 
interphalangeal joint; MCP = 
metacarpophalangeal joint; 
MTP = metatarsophalangeal 
joint.
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In Chapter 4, we set out to identify the Sa antigen, an 
autoantigen that is present in the rheumatoid synovium and 
speciﬁcally recognized by autoantibodies from sera of RA 
patients. The Sa antigen could be identiﬁed as citrullinated 
vimentin. The RA-speciﬁc anti-Sa antibodies thus belong 
to the family of anti-citrullinated protein antibodies.
Because citrulline is a non-standard amino acid, it is 
not incorporated into proteins during translation. Protein-
bound citrulline residues can be generated by posttransla-
tional modiﬁcation of arginine residues by PAD enzymes. 
Chapter 5 gives an elaborate review of literature on these 
enzymes and their possible involvement in human disease. 
The literature data are supplemented with a bioinformatic 
analysis of PAD sequences showing that all ﬁve mamma-
lian PAD genes are encoded in a conserved gene cluster 
and probably are the result of a series of gene duplications 
in a common ancestor. Based on the data provided in this 
chapter, it can be concluded that PAD2 and PAD4 are most 
important in RA.
Macrophages are the predominant cell type in the rheu-
matoid synovium and they are known to be important actors 
in the disease process. In the experiments described in 
Chapter 6 we investigated the expression of PAD enzymes 
in these cells and in their progenitors, the monocytes. We 
observed an upregulation of PAD2 expression at the pro-
tein level and a downregulation of PAD4 at the mRNA level 
during monocyte to macrophage differentiation. Although 
PAD enzymes were present, no citrullinated proteins were 
detectable because the enzymes are normally inactive in a 
low calcium environment. Upon activation of the enzyme 
by raising the intracellular calcium concentration, various 
proteins became citrullinated. The most prominent citrulli-
nated protein could be identiﬁed as citrullinated vimentin.
In Chapter 7, the expression of PAD enzymes and the 
presence of citrullinated proteins in the inﬂamed synovium 
of mice with experimental arthritis is described. The 
citrullinated proteins were not detectable in naive mouse 
synovium. Despite the presence of citrullinated proteins, 
the mice did not produce citrulline-speciﬁc autoantibod-
ies. The absence of citrulline-speciﬁc autoantibodies in 
other animal models of autoimmune disease is described 
in Chapter 8, where we also stress the importance of per-
forming the proper control experiments when surveying 
the presence of these antibodies in animals.
Finally, Chapter 9 provides a general discussion of the 
insights generated by this thesis into the possible role of 
anti-citrullinated protein autoantibodies and citrullinated 
autoantigens in RA.
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Anti-CCP antibody, a highly 
speciﬁc marker for (early) 
rheumatoid arthritis
Clinical and Applied Immunology Reviews 2004, 4: 239-262
Erik R. Vossenaar *
Walther J. van Venrooij *
 • Department of Biochemistry, Section Autoimmune Biochemistry, University of Nijmegen, Nijmegen, The Netherlands
Abbreviations:
ACR American College of Rheumatology
AFA anti-ﬁlaggrin antibodies
AKA ‘anti-keratin’ antibodies
APF antiperinuclear
CCP cyclic citrullinated peptide
CCP1  ﬁrst generation CCP
CCP2 second generation CCP
ELISA enzyme linked immunosorbent assay
HCV hepatitis C virus
HLA human leukocyte antigen
JRA juvenile RA
MTX methotrexate
OR odds ratio
PAD peptidylarginine deiminase
PR palindromic rheumatism
RA rheumatoid arthritis
RF rheumatoid factor
ROC/AUC receiver operating characteristic/area under the curve
SE shared epitope
SNP single nucleotide polymorphisms
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Rheumatoid arthritis (RA) is a common, systemic auto-
immune disease affecting 0.5-1% of the population [10,11]. 
It is characterized by chronic inﬂammation of the synovial 
joints, which commonly leads to progressive joint destruc-
tion and consequent disability and reduction of quality of 
life [32]. Disease outcome may vary from mild symptoms 
to severe systemic disease when joint destruction is accom-
panied by extra-articular manifestations (i.e. rheumatoid 
nodules, vasculitis). Mortality in the latter group is sig-
niﬁcantly increased compared to the former group and the 
general population [33,34].
With more sophisticated and effective therapies becom-
ing available (reviewed in [22]) and with the understanding 
R
 heumatoid arthritis (RA) is a chronic, destructive autoimmune disease 
affecting the joints. With more sophisticated and effective therapies becoming 
available and with the understanding that early intervention is crucial in 
preventing irreversible joint damage, it is more and more important to diagnose 
RA at a very early stage in the disease. To facilitate diagnosis during the early 
stages of the disease, when often not all clinical symptoms are manifest, a 
good serological marker is needed. Antibodies directed to citrullinated proteins 
provide this ability. The most sensitive assay to detect these antibodies is the 
so-called anti-CCP ELISA assay.
In this chapter, the diagnostic and prognostic potential and the general 
utility in clinical practice of anti-CCP antibodies are discussed. Furthermore, 
we elaborate on the mechanisms involved in the generation of citrullinated 
autoantigens and the possible role of the anti-CCP antibodies and their 
antigens in the disease.
that early intervention is crucial in preventing irreversible 
joint damage [23-25], it is more and more important to diag-
nose RA at a very early stage in the disease. Although the 
1987 American College of Rheumatology (ACR; formerly, 
American Rheumatism Association) classiﬁcation criteria 
for RA [26] are often used in clinical practice as diagnostic 
tool for RA, they are not very well suited for the diagnosis 
of early RA [27,28,35]. The ACR criteria rely heavily on 
the expression of clinical symptoms of RA, but in early RA 
these clinical parameters are often not (yet) manifest. There-
fore, a speciﬁc and sensitive (serological) marker, which is 
present very early in the disease, is needed. Rheumatolo-
gists need to be able to target the use of potentially toxic 
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and expensive drugs to those patients where the beneﬁts 
clearly outweigh the risks [35,36]. Therefore a good marker 
should ideally be able to predict the erosive or non-erosive 
progression of the disease. Fortunately, the anti-CCP (cyclic 
citrullinated peptide) antibodies meet the demands for a 
good and useful marker for early RA and this will be the 
focus of this review.
Autoantibodies in RA
RA-associated antibodies
The serum of RA patients contains a large repertoire 
of antibodies directed against self-proteins. Most of these 
autoantibodies, however, can also be detected in patients 
with other (autoimmune) conditions, and are therefore 
not speciﬁc for RA. Even the well known rheumatoid 
factor (RF) antibodies, directed against the Fc domain of 
IgG molecules (reviewed in [37]), which are part of the 
ACR criteria [26] have only moderate speciﬁcity for RA. 
They can be found in patients with other autoimmune 
diseases, in patients with infectious diseases and in 3-5% 
of the healthy population (10-30% for elderly individuals) 
[38,39]. 
Other RA-associated antibodies (reviewed in [40]) 
include anti-RA33 (anti-hnRNP-A2) [41-43], anti-cal-
pastatin [44,45], ANCA (anti-neutrophil cytoplasmic 
antibodies) [46,47], ANA (antibodies to nuclear antigens) 
[48,49], anti-collagen type II [50-52], anti-ﬁbronectin [53], 
and anti-GPI (glucose-6-phosphate isomerase) [54,55]. 
Most of these autoantibodies are also present in a vari-
ety of other autoimmune diseases like systemic lupus 
erythematosus (SLE) and mixed connective tissue disease 
(MCTD) and to some extent also in healthy individuals. 
Fortunately, some autoantibody systems with a better 
speciﬁcity for RA also exist: anti-BiP (p68), anti-Sa and 
anti-citrullinated protein antibodies (APF, AKA, anti-ﬁl-
aggrin, anti-CCP).
RA-specific antibodies
Autoantibodies directed to BiP (heavy chain Binding 
Protein), formerly known as anti-p68, occur in about 64% 
of RA patients and have been reported to be highly spe-
ciﬁc for the disease [56,57]. BiP is a Hsp70 family stress 
protein which normally is ubiquitously expressed in the 
endoplasmic reticulum. During conditions of cellular stress, 
like in the rheumatoid synovium, BiP is overexpressed and 
partly relocates to the cell surface [57]. The major epitopes 
for anti-BiP are N-acetylglucosamine carbohydrate groups 
that are normally not present on BiP, and these modiﬁca-
tions could be important for the relocation [58]. The BiP 
antigen appears to be a target of RA-speciﬁc T-cell immune 
responses as well [57,59,60]. Anti-BiP antibodies can also 
be found in mice with established collagen or pristane 
induced arthritis [61]. No data exist on the predictive value 
or the presence of anti-BiP in early RA. Furthermore, the 
reported speciﬁcity of these antibodies awaits further con-
ﬁrmation by independent clinical studies. 
The Sa system is highly speciﬁc (92-99%), although only 
moderately sensitive (30-40%) for RA [62-65]. Originally, 
the Sa antigen was described as a set of 2 bands of 50 and 
55 kDa that are recognized by RA sera on immunoblots 
containing extracts from normal human spleen or placenta 
[62]. Then, a Sa-like antigen was found in human endothe-
lial cells [66] and more recently, several protein bands of 
various molecular weights have been mentioned as being Sa-
related antigens [67]. The Sa-antigen can also be detected in 
the rheumatoid pannus tissue [62]. The true nature of the 
Sa antigen remained obscure for a long time. Recently, we 
were able to identify the antigen as citrullinated vimentin 
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in which the citrulline moiety acts as the autoantigenic hap-
ten and vimentin as the hapten carrier [203]. Interestingly, 
citrullination of vimentin has been described in mouse and 
human macrophages, cells that are abundantly present in 
the RA synovium [68,69]. Because the Sa antigen is citrul-
linated, the anti-Sa antibodies should be classiﬁed within 
the family of anti-citrullinated protein antibodies.
History of anti-citrullinated 
protein antibodies
The original systems: APF and AKA
In 1964 the antiperinuclear factor (APF) was described 
for the ﬁrst time [70]. These autoantibodies are speciﬁc 
for RA (reviewed in [71]) and can be detected by indirect 
immunoﬂuorescence using human buccal mucosa cells as 
the antigenic substrate. Light and immunoelectron micros-
copy revealed that the perinuclear factor is localized in the 
keratohyalin granules [72,73]. These granules are 0.5-4 µm 
amorphous structures of densely packed proteins located 
in the cytoplasm of epithelial cells. Detailed examination 
revealed precise colocalization of the perinuclear factor 
with (pro)ﬁlaggrin [73].
In 1979, RA speciﬁc antibodies directed against keratin-
ized epithelium of the stratum corneum were described 
[74]. These antibodies can be detected by indirect immu-
noﬂuorescence using rat or human esophagus cryostat 
sections as the antigenic substrate. Based on their immu-
noﬂuorescence pattern, these antibodies were tentatively 
named “anti-keratin antibodies” (AKA) [74]. This name 
turned out to be a rather unfortunate choice, because AKA 
are reactive with ﬁlaggrin instead of keratin [75,76]. So it 
turned out that, although discovered independently, AKA 
and APF antibodies are directed to the same antigen [77]. 
Many reports had beforehand shown, that APF and AKA 
share many features. Although sensitivity of AKA is lower 
than that for APF, presence and titers of both antibodies 
are correlated to each other, to the presence of RF and to 
the severity of the disease (reviewed in [71]).
Filaggrin (ﬁlament aggregating protein), the common 
antigen of APF and AKA, cross-links keratin ﬁlaments in 
order to form very rigid cytoskeletal structures. It is syn-
thesized as a large, heavily phosphorylated precursor pro-
tein, consisting of 10-12 ﬁlaggrin subunits [78]. During the 
ﬁnal stages of differentiation, pro-ﬁlaggrin maturates via 
a multi-step process, which includes dephosphorylation, 
citrullination and cleavage into separate ﬁlaggrin subunits. 
Although the exact mechanisms involved are not com-
pletely understood, it is believed that citrullination of pro-
ﬁlaggrin opens up the structure of the protein, rendering 
it susceptible to cleavage into its separate subunits [79,80]. 
Finally, the mature ﬁlaggrin subunits bind to keratin ﬁla-
ments to form dense macroﬁbrils that protect the keratins 
from proteolytic degradation [81,82].
Citrulline-specific reactivity
Based on the knowledge that mature ﬁlaggrin and not 
pro-ﬁlaggrin is the target of the APF and AKA antibodies 
[73,83,84], synthetic citrulline-containing peptides were 
developed and tested for their reactivity with RA sera [85]. 
Citrulline is a non-standard amino acid, as it is not incor-
porated into proteins during protein translation. It can, 
however, be generated by post-translational modiﬁcation 
of arginine residues by peptidylarginine deiminase (PAD; 
EC 3.5.3.15; reviewed in [86]) enzymes (Figure 1). Using 
a citrulline-containing peptide which was derived from 
ﬁlaggrin sequences in an enzyme linked immunosorbent 
assay (ELISA), antibodies could be detected in up to 48% 
of RA sera with 98% speciﬁcity. Only peptides contain-
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ing citrulline were reactive. Peptides in which citrulline 
was substituted by another amino acid were not reactive 
at all, indicating that the citrulline moiety is the antigenic 
determinant recognized by the APF and AKA antibodies 
[85]. These data were conﬁrmed by the observation that 
ﬁlaggrin puriﬁed from rat esophagus or human epidermis 
is reactive both with RA sera and with speciﬁc anti-citrul-
linated protein antibodies [87]. 
RA sera show a remarkable variety in the reactivity pat-
tern towards different citrulline-containing peptides, indi-
cating that the amino acids ﬂanking the citrulline residue 
are important for the antigenicity of the epitope and that 
anti-citrullinated protein activities such as APF and AKA 
are strongly polyclonal responses [85]. It has been estab-
lished that these antibodies are produced locally in the 
synovium of RA patients [88-90]. This suggests the pres-
ence of citrullinated protein(s) in the RA synovium causing 
an antigen-driven maturation of anti-citrullinated protein 
speciﬁc B cells at the site of inﬂammation in RA. Filaggrin, 
however, is expressed in differentiating epithelial cells, but 
not in the synovium [91]. It thus appears that anti-ﬁlaggrin 
antibodies (AFA) originate from a response against one or 
more synovial citrullinated proteins and that their reaction 
with citrullinated ﬁlaggrin is caused by cross-reactivity. 
Filaggrin is a highly heterogeneous protein, displaying 
considerable sequence variation (~40%) between subunits 
[78]. Furthermore, variable phosphorylation (on average 22 
potential phosphorylation sites per ﬁlaggrin subunit) [78] 
and variable citrullination [92] contribute to an extensive 
charge heterogeneity. Due to these properties, ﬁlaggrin can 
be regarded as a natural library of citrullinated epitopes, 
which makes it a mimic of synovial citrullinated antigens.
Diagnostic potential
The APF and AKA assays never became mainstream 
diagnostic tests, because of their inconvenient and labori-
ous immunoﬂuorescence test format, which hampers inter-
laboratory standardization. To circumvent this problem 
several attempts have been made to set up assays using 
ﬁlaggrin as the antigenic substrate. Immunoblotting and 
ELISA assays using ﬁlaggrin puriﬁed from human skin as 
an antigen performed very well with respect to speciﬁcity 
[93,94]. Sensitivities, however, were quite disappointing 
(41% and 47% respectively, at 99% speciﬁcity) [93,94] and 
appeared to be dependent on the method of puriﬁcation of 
ﬁlaggrin. Slack et al. calculated sensitivities of 12% and 
16% for two different ﬁlaggrin preparations, while only 
one out of ﬁve positive sera reacted with both preparations 
[95]. This reﬂects a major disadvantage of these assays; it 
is difﬁcult to obtain an antigen preparation that is pure 
and contains a reproducible citrulline content. Nogueira et 
al. compared the diagnostic sensitivities of four different 
AFA assays which were 40%, 37%, 22% and 31% (at 99% 
speciﬁcity) for classic AKA immunoﬂuorescence, ﬁlaggrin 
immunoblot, ELISA with ﬁlaggrin puriﬁed from human 
skin and an ELISA using recombinant human ﬁlaggrin 
citrullinated by PAD in vitro, respectively [96]. Concordance 
between the assays was moderate (correlation coefﬁcients 
between 0.50-0.86) [96]. Recently a more sophisticated 
ELISA assay using recombinant rat ﬁlaggrin citrullinated 
in vitro has been described, which showed a sensitivity of 
62% at a speciﬁcity of 99% [97]. So it seems that for AFA 
assays a qualitative good substrate can be obtained by in 
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vitro citrullination of recombinant ﬁlaggrin. Nevertheless, 
preparation of sufﬁcient amounts of puriﬁed recombinant 
ﬁlaggrin is a laborious and specialized task and even with 
in vitro citrullinated proteins, it is difﬁcult to obtain an 
antigen with a reproducible citrulline content. This will 
most likely hamper interlaboratory standardization. Such 
problems do not occur when synthetic citrullinated pep-
tides are used, because in such cases the precise epitopes 
are known [85,98].
The CCP1 and CCP2 systems
To increase the sensitivity of the citrulline-contain-
ing peptide ELISA [85], peptides were modiﬁed to adopt 
a structure in which the citrulline moiety is optimally 
exposed for antibody binding ([98] and our unpublished 
3D-NMR observations). With a single cyclic citrullinated 
peptide (CCP), antibodies could be detected in 68% of RA 
sera with a very high speciﬁcity (98%) [98]. This ﬁlaggrin-
derived cyclic peptide was used as the antigenic substrate 
in the CCP1 test (results described below).
Although the sensitivity of the CCP1 assay was higher 
than that of the classical APF and AKA assays and most 
AFA assays, it was not as high as the sensitivity of the 
IgM-RF [40]. As explained above, the CCP1 peptide is 
derived from ﬁlaggrin sequences, and since ﬁlaggrin is 
not expressed in the synovium, it is most likely not the 
natural antigen for the anti-citrullinated protein antibod-
ies. Other peptides, not related to ﬁlaggrin, could therefore 
potentially provide better epitopes for detection of the anti-
bodies. To obtain such novel peptides, dedicated libraries 
of citrulline-containing peptides were screened with RA 
sera (as described in [99-101]). From these libraries, novel 
citrullinated peptides were obtained and incorporated into 
a second generation CCP test (CCP2). The cyclic peptide(s) 
in the CCP2 test have no homology with ﬁlaggrin or other 
known proteins. This test has a sensitivity comparable to 
the IgM-RF test (82% in a cohort of mainly chronic RA 
patients at 98.5% speciﬁcity, vs. 80% sensitivity for RF) 
[35]. The CCP2 ELISA is commercially available through 
various companies and since all these companies use the 
same type CCP2 peptides, standardization is achieved quite 
easily. The CCP2 test has now been used in several studies 
which will be discussed below.
Clinical performance 
of anti-CCP
A good serological marker should be:
1. Sensitive and highly speciﬁc for the disease
2. Detectable very early in the disease
3. Able to prognose disease outcome
1. Anti-CCP is extremely specific for RA
A good serological marker for RA should be highly 
speciﬁc for the disease and be able to distinguish RA from 
other arthritides that mimic RA. In the original studies of 
Schellekens et al. [98], in which anti-CCP was measured in 
cohorts of RA patients, in patients with other rheumatic 
diseases, in patients with infectious diseases and in healthy 
controls, it could already be concluded that anti-CCP anti-
bodies (anti-CCP1 in this case) are very speciﬁc for RA. 
These results were subsequently conﬁrmed by Bizzaro et al. 
[102], Bas et al. [103] and many others. These earlier studies 
have been reviewed by van Boekel et al. [40]. More recent 
studies conﬁrmed this speciﬁcity also for the second gen-
eration CCP2 test. In a large multicenter trial 78% of RA 
patients, 15% of healthy controls and 50% of disease con-
trols tested positive for IgM-RF, while 79% of RA patients, 
none of the healthy controls and only 5% of disease con-
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trols were positive for anti-CCP2 [104]. In another large 
cohort study anti-CCP2 was positive in 82% of (chronic) 
RA patients, 1% of healthy controls and 2% of disease con-
trols (80%, 1% and 12%, respectively for IgM-RF) [35]. A 
recent study by Pinheiro et al. with 150 RA patients inde-
pendently conﬁrms these results (80% sensitivity at 98% 
speciﬁcity) [105]. CCP2 thus has a comparable sensitivity 
but a much higher speciﬁcity for RA than RF. A summary 
of the results from these cohorts, supplemented with data 
from other cohort studies is given in Table 1. 
In a recent study by Lee and Schur, a somewhat lower 
speciﬁcity of only 90% for CCP2 is reported (66% sensitiv-
ity; RF 72% sensitivity and 80% speciﬁcity) [106]. Most 
of the “false positives” in this cohort were JRA (juvenile 
RA) patients, 29% of whom were positive for anti-CCP. 
Previous reports [107,108] have shown that anti-CCP (CCP1 
at that time) antibodies can be present in a subset of JRA 
patients, mostly in polyarticular, IgM-RF positive (which is 
rare in JRA [109]), erosive JRA patients. The JRA patients 
in the Lee and Schur cohort comprised adults (average age 
31, range 21-50) with longstanding disease (average disease 
duration 21 years) and high prevalence of erosions (87%) 
[106]. Some of these JRA patients might actually have adult 
RA with childhood-onset, which could explain the high 
frequency of anti-CCP antibodies in the JRA group of this 
cohort.
CCP2 IgM-RF
n pos % n pos %
Rheumatoid Arthritis 1117 865 77% 1119 827 74%
Healthy individuals 431 1 0% 335 38 11%
Osteoarthritis 81 7 9% 79 14 18%
Juvenile Rheumatoid Arthritis a 21 6 29% not tested
Various connective tissue diseases b 814 44 5% 573 217 38%
Various inﬂammatory diseases c 225 2 1% 160 14 9%
Various arthropathies d 297 13 4% 72 5 7%
Various viral infections e 188 2 1% 171 43 25%
Various bacterial infections f 147 2 1% 179 21 12%
Various parasitic infections g 93 2 2% 99 22 22%
Total non-RA 2297 79 3% 1668 374 22%
Speciﬁcity 97% 78%
Table 1. Overview of CCP2 
sensitivity and speciﬁcity. 
Combination of CCP2 
cohort studies described 
in [35,104,106]. Other 
CCP2 studies de-
scribed in the text are 
[30,105,116,119,173].
a = includes adult JRA patients (see text for details) [106]
b = including systemic lupus erythematosus, mixed connective tissue disease, scleroderma, Sjögren’s syndrome, CREST syndrome, polymyosi-
tis/dermatomyositis
c = including Crohn’s disease, colitis ulcerosa, polymyalgia rheumatica, vasculitis, Wegener’s Granulomatosis, sarcoidosis, autoimmune 
thyroiditis
d = reactive arthritis, gout, psoriatic arthritis, ﬁbromyalgia, Reiter’s syndrome, inﬂammatory polyarthritis, ankylosing spondylitis
e = including Epstein-Barr, Hepatitis C, Parvovirus B19, Rubella, Viraemia
f = including inﬂammatory endocarditis, Legionella, Lyme borrelia, Yersinia, Salmonella, tuberculosis, Streptococcus pyogenis
g = including malaria, Mycoplasma, Toxoplasma, Chagas’ disease, Schistosoma, Leishmania
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When the level of the anti-CCP titer is taken into account, 
speciﬁcity appears to be  almost absolute. In a study by 
Bizzaro et al. seven out of 232 controls (3%) tested posi-
tive for anti-CCP1, three of them with high titers (>1000 
units; cut-off for CCP1 is 50 units). After reexamination, 
two of the three patients with a high anti-CCP titer were 
diagnosed with RA. The third patient had died. None of the 
four patients that were weakly positive for anti-CCP had 
developed signs of RA [102]. Higher titers of anti-CCP are 
thus almost exclusively observed in RA patients.
Various diseases can be confused with RA in their early 
stages. Patients with early SLE for instance, can be mis-
diagnosed as having RA, because they can be RF positive 
and can present erosive polyarthritis [110]. Mediwake et 
al. showed that anti-CCP status can be used to distinguish 
RA from erosive SLE. In a large cohort of SLE patients, ten 
patients had erosive disease, six of whom were RF positive 
(60%), six were anti-RA33 positive (60%), whereas only 
two were anti-CCP1 positive (20%). Of the non-erosive 
patients, 18% was RF positive, 6% RA-33 positive and 
0.5% was CCP1 positive [111]. Also, patients with chronic 
hepatitis C virus (HCV) infection often display extrahe-
patic manifestations among which arthropathy is common, 
affecting up to 20% of HCV-infected individuals. HCV-
related arthritis is commonly presented as rheumatoid-like, 
symmetrical inﬂammatory polyarthritis involving mainly 
small joints, or, less commonly, as mono- or oligoarthritis, 
usually of the large joints [112,113]. Because many HCV 
infected patients are RF positive, especially those that dis-
play mixed cryoglobulinemia (MC), RF can not be used to 
discriminate HCV-related arthritis from RA [112,114,115]. 
In a group of 50 randomly selected HCV patients, none 
were positive for anti-CCP2 (44% were positive for RF) and 
of 29 HCV patients with MC only 2 tested positive for anti-
CCP2 (76% were RF-positive) [116]. 
An interesting study on palindromic rheumatism (PR) 
showed that these patients may also contain anti-CCP and 
AKA antibodies [117]. PR is characterized by short-lasting 
attacks of acute arthritis that start abruptly and usually 
affect single joints, with no remnant clinical or radiographic 
changes. Some of these patients, and especially those with 
a positive RF, develop a connective tissue disease, mainly 
RA. Anti-CCP1 was found in 56% of patients with pure 
PR (AKA in 36%), about the same proportion of early RA 
patients was positive for anti-CCP (55%). In contrast, only 
2.5% of patients with seronegative spondylarthropathy 
was anti-CCP positive. These data suggest that PR might be 
an incomplete expression of RA, and that the CCP positive 
PR patients may be in the process of developing RA [117].
In conclusion we can say that due to its high speciﬁcity, 
anti-CCP makes a reliable diagnosis of RA possible.
2. Anti-CCP is present early in disease
When a random population of a rheumatology clinic is 
tested for anti-CCP, about 2-5% of the patients test positive 
but do not suffer from RA (our unpublished observations). 
A similar phenomenon can be observed when the popu-
lation of an early arthritis clinic is tested (F. van Gaalen, 
unpublished data). Two recent studies have provided clear 
evidence that such supposedly “false” positives might be 
in the early phase of developing RA. Nielen and coworkers 
measured anti-CCP1 and IgM-RF levels in serial blood sam-
ples of 79 former blood donors who later developed RA. Of 
these patients, 41% became anti-CCP1 positive at a median 
of 4.8 years before the onset of the complaints; 28% at a 
median of 2.0 years for IgM-RF. Anti-CCP antibodies could 
be detected in pre-disease serum samples up to 14 years 
before onset of the ﬁrst symptoms of RA; IgM-RF up to 10 
years. Of the 2138 control samples, 1.1% was positive for 
IgM-RF and 0.6% for anti-CCP1. Thus, anti-CCP detected 
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more positive subjects, longer before the start of the com-
plaints and with a higher speciﬁcity compared to IgM-RF 
[31]. In a similar type of study, Rantapää-Dahlqvist and 
collaborators analyzed early blood samples from 83 blood 
donors who subsequently developed RA. Anti-CCP2 anti-
body was detectable in 25% of the subjects 1.5 to 9 years 
before onset of the ﬁrst symptoms of the disease. In the 
last 1.5 years before presentation of the ﬁrst symptoms, 
the sensitivity of anti-CCP2 increased to 52%. More than 
70% of the patients were anti-CCP2 positive at their ﬁrst 
visit at the clinic. RF could also be detected in the pre-
disease sera, albeit at a lower sensitivity (IgM-RF 15% and 
30%; IgG-RF 12% and 27%; IgA-RF 29% and 39%, more 
than 1.5 years and less than 1.5 years before disease onset, 
respectively). They conclude that anti-CCP antibody has 
the highest ability to predict the future development of 
RA [30].
Other recent studies point to the same conclusion. Jan-
sen and coworkers tried to discriminate RA from undif-
ferentiated polyarthritis, and found that the combined 
presence of IgM-RF and anti-CCP1 is able to predict which 
patients with early arthritis ultimately develop RA with a 
sensitivity of 55.4% and a speciﬁcity of close to 97% [118]. 
Similar observations were made by Van Gaalen et al. [119]. 
In a large cohort of 936 patients with recent onset arthritis, 
318 patients could not be properly classiﬁed and were cat-
egorized as undifferentiated arthritis (UA). After 3 years of 
follow-up 40% of these UA patients had developed RA. Of 
the UA patients that were negative for anti-CCP2 at base-
line, 25% developed RA. In contrast, of the UA patients 
with a positive anti-CCP2 test at baseline 93% progressed 
to RA (odds ratio 37.8). 
The conclusion from all these studies is that anti-CCP 
antibodies are present early in disease, and that their pres-
ence is able to accurately predict the development of RA. 
3. Anti-CCP predicts erosive disease
It is known for some time that APF/AKA/AFA are able 
to predict joint involvement in (early) RA patients. APF/
AKA/AFA-positive patients clearly exhibit higher radio-
logical damage scores than negative patients [120-125]. 
Because the APF/AKA/AFA belong to the same family of 
anti-citrullinated protein antibodies as anti-CCP, it may 
be expected that also anti-CCP antibodies are able to pre-
dict erosive disease.
Kroot and coworkers [126] were the ﬁrst to study the 
predictive value of anti-CCP1 in patients with recent-
onset rheumatoid arthritis. Their results with this rela-
tively unsensitive ﬁrst generation CCP test clearly showed 
the enormous potential of these antibodies. Patients with 
anti-CCP1 had developed signiﬁcantly more severe radio-
logical damage after 6 years of follow-up than patients 
without anti-CCP1. However, in multiple regression 
analysis the additional predictive value of this antibody 
in this cohort of patients was only moderate [126].
Visser et al. used CCP1 serology as an additional help 
in predicting disease outcome. A standardized diagnostic 
evaluation was performed on 524 newly referred patients 
with early arthritis. Potentially diagnostic determinants, 
among them IgM-RF and CCP1, were entered in a logistic 
regression analysis. Arthritis outcome was recorded at 2 
years’ follow-up. The discriminative ability of the model 
and various parameters was expressed as a receiver oper-
ating characteristic (ROC) area under the curve (AUC). 
The ROC/AUC of the model was 0.84 for discrimination 
between self-limiting and persistent arthritis, and 0.91 
for discrimination between persistent non-erosive and 
persistent erosive arthritis. The discriminative abilities 
of the revised 1987 ACR criteria for rheumatoid arthritis 
were signiﬁcantly lower with ROC/AUC values of 0.78 
and 0.79. The developed prediction model consisted of 
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7 variables, in which anti-CCP1 had the highest weight 
factor [29].
A recent study from Vencovský and coworkers con-
ﬁrmed that anti-CCP antibodies are able to predict erosive 
and progressive disease [127]. In a prospective study they 
measured baseline levels of several autoantibodies, and 
found that signiﬁcant differences in erosions and disease 
progression were detected by anti-CCP1, AKA and APF 
(as described above, all three antibody speciﬁcities are 
directed to citrullinated antigens) and by RF (IgM, IgA 
and IgG). Combined analysis of anti-CCP1 and IgM-RF 
provided the most accurate prediction [127].  Meyer and 
coworkers followed 191 patients with recent onset RA pro-
spectively for 5 years [128]. The serum samples of these 
patients were examined for AKA, APF and CCP1; erosions 
were evaluated using Sharp scores modiﬁed as described 
by van der Heijde [129]. Their results showed that the 
likelihood of a total Sharp score increase after 5 years 
was signiﬁcantly greater among patients with anti-CCP 
antibodies (odds ratio 2.5) than patients with RF (odds 
ratio 0.7). They concluded that antibodies to citrullinated 
proteins/peptides are good predictors of radiographic 
joint damage [128].
Jansen et al. investigated radiographic progression 
of RA in a group of 282 early arthritis patients, which 
included patients with undifferentiated oligo- and poly-
arthritis [130]. Variables most predictive for radiographic 
progression of the disease after 2 years of follow-up were 
anti-CCP positivity (32% anti-CCP1 positive at baseline) 
and joint damage at entry [130]. In a study by Manetti 
and coworkers, early arthritis patients that presented 
bone erosions were signiﬁcantly more often anti-CCP2 
positive and on average with higher titer than patients 
without bone lesions [131]. Their data indicate that anti-
CCP antibodies can be a useful marker in the early phase 
of the disease to differentiate subjects likely to have pro-
gressive bone erosions from those with self-limiting or 
non-erosive disease, especially when high antibody titers 
are presented.
In a group of patients with Felty’s syndrome (very severe 
RA complicated with leukopenia and splenomegaly), very 
high anti-CCP titers were observed in all patients (>1000 
CCP1 Units, n=12, our unpublished observations).
All these studies indicate that presence of anti-CCP 
antibodies is correlated to erosive disease progression. 
The antibodies can therefore be used in clinical practice 
to help in planning a therapeutic strategy.
Take home message
The data discussed above, show that anti-CCP indeed 
is a good serological marker for RA. CCP is well suited as 
a front line diagnostic test for RA and especially early RA, 
because it can often be detected before complete clinical 
manifestation of the disease. CCP can also help to identify 
candidates for aggressive treatment because of its prog-
nostic potential. Due to its high speciﬁcity for RA, anti-
CCP can be used to differentiate RA from other forms of 
arthritis that may be confused with RA because they can 
be erosive and RF positive. In RF seronegative patients, 
CCP can be helpful in conﬁrming the diagnosis of RA, 
because approximately 40% of RF negative RA patients is 
positive for anti-CCP2. 
Addition of anti-CCP to the ACR criteria would improve 
the accuracy of the criteria. Because, in most studies, a 
combination of IgM-RF and anti-CCP has a higher diag-
nostic and prognostic potential than either of these sero-
logical markers alone, it seems logical to add anti-CCP as 
an eighth criterion.
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Citrullinated autoantigens
Local presence of citrullinated autoanti-
gens at the site of inflammation in RA
The anti-CCP antibodies are probably produced locally 
in the synovium as they constitute a higher proportion 
of IgG in synovial ﬂuid and synovial tissue compared to 
serum (1.4 and 7.5 fold, respectively) [88,89]. Furthermore 
anti-CCP producing plasma cells have been isolated from 
the synovium of RA patients [88,90]. This local antibody 
production requires the existence of citrullinated antigens 
in the inﬂamed synovium and consequently also the pres-
ence of PAD enzymes. Five isotypes of PAD exist in mam-
mals (reviewed in [86]). PAD1 and PAD3 are mainly found 
in epidermis and hair follicles [132-135]. PAD2 is expressed 
in a variety of tissues, including muscle, brain and hemo-
poietic cells [136-138], while PAD4 (this human enzyme 
was formerly known as PAD5) is predominantly found in 
hemopoietic cells [139-141]. The recently described PAD6 
(originally annotated as ePAD) is only expressed in egg 
cells and embryonic tissue [69,142].
Recently, the existence of 17 single nucleotide polymor-
phisms (SNPs) in the PAD4 gene was reported by Suzuki et 
al. [143]. Because the SNPs are located closely together on 
the chromosome, they segregate together in distinct haplo-
types. Two haplotypes account for 85% of all individuals 
investigated. One of these two major haplotypes was more 
frequently present in Japanese RA patients than in controls. 
RA patients that are homozygous for the RA-susceptible 
PAD4 haplotype were signiﬁcantly more often positive 
(87%) for anti-citrullinated protein antibodies (AFA) than 
other RA patients (67%; P<0.05). Four of 17 SNPs are 
located in exons of PAD4, two of which are strongly cor-
related with RA (P<0.001). Three of the four exonic SNPs 
result in amino acid substitutions. Possible consequences 
for protein function were not investigated, but the authors 
did show that the RA-susceptible haplotype increases PAD4 
mRNA stability. This could result in more PAD4 enzyme 
being produced, and subsequently lead to increased citrul-
lination of proteins and an increased chance of developing 
anti-CCP antibodies [143].
Proteins are citrullinated during cell death
An example of a citrullinated protein present in inﬂamed 
RA joints is extravascular citrullinated ﬁbrin [144]. Citrul-
linated ﬁbrin(ogen) is readily recognized by RA sera 
[144,145]. In inﬂamed RA synovia the oxygen metabolism is 
in disequilibrium, which leads to sites with oxygen excess 
(and subsequent generation of reactive oxygen species) 
and on the other hand to sites of hypoxia, which can cause 
synovial tissue micro-infarctions [146,147]. At these sites, 
plaques of extravascular ﬁbrin can be found. The inﬂamed 
synovium also contains many PAD2-expressing macro-
phages and sometimes PAD4-containing granulocytes 
[69,141,148]. Normally, PAD enzymes are present intracel-
lularly (either in the cytosol or, in the case of PAD4, in 
the nucleoplasm [141]) but they are not active [69]. Calcium 
ions are required for activity of the PAD enzymes, but the 
cytosolic calcium concentration in normal cells (10–7 M) is 
much lower than the threshold Ca2+ concentration for PAD 
activity (~10–5 M, our unpublished observations and [149]). 
When cells are dying, for example as a result of extensive 
oxidative stress in the inﬂamed synovium, PAD enzymes 
might leak out of the cells, become activated (the extra-
cellular Ca2+ concentration is ~10–3 M, sufﬁcient for PAD 
activity [149]) and induce the citrullination of extracellu-
lar proteins, like ﬁbrin. Furthermore, the integrity of the 
plasma membrane is lost during cell death [150,151], causing 
inﬂux of Ca2+ from the extracellular space and subsequent 
activation of intracellular PAD enzymes [68,69,141,152,153]. 
29Ant i - CCP ant ibody, a h ighly spec i f ic  mar ke r f o r  RA
Citrullination of intracellular proteins after calcium inﬂux 
has been described in granulocytes (citrullination of his-
tones) [141,153] and macrophages (citrullination of vimen-
tin) (Figure 2) [68,69].
Although it has not unequivocally been shown that 
citrullinated vimentin is present in the inﬂamed synovium 
of RA patients, much circumstantial evidence suggests it is. 
The cells of the synovial lining are of mesenchymal origin 
and thus contain vimentin [20]. The majority of these cells 
are inﬁltrated macrophages that show signs of activation 
[148] (in RA 80-100% of synovial lining cells are macro-
phage-like cells, compared to 20-30% in normal synovium 
[14]). Short-term activated macrophages are protected from 
apoptosis, whereas long-term (>24 hours) activated macro-
phages are very prone to cell death [154]. Calcium inﬂux 
in the dying macrophage triggers activation of PAD and 
subsequent citrullination of vimentin (and possibly other 
cellular proteins) [69]. Furthermore, it has been suggested 
that the Sa antigen, which can be detected in the RA syno-
vial tissue [62], is identical to citrullinated vimentin [66].
As explained above, RA sera showed a remarkable 
variety in their reactivity pattern towards different 
citrulline-containing peptides, which is indicative of a 
polyclonal immune response, possibly caused by the exis-
tence of multiple citrullinated antigens [85]. Therefore, it 
is not unlikely that next to citrullinated ﬁbrin(ogen) and 
citrullinated vimentin, also other citrullinated proteins 
are autoantigenic in RA. Indeed, the presence of various 
unidentiﬁed citrullinated proteins has been described in 
the RA synovium [144].
Possible pathoimmunological 
role in RA
Many animal models are being used to study the 
mechanisms of inﬂammation in RA (for an overview 
see [155]). We recently showed that synovial proteins 
are citrullinated during inﬂammation in both an acute 
(streptococcal cell wall arthritis) and a chronic destruc-
tive (collagen-induced arthritis) mouse model for arthri-
tis [156]. One of the citrullinated proteins in the inﬂamed 
mouse synovium could be identiﬁed as ﬁbrin. However, 
in contrast with the human disease, the mice did not pro-
Figure 2. Citrullination of proteins following cell death. Mac-
rophages and granulocytes express PAD enzymes (PAD2 and PAD4 
respectively). These enzymes are inactive under physiological 
conditions, because cytosolic Ca2+ concentrations (required for 
PAD activity) are normally too low. During death of these cells, 
Ca2+ homeostasis is lost and Ca2+ can enter the cell (1), thereby 
activating the PAD enzymes. Intracellular proteins (like vimentin 
in macrophages or histones in granulocytes) are citrullinated (2) 
and can potentially leak out of the dead cells (3). Furthermore, 
PAD enzymes can leak out of the dead cells (4) and citrullinate 
extracellular proteins (like ﬁbrin) (5). The citrullinated proteins can 
be exposed to the immune system (6), which could –given the right 
conditions (genetic factors and danger signals) are present– lead 
to an immune response (7). 
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duce antibodies against the citrullinated proteins [156]. 
In fact none of many animal models of arthritis tested 
(including rodent, canine and primate models) appears to 
be positive for anti-CCP (our unpublished observations). 
It thus appears that the citrullination of synovial 
proteins is an inﬂammation-associated process, not a 
process speciﬁc for RA. But why is the humoral response 
so speciﬁc for RA and does it contribute to the disease 
process?
The HLA connection
The anti-CCP antibodies are mainly of the IgG class, 
although IgM and IgA anti-CCP can also be detected, 
albeit at a much lower prevalence. IgG1 is the prevailing 
subclass; roughly a quarter of the anti-CCP positive sera 
also contain IgG4, while IgG2 and IgG3 are rarely found 
(our unpublished observations and [157]). This subclass 
distribution is characteristic of a T cell dependent anti-
body production and thus suggests HLA involvement 
[158]. The genetic predisposition for RA by certain HLA 
haplotypes, e.g. HLA-DR4 (HLA-DRB1*0401 and *0404) 
has been known for over 25 years [11]. 
Recent molecular modeling data indicate that peptides 
containing citrulline, but not arginine, can be bound by 
*0401 MHC molecules [159]. This citrulline-speciﬁc inter-
action might be the basis of a citrulline-speciﬁc immune 
response. T cell proliferation assays with HLA-DRB1*0401 
transgenic mice showed that stimulation with citrul-
linated peptides, not with arginine peptides, induced 
proliferation and activation of T-cells [159]. These data 
suggest that the speciﬁc structure of HLA-DR4 molecules 
plays an important role in the induction of autoimmunity 
to citrullinated proteins.
Although there is not an absolute requirement for 
HLA-DR4 in order to develop anti-CCP antibodies, there 
is a strong correlation between HLA-DR4 status and anti-
CCP positivity in RA patients [160]. As described above, 
presence of anti-CCP antibodies often precedes onset of 
clinical symptoms of RA and can therefore predict devel-
opment of RA [30]. In an expansion of this study, Ran-
tapää-Dahlqvist and coworkers observed that anti-CCP2 
antibodies combined with the presence of HLA-DR4 
genes had a higher accuracy in predicting RA (OR 66.8), 
compared to anti-CCP2 (OR 25.1) or HLA-DR4 (1.9) alone 
[161].
The modified self protein
Even if the correct genetic background is present, addi-
tional factors are needed to induce an immune response 
against self proteins. Many known autoantigens become 
modiﬁed during cell death and in particular during apop-
tosis (for an overview [162]). These modiﬁcations include 
proteolytic cleavage by caspases or granzyme B [163], 
(de)phosphorylation [164,165], transglutamination [166] 
but also citrullination [68,69]. When these modiﬁed self 
proteins are inefﬁciently cleared, they will be presented 
to the immune system and might not be recognized as 
‘self’ [167]. If sufﬁcient ‘danger signals’ are present (like 
in an inﬂammatory environment), this can lead to an 
immune response against the modiﬁed proteins [167,168]. 
In this manner, an initial small inﬂammation (caused by 
an external factor) may cause the death of inﬂammatory 
cells and consequently induce the citrullination of syno-
vial proteins (Figure 2) [156]. In an appropriate genetic 
environment, this may lead to presentation of citrul-
linated peptides by antigen presenting cells (APCs) and 
consequently to an activation of T cells. Given the right 
conditions are present, this initial immune response can 
snowball into a systemic disease that becomes manifest 
many years later.
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Importance of anti-CCP autoantibodies in the 
disease
Although no direct evidence exists for a role of anti-CCP 
antibodies in the pathophysiology of RA, several observa-
tions suggest they might. First, high anti-CCP antibody 
titers are correlated with severe and erosive disease progres-
sion as discussed above. Second, the predominance of IgG1 
anti-CCP is compatible with effector mechanisms involving 
complement activation and/or the engagement of Fc gamma 
receptors (our unpublished observations and [157,158]). 
Furthermore, treatment responses after B cell depletion by 
anti-CD20 antibody therapy (rituximab) suggest an impor-
tant function for B cells in the pathology of RA [19,169,170]. 
In a group of RA patients treated with rituximab, levels of 
circulating anti-CCP and RF (only IgA-RF and IgG-RF) anti-
Figure 3. Possible role of anti-CCP antibodies in the pathophysiology of RA. 
Inﬂammatory cells inﬁltrate the inﬂamed RA synovium and become activated (1). The activated cells 
produce various inﬂammatory mediators (indicated by the yellowish circle). The microvasculature in 
the inﬂamed synovium is in disequilibrium, partly due to the action of the inﬂammatory mediators. 
This leads to sites of hypoxia, which can cause synovial tissue micro-infarctions (2). Fibrinogen can 
leak into the synovium and form plaques of extravascular ﬁbrin (indicated as a green mesh). On the 
other hand, the microvasculatory imbalance can lead to sites of oxygen excess and subsequent gen-
eration of reactive oxygen species. These reactive oxygen species can cause death of the inﬁltrated 
cells (3). As described in Figure 2, PAD enzymes may leak out of the dying cells and become activated 
by the high concentration of extracellular Ca2+ (4). Subsequently, extracellular proteins (including 
the extravascular ﬁbrin) will be citrullinated. Anti-CCP antibodies, that are actively produced in 
the synovium (5), can bind to the citrullinated proteins. The immune complexes that are formed can 
be bound by inﬂammatory cells via their Fcγ receptors (6) which causes an activation of the cells. 
The activated cells produce novel cytokines to maintain the pool of inﬂammatory mediators in the 
synovium. This completes the circle and the inﬂammation process will continue. 
Abbreviations used: IL, interleukins; TNF, tumour necrosis factors; IFN, interferrons; GFs, growth 
factors; mono, monocytes; gra, granulocytes; DC, dendritic cells; mϕ, macrophages. White arrows 
indicate molecular signals.
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bodies decreased signiﬁcantly more than their correspond-
ing total serum immunoglobulin classes (IgM-RF decrease 
was in parallel with total IgM decrease) [171]. In contrast, 
anti-bacterial antibodies did not signiﬁcantly decrease dur-
ing the treatment. The majority of the patients (70%) showed 
a marked clinical improvement, which lasted on average 15 
months. Relapse was closely correlated with a rise in levels 
of autoantibodies and preceded by return of B cells [171]. A 
drop of anti-CCP and RF titers was also observed by Vale-
sini and colleagues in RA patients that were treated with 
anti-TNFα (inﬂiximab, reviewed in [172]) therapy in com-
bination with low-dose methotrexate (MTX) [173]. Serum 
titers of anti-CCP and IgM-RF decreased signiﬁcantly after 
6 months of therapy (P=0.0003 and P=0.02 respectively), 
while no signiﬁcant change of anti-CCP levels was observed 
in patients treated with MTX alone. Clinical response and 
changes in anti-CCP titers were correlated; patients with 
best clinical improvement during the therapy had lowest 
anti-CCP titers at baseline and showed strongest decrease 
in titer during treatment [173]. All these data suggest that 
anti-CCP antibodies might be involved in the disease pro-
cess in RA.
Interesting in this respect is a recent study by Lard et al. 
[174] showing that a speciﬁc IL-10 promoter polymorphism 
is associated with progression of joint damage. IL-10 is a 
pleiotropic cytokine (reviewed in [175]). It has many anti-
inﬂammatory functions (i.e. inhibition of production of 
pro-inﬂammatory cytokines, inhibition of APC maturation, 
etc.), but can also stimulate inﬂammation by enhancing 
B cell proliferation, differentiation and antibody produc-
tion [176,177]. The speciﬁc single nucleotide polymorphism 
(–2849 (AG/GG)) that is described in the Lard study, is 
associated with high IL-10 production and consequently 
with high antibody production [174]. Anti-CCP positive RA 
patients with the “high IL-10 haplotype” have signiﬁcantly 
higher anti-CCP titers and more severe erosions than anti-
CCP positive patients with a “low IL-10 haplotype” [174]. 
A possible mechanism by which anti-CCP antibodies 
could contribute to the progression of the disease is depicted 
in Figure 3. An initial small inﬂammation can lead to the 
death of PAD-containing cells and the generation of syno-
vial citrullinated proteins as described above and shown in 
detail in Figure 2. In anti-CCP positive patients, the locally 
produced anti-CCP antibodies will form immune complexes 
with these citrullinated proteins. The immune complexes 
will subsequently cause activation of inﬂammatory cells 
and  production of pro-inﬂammatory cytokines. The cyto-
kines promote inﬁltration of more inﬂammatory cells into 
the synovium, that will eventually die and give rise to the 
production of more citrullinated proteins. In this manner, 
anti-CCP antibodies might contribute in the perpetuation 
of the inﬂammations and the chronicity of the disease.
The future of CCP
The current second generation CCP system meets many 
of the requirements of a useful serological marker for RA. 
It is highly speciﬁc for the disease, can be detected early in 
the disease and because of its prognostic potential, it may 
provide an indication for aggressive treatment. With regard 
to the sensitivity of anti-CCP, there still is some room for 
improvement. The ideal marker would have a sensitivity of 
100%, but because RA is such a complex and diverse condi-
tion, absolute sensitivity is impossible. As described above, 
the antibody response to citrullinated epitopes is strongly 
polyclonal. By increasing the number of citrullinated epit-
opes that are presented in the CCP test, it should be possible 
to increase the sensitivity of the assay. Knowledge on the 
identity of the citrullinated candidate autoantigens could 
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be helpful in designing such additional epitopes. In prin-
ciple, it is also possible to use the candidate autoantigens 
described above, citrullinated ﬁbrin(ogen) and citrullinated 
vimentin, as antigens in diagnostic assays. The use of entire 
proteins does, however, pose some major problems. First 
it is difﬁcult to prepare sufﬁcient amounts of high quality 
antigen and to control the degree of citrullination of these 
antigens. A bigger problem is the existence of circulating 
antibodies directed against the non-citrullinated protein. 
Because these antibodies are not directed against the citrul-
line moiety, they are not speciﬁc for RA and can therefore 
lead to false positives. Anti-vimentin autoantibodies for 
instance, have been described in autoimmune diseases [178], 
infectious diseases [179,180] and even in healthy individu-
als [181]. The use of synthetic citrullinated peptides gives 
absolute control over the exact epitopes presented. Peptides 
that give false positive results (some peptides are reactive 
with sera even when citrulline is replaced by arginine, our 
unpublished observations) can be selectively left out. That 
is why an approach using synthetic peptides as antigenic 
substrates should be preferred. Recent developments in 
microarray technology have opened up the possibility to 
measure reactivity against a large number of individual 
peptides at the same time [182]. If the availability of this 
technology improves, peptide microarrays could become a 
platform for a “third generation CCP” test.
A big pro of antigen-array technology is the ability to 
obtain multiplex autoantibody proﬁles with the ease of 
use and speed of a single ELISA [182-184]. Sophisticated 
computer programs are needed to assess the presence of 
hundreds of autoantibody markers and to link each auto-
antibody proﬁle to a certain diagnosis. This allows clini-
cians to obtain serological information to aid diagnosis of a 
wide variety of autoimmune diseases. Although this array 
technology looks very promising, it is still in its childhood. 
Future studies need to conﬁrm proof of concept. Until that 
time, the CCP2 ELISA is the best diagnostic marker for RA.
Conclusion
Anti-CCP antibodies meet all the requirements of a good 
serological marker for RA. Their high speciﬁcity and prog-
nostic value make them a valuable diagnostic tool. Further-
more, all the available experimental data is compatible with 
a possible role in the disease process. 
Currently, the revised 1987 ACR criteria are considered 
the ‘gold standard’ for the classiﬁcation of RA. Incorpo-
ration of anti-CCP positivity as an extra criterion would 
improve the accuracy of the ACR criteria [29,119]. There-
fore, we suggest to add anti-CCP as an eighth criterion.
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The presence of antibodies directed to citrullinated pro-
teins in serum of patients with rheumatoid arthritis (RA) 
has been described in great detail (reviewed in [185]). These 
antibodies (e.g. anti-perinuclear factor (APF) antibodies 
[70], so-called anti-‘keratin’ antibodies (AKA) [74], anti-ﬁl-
aggrin antibodies (AFA) [93,97], anti-Sa antibodies [62,186] 
and anti-cyclic citrullinated peptide (anti-CCP) antibodies 
[35,98]) can be detected in up to 80% of RA patients with 
98% speciﬁcity and are directed against proteins containing 
the amino acid citrulline. Citrulline is a nonstandard amino 
A
 ntibodies directed to citrullinated proteins are highly speciﬁc for rheumatoid 
arthritis (RA) and are produced locally at the site of inﬂammation. Although 
the presence of citrullinated proteins in the rheumatoid synovium has been 
described in literature, it is uncertain if their presence is speciﬁc for RA. The 
present study was undertaken to investigate this. 
Anti-citrullinated protein antibodies constituted a 1.4 fold higher proportion 
of IgG in synovial ﬂuid compared to serum, which is indicative of a local 
production of the antibodies. The presence of citrullinated proteins in the 
synovial tissue was investigated by immunohistochemical analysis of synovial 
tissue of RA patients and of patients with other arthropathies using a variety 
of speciﬁc antibodies to citrullinated proteins. Citrullinated proteins could be 
observed in the lining layer, the sublining and in extravascular ﬁbrin deposits 
in inﬂamed synovial tissue of both RA and non-RA patients. The presence of 
citrullinated proteins in the inﬂamed synovium is thus not speciﬁc for RA, but 
may rather be an inﬂammation-associated phenomenon. The high speciﬁcity of 
the anti-citrullinated protein antibodies is, therefore, most likely the result of 
an abnormal humoral response to these proteins.
acid; it is not incorporated into proteins during translation. 
It can be generated, however, by posttranslational modiﬁ-
cation of arginine residues by peptidylarginine deiminase 
(PAD, EC 3.5.3.15) enzymes (reviewed in [86]). 
The antibodies appear to be produced locally at the site 
of inﬂammation, i.e. the synovium, as they constitute a 
higher proportion (7.5 fold) of IgG in synovial tissue than 
in paired serum samples [88]. They are produced by local 
plasma cells, as signiﬁcant amounts of the antibodies could 
be detected in culture supernatants of synovial tissue frag-
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ments of AFA-seropositive RA patients [88]. Furthermore, 
anti-CCP producing B cells can be detected in the synovial 
ﬂuid (SF) of RA patients. B cells isolated from the SF or bone 
marrow of anti-CCP-positive RA patients, but not of anti-
CCP-negative patients, actively produced IgM-anti-CCP 
antibodies without stimulation, whereas B cells from the 
peripheral blood (PB) required stimulation in order to pro-
duce such antibodies [90]. The local presence of anti-CCP-
secreting cells in the inﬂamed joints provides evidence for 
an antigen-driven maturation of CCP-speciﬁc B cells at the 
site of inﬂammation in RA and thus suggests the presence 
of citrullinated synovial proteins in the synovium. It has 
previously been suggested that the presence of citrullinated 
proteins in synovial tissue might be speciﬁc for RA [187]. 
Alternatively, it is conceivable that the humoral response 
to citrullinated proteins rather than the presence of these 
proteins is speciﬁc for RA [156].
Therefore, the aim of this study was to investigate if 
citrullinated proteins are detectable in RA synovium and 
disease controls using various antibodies for immunohis-
tochemistry. We used recombinant antibodies directed to 
citrullinated proteins selected from patient-derived phage 
display libraries (RA3 and A2-2) [188], as well as IgG anti-
bodies puriﬁed with CCP1 peptide [98] obtained from the 
serum of RA patients were used. For comparison with pre-
vious studies [144,187] antibodies to chemically modiﬁed 
citrulline (anti-MC) [189-191] and commercially available 
anti-L-citrulline antibodies [192,193] were used.
Results
Clinical features
The study group with active RA used for immunohisto-
chemical analysis consisted of 17 females and 6 males. The 
mean age in this group was 63 ± 12 (± standard deviation, 
SD) years (range 41-80), the mean duration of disease was 
5.2 ± 2.7 (0.5-12) months at the time of synovial biopsy. 
The mean serum level of C-reactive protein (CRP) was 49 
± 33 (11-118) mg/l. Erosions were present in 17 of the 23 
patients. Twenty patients were seropositive for IgM-RF. 
Fifteen out of 21 (71%) RA patients were seropositive for 
anti-CCP; anti-CCP status was not available for 2 patients. 
Most of the patients were treated with nonsteroidal anti-
inﬂammatory drugs (NSAIDs); 2 of the RA patients also 
used disease-modifying antirheumatic drugs (DMARDs) at 
the time of arthroscopy. None of the patients were treated 
with corticosteroids. The control group consisted of in total 
12 females and 19 males. The mean age in this group was 
IgG anti-CCP (U/mg IgG)
0 100 200 300 400 500
0
100
200
300
400
500
serum
Sy
no
vi
al
 f
lu
id
serum
Mean ± SD
SF
mean ± SD
ratio
SF/serum
n
IgG 109.1 ± 73.8 159.1 ± 125.2 1.4* 14
IgM 372.6 ± 169.3 605.1 ± 702.3 1.6* 18
IgA 406.6 ± 610.7 811.1 ± 1130.9 2.8 7
Table 1 (). Comparison 
of relative Ig class-spe-
ciﬁc anti-CCP antibodies in 
paired samples of serum and 
SF of RA patients. Concen-
trations are expressed as 
class-speciﬁc anti-CCP1 
Units/total mg of class-spe-
ciﬁc Ig. *Wilcoxon signed 
rank test: P<0.05
Figure 1 (). Compari-
son of relative IgG anti-CCP 
antibody concentrations 
(expressed in anti-CCP1 
Units/mg total IgG) in 
paired samples of serum and 
SF of RA patients (n=14). 
Dots above the diagonal 
represent patients in which 
the anti-CCP concentra-
tion in SF is higher than in 
serum. Anti-CCP antibodies 
constitute on average a 1.4 
fold higher proportion of 
IgG in synovial ﬂuid com-
pared to serum.
39C i t r u l l ina ted p rote ins in the in f l amed s ynov ium
51 ± 19 (22-84 years), the mean duration of disease was 8.9 
± 13.7 (0-60 months). The mean serum level of CRP was 27 
± 32 (3-125) mg/l. From 4 patients, no CRP data were avail-
able. In none of the patients erosions were present. From 
3 patients, RF status was not available, one patient was 
seropositive for IgM rheumatoid factor. None of the disease 
controls were anti-CCP positive; anti-CCP status was not 
available for 2 patients.
Anti-CCP antibodies constitute a higher propor-
tion of Ig in synovial fluid than in serum
Concentrations of total IgG, IgM and IgA and of Ig class-
speciﬁc anti-CCP1 antibodies were measured in paired SF 
and serum samples from 21 RA patients. Fourteen patients 
were positive for IgG anti-CCP1 antibodies both in the 
serum and in the SF. Relative concentrations of the anti-
bodies (corrected for the total amount of IgG present) were 
on average 1.4 fold higher in SF compared to serum (Fig-
ure 1; Table 1; Wilcoxon signed rank test: P<0.05). There 
was a signiﬁcant correlation between the concentration of 
the anti-CCP antibodies in serum and SF (Spearman rank 
correlation r
s
= 0.90; P<0.0001). Also for IgM and IgA, the 
relative concentration of anti-CCP antibodies was higher in 
the SF than in the serum, although for IgA the difference 
was not statistically signiﬁcant due to the small sample size 
(n=7). Our results thus support the notion that anti-CCP 
antibodies are produced locally in the synovium of RA 
patients. Consequently, citrullinated proteins should most 
likely be present in the inﬂamed synovial tissue.
Citrullinated proteins can be detected in 
synovium of RA and control patients
To investigate the presence of citrullinated proteins in 
the synovial tissue, immunohistochemistry with various 
anti-citrullinated protein antibodies was performed. After 
staining, coded sections were analyzed in a random order. 
Qualitative scores (+/–) were determined independently for 
4 different morphological areas of the tissue sections: the 
intimal lining layer, the synovial sublining, the ﬁbrin depos-
its, and endothelial tissue. Staining of citrullinated proteins 
could be observed in both RA patients and disease controls 
(Table 2).
Staining with RA3 antibodies (Table 2 and Figure 2) was 
present in both RA and non-RA synovial tissue and was 
localized in the intimal lining layer, endothelium, and ﬁbrin 
deposits. In the majority of the sections, extracellular stain-
ing was observed corresponding to ﬁbrin deposits. Staining 
was also observed in  the cytoplasm of lining cells and in the 
cytoplasm of endothelial cells. The control stainings (using 
recombinant antibody SB12, directed to the Pfs48/45 protein 
of the malaria parasite Plasmodium falciparum [194]; the con-
trol antibody contained the same tags as the RA3 antibody) 
were all negative. 
Staining with A2-2 antibodies (Table 2 and Figure 3) was 
mainly observed in the cytoplasm of sublining cells, in both 
RA and non-RA synovial tissue. The intimal lining layer and 
the ﬁbrin deposits were stained with A2-2 antibodies in many 
RA tissues, and only in a minority of non-RA tissues (Fisher’s 
exact test P<0.05). Staining of endothelial cells was rare. The 
control stainings (using recombinant antibody SB12 [194] 
with the same tags as the A2-2 antibody) were all negative. 
Ab group n lining (%) sublin. (%) ﬁbrin (%) endoth. (%)
RA3
RA 15 8 (53) 6 (40) 13 (87) 7 (47)
controls 15 5 (33) 5 (33) 9 (60) 3 (20)
A2-2
RA 23 12 (52) * 21 (91) 15 (65) * 1 (4)
controls 31 4 (13) 22 (71) 5 (16) 3 (10)
CCP1 Abs
RA 23 6 (26) 21 (91) 6 (26) 4 (17)
controls 31 14 (45) 23 (74) 6 (19) 2 (6)
Table 2. Immunohistochem-
ical detection of citrullinat-
ed proteins in RA patients 
and controls. Abbreviations: 
sublin. = sublining; endoth. 
= endothelium; CCP1 Abs = 
CCP1-puriﬁed antibodies. 
*Fisher’s exact test RA vs. 
controls P<0.05.
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Figure 2 (). Immuno-
histochemical staining of 
citrullinated proteins in 
synovial tissue using citrul-
line-speciﬁc RA3 antibody. 
 
Figure 3 (). Immu-
nohistochemical staining 
of citrullinated proteins in 
synovial tissue using citrul-
line-speciﬁc A2-2 antibody.
Figure 4 (). Immuno-
histochemical staining of 
citrullinated proteins in 
synovial tissue using CCP1-
puriﬁed antibodies. 
Figure 5 (). Immu-
nohistochemical staining 
of citrullinated proteins in 
synovial tissue using anti-
MC antibody.
Figure 6 (). Immuno-
histochemical staining 
of citrullinated proteins 
in synovial tissue using 
anti-L-citrulline antibody 
(Biogenesis).
Figures 2-6. A. RA synovial tissue stained with anti-citrulline 
antibody. B. control staining of RA synovium. C. non-RA synovial 
tissue stained with anti-citrulline antibody. D. control staining of 
non-RA synovium.
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CCP-puriﬁed HRP-conjugated human antibodies 
(Table 2 and Figure 4) showed a scattered staining pattern 
with intense staining, particularly in the synovial sublin-
ing and to a lesser extent in the intimal lining layer, in 
both RA and non-RA tissues. In both groups endothelium 
was rarely stained. Positive staining on granulocytes 
could also be detected by these antibodies. Fibrin deposits 
were stained in only a minority of tissues in both groups. 
The control stainings (using IgG antibodies from RA sera 
puriﬁed with non-citrullinated peptide cf0-cyc2, [98]) 
were all negative.
Sub-analysis was performed to investigate the correla-
tion between anti-CCP antibody levels or CRP levels and 
staining with any of the three antibodies in any of the 
four sub-compartments. In RA patients, there was neither 
correlation between anti-CCP titers and staining of citrul-
linated proteins nor between CRP levels and stainings. 
In control patients, however, there appeared to be a gen-
eral trend towards higher CRP levels in patients with posi-
tive staining. Patients that had positive staining of ﬁbrin 
deposits with RA3 antibody had signiﬁcantly higher CRP 
values (P<0.05) than patients without positive staining. 
Likewise, signiﬁcantly higher CRP values were observed 
in patients with positive A2-2 antibody staining of the 
sublining layer, and with positive CCP-puriﬁed antibody 
staining of the intimal lining layer. In all other cases P 
values were not signiﬁcant (indicated in Table 2).
Correlation between anti-CCP titers and frequency of 
staining could not be investigated in control patients, 
because all control patients were anti-CCP negative.
There appeared to be a trend towards a higher fre-
quency of positive staining in RA patients compared to 
control patients, although statistical signiﬁcance was only 
reached for A2-2 staining of the intimal lining layer and 
the ﬁbrin deposits.  In all other cases differences were not 
statistically signiﬁcant. The presence of citrullinated pro-
teins in the synovium was clearly not speciﬁc for RA.
Anti-modified citrulline antibodies
Staining with anti-MC antibodies (Figure 5) was observed 
in the majority of RA tissues. Non-RA tissues were also 
stained but not as intensely as RA tissues. Extravascular 
ﬁbrin deposits and the sublining layer were stained. In 
RA patients, the intimal lining layer was also stained. The 
control stainings (leaving out the diacetyl monoxime and 
antipyrine during chemical modiﬁcation) were negative.
Anti-L-citrulline antibodies
The majority of RA tissues and a minority of non-RA 
tissues showed positive staining with the commercially 
available rabbit anti-L-citrulline antibody (Biogenesis, Fig-
ure 6), consistent with our previous observations [195]. In 
general, only a few cells in the synovial sublining, with 
clear plasma cell morphology, were positive. In addition, 
the irrelevant antibody control (Rabbit anti-FITC) showed 
similar staining patterns, indicating non-speciﬁc binding 
of rabbit immunoglobulins to plasma cells. The intimal lin-
ing layer, ﬁbrin, and endothelium were not stained by this 
antibody.
Discussion
Autoantibodies directed to citrullinated proteins are 
highly speciﬁc for RA and are present very early in the 
disease. The association of high titers of the antibodies 
with erosive disease outcome suggests a possible role in the 
pathophysiology of the disease [185]. If such a functional 
relationship exists, the antibodies are expected to be pres-
ent at the site of inﬂammation. Therefore, we investigated 
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if these antibodies are present in higher concentrations in 
the SF compared to the serum. By comparing paired samples 
of serum and SF, we observed that anti-CCP antibodies 
constitute a higher proportion of IgG in SF than in serum. 
In addition, there was a clear correlation between anti-CCP 
levels in serum and SF. Taken together, this indicates that 
the anti-CCP antibodies are produced locally in the inﬂamed 
synovial compartment. Another study  reported, however, 
equal titers of anti-citrullinated proteins antibodies (AFA) in 
serum and SF [88]. In that study the antibody titers were 
expressed in units/ml. Because total IgG concentrations are 
signiﬁcantly higher in serum that in SF, antibody concen-
trations should preferentially be expressed in Units/mg IgG. 
Doing so, one would see that also in that study, anti-citrul-
linated protein antibodies constitute a higher proportion of 
IgG in SF compared to serum [88]. Data from SF samples of 
non-RA patients is not included in this study, because pre-
vious analyses of SF samples from more than 100 non-RA 
patients (mainly osteoarthritis (OA)) did not yield any anti-
CCP positive samples (our unpublished observations).
Further support for the notion that anti-CCP antibodies 
are produced locally in the synovial compartment comes 
from the observation that in RA patients the antibody levels 
constitute a 7.5 fold higher proportion of IgG in synovial tis-
sue compared to serum [88]. Moreover, plasma cells produc-
ing anti-citrullinated protein antibodies could be isolated 
from RA synovial tissue [88]. Another study  showed that 
peripheral blood (PB) B cells are only capable of producing 
anti-CCP antibodies upon stimulation with CD40-ligand and 
IL-10 or with anti-CD3-activated T cells [90]. In contrast, SF 
B cells from anti-CCP seropositive RA patients spontaneously 
produced IgM anti-CCP antibodies [90]. Consistent with 
these data we found that IgM anti-CCP antibodies constitute 
a higher proportion of IgM in RA SF compared to serum, 
suggesting that  IgM anti-CCP secreting B cells are present 
in the inﬂamed joints. This is indicative of an antigen-driven 
maturation of CCP-speciﬁc B cells at the site of inﬂammation 
in RA [90]. Therefore, it is likely that citrullinated proteins 
are present in the inﬂamed RA synovium.
The data presented here conﬁrm and extend previous 
studies showing the presence of citrullinated proteins in 
RA synovial tissue [144,187]. We observed staining in the 
cytoplasm of various inﬁltrating cells as well as in deposits of 
extravascular ﬁbrin. Western blotting previously conﬁrmed 
that a variety of citrullinated proteins may be present, one 
of which could be identiﬁed as citrullinated ﬁbrin [144]. Of 
importance, our study shows for the ﬁrst time that the pres-
ence of citrullinated proteins is not speciﬁc for rheumatoid 
synovial tissue, as these proteins can be detected in various 
inﬂammatory arthritides. This was conﬁrmed using several 
antibodies, which recognize different sets of citrulline-
containing epitopes. It should be noted that the antibody 
response against citrullinated proteins in RA patients is 
very heterogeneous. Each patient serum recognizes a differ-
ent subset of citrullinated peptides [85]. This indicates that 
various citrullinated epitopes exist on (several) synovial 
proteins. 
The recombinant antibodies RA3 and A2-2 were selected 
from patient-derived phage display libraries for their reactiv-
ity with citrullinated peptides [188]. In addition, HRP-conju-
gated human IgG antibodies were puriﬁed with CCP1 peptide 
from a pool of CCP-seropositive RA sera. All three types of 
antibodies are reactive with most citrullinated peptides (and 
not with non-citrullinated control peptides) in ELISA and 
are positive in APF and AKA immunoﬂuorescence tests. The 
antibodies stain the corniﬁed layer of the epidermis, which 
contains citrullinated ﬁlaggrin and keratins [196]. Further-
more, they recognize citrullinated ﬁlaggrin (AFA test) iso-
lated from human epidermis. The antibodies also recognize 
in vitro citrullinated ﬁbrinogen (but not unmodiﬁed ﬁbrino-
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gen) on Western blots. It should be noted that the RA3 anti-
body is strongly reactive with both the Aα- and Bβ-chain of 
ﬁbrinogen, whereas A2-2 is strongly reactive with Aα, but 
it shows only moderate reactivity with the Bβ-chain [188] 
(the γ-chain of ﬁbrinogen can not be citrullinated because 
it does not contain arginine residues). This may explain the 
observed differences in the frequency of staining the ﬁbrin 
deposits with both antibodies (Table 2).
For comparison with previous studies we also used anti-
bodies to chemically modiﬁed citrulline (anti-MC) [144] and 
anti-L-citrulline antibodies from Biogenesis [187] on a limited 
number of synovial tissue sections. Ideally, such antibod-
ies recognize all citrullinated proteins, independent of the 
amino acids ﬂanking the citrulline residues. The antibodies 
must also be unreactive with free L-citrulline, because this 
is also present in the synovium as a byproduct of NO-syn-
thesis. The anti-MC antibodies, that were used in the study 
by Masson-Bessière and colleagues [144] as well as in a 
study investigating the expression of citrullinated proteins 
in animal models of arthritis [156] target chemically modi-
ﬁed citrullines. In this method, developed by Senshu and 
coworkers, the citrulline side-chain is speciﬁcally modiﬁed 
by chemical treatment into complex structures that are so 
bulky, that the inﬂuence of ﬂanking amino acids on epitope 
recognition becomes negligible [189-191]. Non-citrullinated 
proteins cannot be modiﬁed by the chemical treatment and 
are thus not recognized by these antibodies.
Our use of anti-MC antibodies conﬁrmed the ﬁndings 
obtained with the recombinant RA3 and A2-2 antibodies as 
well as with the CCP-puriﬁed human antibody: the presence 
of citrullinated proteins is not speciﬁc for RA synovium, 
although staining tended to be more intense in RA compared 
to disease controls. This tendency may be explained by the 
fact that the RA patients had higher CRP levels (49 ± 33) 
than the control group (27 ± 32). In control patients there 
appeared to be a slight trend towards higher CRP levels in 
patients with positive staining, supporting the idea that 
citrullinated proteins are generated during inﬂammation; 
patients with more active inﬂammation will thus be more 
likely to produce citrullinated proteins.
Immunohistochemical staining with the anti-L-citrulline 
antibody from Biogenesis [187,195] revealed a pattern that 
was quite different from that obtained with the other meth-
ods described above: we observed scarcely dispersed cells 
with plasma cell morphology, but no staining of extracellular 
structures. We have previously suggested that this antibody 
may not be the antibody of choice for the detection of citrul-
linated proteins [195]. These rabbit antibodies have been 
raised against poly L-citrulline conjugated to KLH and were 
generated for the detection of nitric oxide synthase activity, 
which yields L-citrulline as a byproduct [192,193]. This is 
illustrated by the fact that the staining can be completely 
abolished by competition with free L-citrulline [187]. The 
staining observed with these antibodies might in part be 
explained by unspeciﬁc binding of rabbit IgGs to (rheuma-
toid factor positive) plasma cells, since we observed similar 
staining patterns using an irrelevant control antibody (rabbit 
anti-FITC) and demonstrated double staining with plasma 
cell markers [195]. 
Two possible explanations may be considered for the high 
speciﬁcity of the anti-citrullinated protein antibodies for RA. 
One explanation might be that there is an RA-speciﬁc expres-
sion of citrullinated antigens in the rheumatoid synovium 
that leads to an immune response. Alternatively, the presence 
of citrullinated proteins could be a common phenomenon in 
any inﬂamed synovial tissue, but RA patients might have an 
abnormal humoral response to these proteins.
The existence of genetic polymorphisms in the PAD4 gene 
[143] supports the ﬁrst possibility (discussed in [197,198]). A 
certain haplotype of PAD4 that is associated with suscepti-
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bility for RA in Japanese patients encodes for an mRNA with 
increased stability. This could result in increased production 
of PAD4 and – after activation of PAD4 – to increased citrul-
lination of proteins. Although it has been shown that RA 
patients who were homozygous for the susceptible haplotype 
were signiﬁcantly more often positive for anti-citrullinated 
protein antibodies compared to heterozygous patients or 
patients homozygous for the non-susceptible haplotype, 
the actual (enhanced) presence of citrullinated proteins was 
unfortunately not investigated in that study [143].
Our current observation that citrullination of synovial 
proteins is not speciﬁc for RA, is supported by animal stud-
ies showing that various synovial proteins, including extra-
vascular ﬁbrin, are citrullinated during inﬂammation [156]. 
The citrullinated proteins could be detected in a model of 
chronic inﬂammation (collagen-induced arthritis) as well as 
in a model of more acute joint inﬂammation (streptococcal 
cell wall-induced arthritis).
In the present study the expression of citrullinated pro-
teins in the non-RA group was not associated with circulat-
ing anti-CCP antibodies. Similarly, animal studies revealed 
that arthritic mice did not produce anti-citrullinated protein 
antibodies despite the presence of citrullinated proteins 
[156,199]. Thus, the high speciﬁcity of the anti-citrulli-
nated protein antibodies for RA appears to be the result of 
an abnormal humoral response rather than disease-speciﬁc 
expression of citrullinated proteins. 
Indeed, it has recently been shown that citrullinated pep-
tides can be bound much more efﬁciently by DR4 molecules 
than corresponding non-citrullinated peptides [159]. Thus, 
the genetic background associated with RA [200] might 
provide the possible basis of a citrulline-speciﬁc immune 
response in rheumatoid synovial tissue. 
In conclusion, the highly speciﬁc presence of anti-citrul-
linated protein antibodies in RA cannot be explained by 
speciﬁc expression of citrullinated proteins at the site of 
inﬂammation. More likely, RA patients exhibit an abnormal 
humoral response to citrullinated proteins that may be pres-
ent in any form of (synovial) inﬂammation.
Patients and Methods
Patients
Synovial biopsy samples were obtained from an actively 
inﬂamed joint of 23 patients with RA [26] and 31 control patients. 
Disease duration in the RA patients was less than 1 year, as mea-
sured from the ﬁrst clinical signs of arthritis irrespective of which 
joint was initially affected. Clinical inﬂammation was deﬁned as 
both joint swelling and pain at physical examination. The control 
group included 8 patients with inﬂammatory osteoarthritis (OA) 
[201], 5 patients with reactive arthritis (ReA), and 14 patients with 
other inﬂammatory joint disease (e.g. undifferentiated arthritis, 
gout, and calcium pyrophosphate dihydrate crystal deposition 
disease). Furthermore, the control group contained 4 patients 
with non-inﬂammatory joint disease. 
Laboratory assessments included the measurement of serum 
levels of CRP and rheumatoid factor. Radiographs of hands and 
feet were obtained for diagnostic purposes. 
All patients gave their informed consent, and the study pro-
tocol was approved by the Committee of Medical Ethics of the 
Academic Medical Center, University of Amsterdam.
Antibodies
Rabbit antibodies directed against chemically modiﬁed 
citrulline (anti-MC antibodies) were a kind gift of Dr. Tatsuo 
Senshu (Yokohama, Japan) and have been described previously 
[189,190]. Rabbit antibodies directed against L-citrulline (Bio-
genesis antibodies) were obtained from Biogenesis (Poole, Dor-
set, UK).
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Recombinant patient-derived antibodies (RA3 and A2-2) 
have been described recently [188]. Brieﬂy, a phage-library of 
random combinations of heavy and light chain variable frag-
ments was constructed from mRNA isolated from bone marrow 
samples of anti-CCP-seropositive RA patients. Phages bearing 
recombinant antibodies speciﬁc for CCP peptides were selected 
by several rounds of panning. Anti-CCP-speciﬁc antibody 
clones were recloned into a pUC119 plasmid vector containing a 
VSV-G tag (derived from vesicular stomatitis virus G-protein), 
a His
6
 tag and a mouse Cκ-domain tag to facilitate detection 
and enhance stability of the recombinant antibodies. Bacteria 
(E. coli) containing the antibody constructs were grown in 500 
ml cultures and antibody expression was induced by addition 
of isopropyl-β-D-thiogalactopyranoside (IPTG). Antibodies 
were puriﬁed from periplasmic fractions by Ni-NTA (Qiagen) 
chromatography followed by dialysis against PBS.
In addition, anti-CCP antibodies were puriﬁed from a pool 
of strong anti-CCP positive RA sera. Serum was diluted 10 
times in PBS
500
 (PBS containing 500 mM NaCl, 0.05% Nonidet-
P40 (NP-40)) and coupled to a protein-G Sepharose column 
(Amersham-Pharmacia). After extensive washing with PBS
500
, 
bound IgG molecules were eluted with elution buffer (100 mM 
glycine·HCl pH 2.5, 500 mM NaCl, 0.05% NP-40). Collected 
fractions were neutralized with 1 M Tris (~pH 11) and dial-
ysed against PBS
500
. Fractions containing IgG (as determined 
by ELISA) were further puriﬁed on a CCP1-peptide column. 
Biotinylated CCP1 peptide (cfc1-cyc2, [98]) was kindly synthe-
sized by Dr. Jan-Wouter Drijfhout (Leiden, The Netherlands) 
and coupled in PBS to a HiTrap Streptavidin-Sepharose HP 
(Amersham-Pharmacia) column. Puriﬁed IgG fractions were 
applied to the column. After extensive washing with PBS
500
, 
bound antibodies were eluted by pH shock with elution buf-
fer, immediately neutralized with 1 M Tris (~pH 11) and dia-
lyzed against PBS. Fractions containing anti-CCP antibodies 
(as determined by ELISA) were pooled and concentrated by 
centrifugation over a Centricon column (10 kDa cut-off, Mil-
lipore). Because human antibodies cannot be used directly for 
immunohistochemistry on human tissue sections (a secondary 
anti-human IgG antibody will also detect IgG that is present in 
the tissue), the antibodies were directly conjugated to horse-
radish peroxidase (HRP). Labeling of CCP-puriﬁed antibod-
ies with HRP (a kind gift of Dr. Will Roeffen, Nijmegen, The 
Netherlands) was performed using the periodate method with 
a molar input HRP/IgG ratio of 4 [202]. After dialysis against 
PBS, the labeled antibodies were supplemented with thimerosal 
(0.01%), glycerol (50%), and fetal calf serum (1%), and stored 
at –20°C. 
Measurement of antibodies to citrullinated proteins
The presence of antibodies to citrullinated proteins in serum 
and synovial ﬂuid was investigated by the Rapscan RA kit (CCP1 
test; Euro-Diagnostica b.v., Arnhem, The Netherlands) accord-
ing to the manufacturer’s instructions. To determine IgM, or IgA 
anti-CCP titers, isoclass-speciﬁc secondary antibodies (Dako) 
were used instead of the supplied (IgG-speciﬁc) secondary 
antibody. Total IgG, -M and -A concentrations in serum and SF 
were determined by nephelometry on a Cobas Fara-2 centrifugal 
analyzer (Roche).
Synovial biopsy
Small-bore arthroscopy (2.7 mm arthroscope, Storz, Tuttlin-
gen, Germany) was performed under local anesthesia, as previ-
ously described in detail [203]. Synovial biopsies were obtained 
from the entire joint using a 2 mm grasping forceps (Storz). At 
least 6 tissue samples per patient were collected and snap-frozen 
en bloc in Tissue-Tek OCT (Miles, Elkhart, IN). Frozen blocs 
were stored in liquid nitrogen until sectioned for staining. Sec-
tions of 5 µm were cut in a cryostat and mounted on glass slides 
(Star Frost adhesive slides, Knittelgläser, Germany); slides were 
stored at –70°C until use.
46 Chapte r 3
Immunohistochemistry
Recombinant patient-derived antibodies (RA3 and A2-2). Sec-
tions were ﬁxed in acetone and endogenous peroxidase activity 
was inhibited using 0.1% sodium azide and 0.3% hydrogen per-
oxide in PBS. Primary antibodies were incubated for 60 min fol-
lowed by incubation of HRP-conjugated goat anti-mouse (Dako) 
for 30 min. Enhancement of the signal was performed with bio-
tinylated tyramide (Perkin & Elmer) for 15 min and HRP-con-
jugated streptavidin (Dako). HRP activity was detected using 
hydrogen peroxide as substrate and amino ethylcarbazole (AEC) 
as dye. Slides were counterstained with Mayer’s hematoxilyn 
and mounted in Kaiser’s glycerol gelatin (Merck).
CCP-puriﬁed HRP-conjugated human antibodies. Immuno-
histochemistry was performed as described for RA3 and A2-2 
antibodies, except that incubation with HRP-conjugated goat 
anti-mouse secondary antibody was omitted.
Anti-MC antibodies. Prior to incubation with the primary 
antibody, sections were treated for 3 hours at 37°C in modiﬁ-
cation solution consisting of 2 parts solution A (0.025% (w/v) 
FeCl
3
, 4.6 M H
2
SO
4
, 3.0 M H
3
PO
4
), 1 part solution B (1% diacetyl 
monoxime, 0.5% antipyrine, 1 M acetic acid) and 1 part H
2
O. 
Control sections were incubated in a mixture of 2 parts solution 
A and 2 parts H
2
O. After extensive washing with PBS, slides 
were subsequently incubated with 3% H
2
O
2
 in methanol (15 
min), with 5% normal swine serum (Dako X0901) and 1% BSA 
in PBS (30 min). Samples were incubated overnight at room tem-
perature with 0.125 µg/ml anti-MC antibodies in PBS plus 1% 
BSA. After washing the sections were incubated for 30 min at 
room temperature with biotinylated swine anti-rabbit second-
ary antibody (Dako E0431) diluted 1:200 in PBS plus 1% BSA. 
Finally, the slides were incubated for 30 min with Vectastain 
ABC reagent (Vector Labs) and subsequently developed using 
hydrogen peroxide as substrate and diaminobenzidine (DAB, 
Sigma) as dye. Slides were counterstained with nuclear red to 
reveal tissue morphology.
Biogenesis antibodies. Immunohistochemistry was performed 
as described previously [187,195].
Microscopic analysis
After immunohistochemical staining, coded sections were ana-
lyzed in a random order by one observer (TS). Qualitative scores 
(+/–) were determined for each section.
Statistical analysis
The Wilcoxon signed rank test was used to compare relative 
concentrations of anti-CCP antibodies in paired samples of serum 
and SF. The Spearman rank correlation test was used to calculate 
the extent of association of serum and SF concentration of the 
anti-CCP antibodies. The Fisher’s exact test was used to investi-
gate differences in frequency of staining between RA patients and 
controls. The independent-samples t test was used to investigate 
correlation between anti-CCP titers, or CRP levels and frequency 
of staining. 
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Many autoantibodies, directed against a variety of 
autoantigens, can be detected in the serum of rheuma-
toid arthritis (RA) patients. Most of these autoantibodies 
(reviewed in [40,204]), are also found in patients with other 
diseases and are therefore not speciﬁc for RA. Even the well 
known rheumatoid factor (RF) antibodies, directed against 
the Fc part of IgG (reviewed in [37]), are not very speciﬁc 
for RA [38,39]. Nevertheless, RF still is the most commonly 
used serological marker for RA. Antibodies directed to the 
Sa antigen have a much higher speciﬁcity for RA. This auto-
immune system was ﬁrst described using the serum of an 
RA patient named Sa… The antibodies target a doublet of 
protein bands of approximately 50 kDa on western blots of 
normal human placenta, spleen and rheumatoid synovial 
tissue extracts [62]. 
In a recent review [66] it was suggested that the Sa anti-
gen is be identical to citrullinated vimentin, but data to 
support that statement was not given at that time. In this 
report, we provide such data and show that the Sa anti-
gen is indeed citrullinated vimentin. We show that anti-Sa 
A
 ntibodies directed to the Sa antigen are highly speciﬁc for rheumatoid arthritis 
(RA) and can be detected in approximately 40% of RA sera. The antigen, a 
doublet of protein bands of about 50 kDa, is present in placenta and in RA 
synovial tissue. Although it has been speculated that the Sa antigen is citrul-
linated vimentin, experimental proof for this claim has never been published. 
In this study, we investigated the precise nature of the Sa antigen. Peptide 
sequences that were obtained from highly puriﬁed Sa antigen were unique 
to vimentin. Recombinant vimentin, however, was not recognized by anti-Sa 
reference sera. In vivo, vimentin is subjected to various posttranslational 
modiﬁcations, including citrullination. Since antibodies to citrullinated 
proteins are known to be highly speciﬁc for RA, it was investigated if Sa was 
citrullinated. Our data show that Sa indeed is citrullinated vimentin. Anti-Sa 
antibodies thus belong to the family of anti-citrullinated protein/peptide 
antibodies. The presence of the Sa antigen in RA synovial tissue, and the 
recent observation that vimentin is citrullinated in dying human macrophages, 
make citrullinated vimentin an interesting candidate autoantigen in RA 
and may provide new insights on the potential role of citrullinated synovial 
antigens and the antibodies directed to them in the pathophysiology of RA.
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antibodies target citrullinated epitopes and not unmodi-
ﬁed vimentin, which makes them member of the family 
of antibodies directed to citrullinated proteins (reviewed 
in [185]). Because citrulline, the antigenic determinant for 
these autoantibodies, is a nonstandard amino acid, it is not 
incorporated into proteins during translation. It can, how-
ever, be generated posttranslationally by enzymatic citrul-
lination (deimination) of arginine residues. This conversion 
is catalyzed by the enzyme peptidylarginine deiminase 
(PAD, EC 3.5.3.15, reviewed in [86]). Because antibodies to 
citrullinated proteins are very speciﬁc for RA, are detect-
able very early in the disease, sometimes even during the 
pre-clinical phase of RA [30,31] and are able to predict 
clinical disease outcome [126-128], it is likely that these 
antibodies will become progressively more valuable for the 
clinician.
We discuss the new perspective provided by our obser-
vation that Sa is citrullinated vimentin on the potential 
role of citrullinated antigens and the antibodies directed to 
them in RA pathophysiology.
Results
Characterization of the Sa antigen
Antibodies directed to Sa are highly speciﬁc for RA. To 
investigate the identity of the Sa antigen, we performed a 
multi-step puriﬁcation procedure as described in the Meth-
ods section. The accuracy of each step of the procedure 
was monitored by immunoblotting using anti-Sa reference 
serum. The result of ﬁnal puriﬁcation is shown in Figure 1, 
where the estimated molecular weight of Sa is ~50 kDa and 
its pI is 5.0. Two peptide sequences were obtained (indi-
cated in Figure 2; peptide 72-86 was obtained twice) that 
uniquely matched the sequence of vimentin. The calculated 
molecular weight (54 kDa) and pI (5.1) of vimentin closely 
resemble those of Sa.
Discordance between anti-Sa and anti-
unmodified vimentin but strong concor-
dance between anti-Sa and anti-CCP status
To conﬁrm that Sa is vimentin, we prepared immunoblots 
containing human recombinant vimentin. Anti-vimentin 
reactivity was only observed at lower serum dilutions in a 
subset of the patients, irrespective of their anti-Sa or disease 
status (results not shown). Concordance between reactiv-
ity to Sa and reactivity to vimentin was thus not observed. 
Vimentin is known to undergo several posttranslational 
modiﬁcations, including phosphorylation and citrullination 
Figure 1. Puriﬁcation 
of placental Sa antigen. 
Placental Sa antigen was 
puriﬁed by anion exchange 
chromatography from 
extracts of placenta and 
subsequently puriﬁed by 
two dimensional gelelec-
trophoresis according to a 
three-step procedure de-
scribed by Liang et al. [223]. 
First, proteins are separated 
by molecular weight, then 
proteins of appropriate 
molecular weight were 
separated by isoelectric 
focusing and ﬁnally proteins 
with appropriate pI were 
separated once more by 
molecular weight. Each step 
of the procedure was moni-
tored by western blotting 
with an anti-Sa reference 
serum. Shown here is the 
ﬁnal gel, which was stained 
with Coomassie Briljant 
Blue. The double band in 
lane 2 is the Sa antigen 
which was cut out and used 
for microsequencing. Each 
lane represents a portion of 
the IEF gel (approximate pI 
is listed above the gel).
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Figure 2. Amino acid sequence of vimentin with Sa microse-
quences. Sequence of human vimentin (Swissprot: P08670). Two 
distinct peptides that were obtained by microsequencing are 
indicated in grey. Peptide 72-86 was obtained twice, VD84-85 was 
ambiguous in one of the peptides, R78 could not be sequenced in 
both peptides. All arginines are given in capital and bold, because 
they can potentially be modiﬁed to citrulline by PAD.
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[68,205]. Since antibodies directed to citrullinated proteins 
are very speciﬁc for RA [40] we investigated if anti-Sa sera 
are reactive with citrullinated epitopes. The vast majority 
(96%) of anti-Sa positive RA patients tested positive for 
anti-CCP2 as well as did a substantial proportion (60%) of 
the anti-Sa negative RA patients (Figure 3). Anti-Sa negative 
RA sera had a signiﬁcantly (Mann-Whitney test: P<0.0005) 
lower anti-CCP2 titer (263 ± 110 Units; mean ± SEM) than 
anti-Sa positive sera (852 ± 96 Units). These results suggest 
that anti-Sa sera contain antibodies that are reactive with 
citrullinated epitopes. None of the control sera tested posi-
tive in either of the two assays (12 ± 0.4 Units). 
The placental Sa antigen is citrullinated vimentin
To investigate whether Sa is citrullinated vimentin, 
we used a method to detect citrullinated proteins in cell 
extracts or ﬁxed cells. In this method, the citrulline side-
chain is speciﬁcally modiﬁed by chemical treatment into 
complex structures that are so bulky, that the inﬂuence of 
ﬂanking amino acids for epitope recognition becomes neg-
ligible [68,69,189-191]. Citrullinated proteins are detected 
(after chemical treatment) by antibodies speciﬁcally target-
ing those modiﬁed citrullines (anti-MC). Non-citrullinated 
proteins cannot be modiﬁed by the chemical treatment and 
are thus not recognized by the speciﬁc antibodies. 
We prepared three identical immunoblots (Figure 4) 
containing semi-puriﬁed placental Sa antigen, human 
recombinant vimentin, and in vitro citrullinated human 
recombinant vimentin. The Sa antigen was recognized by 
anti-Sa reference serum, by anti-vimentin antibodies, and 
anti-MC antibodies (lanes 1, 4 and 7, respectively), indi-
cating that the antigen is indeed citrullinated vimentin. 
Furthermore, citrullinated vimentin was recognized by 
the anti-Sa serum, whereas unmodiﬁed vimentin was not 
(lanes 3 and 2, respectively), indicating that the presence 
of citrulline residues is essential for the autoantigenicity of 
vimentin. The differences in the positions of the bands can 
be attributed to the extent of posttranslational processing. 
Data in literature show decreased mobilities with increased 
citrullination of ﬁlaggrin and trichohyalin [92]. Further-
more, the increased mobility of the Sa antigen compared to 
the recombinant proteins may be the result of partial pro-
teolytic processing as this has been described for keratins 
in the corniﬁed layer of the epidermis [196,206,207]. 
In addition, we performed immunoprecipitation experi-
ments. Vimentin was immunoprecipitated from the semi-
puriﬁed Sa preparation with a monoclonal anti-vimentin 
antibody. Immunoprecipitated vimentin was stained both 
by anti-MC antibodies and anti-Sa reference serum (Fig-
ure 5), conﬁrming that citrullinated vimentin is the anti-
genic Sa protein.
Discussion
Autoantibodies against the placental Sa antigen were 
described for the ﬁrst time over a decade ago [62]. Since 
Figure 3. Comparison of 
anti-CCP titers in Sa+ and 
Sa– patients. To investi-
gate a possible relation-
ship between anti-Sa and 
anti-CCP autoantibodies, 
we compared anti-CCP2 an-
tibody titers in 46 anti-Sa 
positive RA sera, 15 anti-Sa 
negative RA sera and 26 
control sera. 96% of anti-Sa 
positive RA patients, 60% 
of Sa-negative RA-patients 
and none of the control 
patients was positive for 
anti-CCP2. Anti-Sa positive 
RA sera had a signiﬁcantly 
higher (P<0.0005) anti-CCP 
titer (852 ± 96 Units; mean 
± SEM) than anti-Sa nega-
tive sera (263 ± 110 Units).
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then, this autoimmune system has proven to be highly 
speciﬁc for RA in populations of patients from Europe, 
America, and Asia [66]. The mean sensitivity of the assay is 
37% (range 21-43%) with 98% speciﬁcity (range 92-100%) 
and a positive predictive value between 95 and 99% [66].
Although it was previously suggested that Sa might be 
identical to citrullinated vimentin [66], evidence for this 
statement has not been published. This had led to confusion 
on the exact nature of the antigen in the related literature. 
Indeed, it was proposed that Sa could be identical to the 
glycolytic enzyme α-enolase [208] or to calpastatin [209], 
the natural inhibitor of calpains. Both types of autoanti-
bodies, however, turned out to be independent autoimmune 
systems associated but not speciﬁc for RA [45,210]. Other 
workers have claimed that apolipoprotein-A-1-binding pro-
tein could be (part of) the Sa antigen [211]. More recently, 
autoantibodies not speciﬁc for RA and directed to a 68 kDa 
placental protein were reported [67]. Nevertheless, the 
authors still choose, inappropriately, to label this antigen 
Sa. We thus deemed it important to report the experimental 
evidence on the exact nature of the Sa antigen.
We obtained several peptide sequences from highly 
puriﬁed preparations of Sa antigen that were unique to 
the intermediate ﬁlament protein vimentin. Autoantibod-
ies directed to vimentin have been described many years 
ago in RA [212] as well as in other autoimmune diseases 
[178,212], infectious diseases [179,180] and even in healthy 
individuals [181]. Those anti-vimentin autoantibodies, 
which are mainly of the IgM class, are not speciﬁc for RA. 
In contrast, anti-Sa antibodies are highly speciﬁc for RA 
and are predominantly IgG [62]. 
Here, using recombinant human vimentin, we found IgG 
anti-vimentin antibodies in only a few sera. The antibodies 
were only found in low titers, were not related to anti-Sa 
positivity and had no disease speciﬁcity. Thus we conclude 
that anti-Sa sera do not target native (unmodiﬁed) vimen-
tin.
Many known autoantibodies are directed against 
proteins that become modiﬁed during cell death and 
in particular during apoptosis (reviewed in [162,213]). 
These modiﬁcations include proteolytic cleavage by cas-
pases or granzyme B [163], transglutamination [166], 
(de)phosphorylation [164,165], and also citrullination 
[68,214]. When these modiﬁed self proteins are inefﬁciently 
cleared, they may be presented to the immune system and 
might be recognized as ‘non-self’ [167]. If sufﬁcient ‘danger 
signals’ are present (like in an inﬂammatory environment), 
this can lead to an immune response against the modiﬁed 
proteins [167,168]. Vimentin can be subjected to various 
posttranslational modiﬁcations that could be important for 
its autoantigenicity. Those modiﬁcations are not present 
in the recombinant vimentin, which could readily explain 
why we did not observe signiﬁcant anti-vimentin reactivity 
in anti-Sa positive patients.
Intermediate ﬁlaments are a major component of the 
cytoskeleton of eukaryotic cells. Together with the actin 
microﬁlaments and microtubules, they form an integrated 
network that is responsible for the mechanical integrity 
of the cell and is critically involved in processes such as 
cell division, motility, and plasticity. Although there are 
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Figure 4. Placental Sa 
antigen is citrullinated 
vimentin. Three identical 
immunoblots containing 
semi-puriﬁed placental Sa 
antigen (100 µg; lanes 1, 
4, 7), human recombinant 
vimentin (50 ng; lanes 2, 
5, 8) and in vitro citrul-
linated human recombinant 
vimentin (50 ng; lanes 3, 6, 
9) were stained with either 
anti-Sa reference serum 
(left panel), anti-modi-
ﬁed citrulline antibodies 
(anti-MC; middle panel) and 
anti-vimentin antibodies 
(right panel). Sa antigen is 
recognized both by anti-MC 
antibodies and anti-vimen-
tin antibodies (lanes 4 and 
7, respectively), indicating 
that the antigen is indeed 
citrullinated vimentin. 
Citrullinated vimentin was 
recognized by the anti-Sa 
serum, whereas unmodiﬁed 
vimentin was not (lanes 3 
and 2, respectively), indi-
cating that the presence of 
citrulline residues is essen-
tial for the autoantigenicity 
of Sa. Molecular weight 
markers are indicated on 
the left.
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at least ﬁve distinct classes of intermediate ﬁlaments, cells 
of mesenchymal origin and most cells in culture contain 
intermediate ﬁlaments composed of vimentin. Vimentin 
intermediate ﬁlaments are dynamic structures [215] and 
their ﬂexible organization is important for various cellular 
processes [216]. The ﬁlaments are composed of homopoly-
mers of vimentin subunits [217]. The polymerization of 
the free subunits into ﬁlaments is a reversible process, in 
which phosphorylation is an important regulating factor; 
free vimentin subunits are more heavily phosphorylated 
(on their amino terminal head domain) than polymerized 
vimentin [205,215]. Vimentin can also be citrullinated, 
which means that some of its arginine residues are deimi-
nated to citrulline residues. This modiﬁcation of vimentin 
has been described to occur in dying macrophages [68,69]. 
It is known that citrullination of the amino terminal head 
domain by PAD induces disassembly of the vimentin 
ﬁlaments in vitro [214]. Therefore, citrullination may be 
involved in the disassembly of the vimentin cytoskeleton 
during cell death, when the network of vimentin ﬁlaments 
collapses into perinuclear aggregates. The phosphorylation 
and citrullination of vimentin may account for the small 
differences between calculated and observed molecular 
weight/pI values (53.6/5.1 vs. ~50/5.0) and also for the dif-
ferences in gel mobility observed in Figure 4. Larger varia-
tions in molecular weight/pI values of vimentin have been 
reported elsewhere (66.9/5.6 and 48.6/4.6) [218].
The existence of citrullinated vimentin provided us with 
new clues on the nature of the Sa antigen. Autoantibodies 
directed to citrullinated proteins are highly speciﬁc for 
RA (reviewed in [185]). Besides their high speciﬁcity, they 
share more features with the anti-Sa antibodies. They can 
be detected very early in the disease and can often predict 
clinical outcome of the disease [29,30,160]. Furthermore, 
both types of autoantibodies correlate with the presence 
of HLA-DR shared epitope [160,161]. To investigate if anti-
Sa sera are indeed directed against citrullinated epitopes, 
we tested 87 sera of known anti-Sa status in the anti-CCP2 
assay. Our aim was not to compare the two assays, since we 
did not test large numbers of randomly selected patients, 
but to investigate the concordance in anti-Sa and anti-CCP 
antibody status. Of the anti-Sa positive RA sera, most were 
also positive for anti-CCP. Of anti-Sa negative RA sera, a 
considerable proportion was anti-CCP positive, albeit at a 
lower titer. The anti-CCP titers of anti-Sa positive patients 
was on average more than three fold higher than anti-CCP 
titers of anti-Sa negative RA patients. It thus appears that 
mainly sera that are strongly positive for anti-CCP will 
Figure 5. Anti-vimentin 
can immunoprecipitate 
Sa antigen from placen-
tal extract. Vimentin was 
immunoprecipitated from 
semi-puriﬁed placental 
extract with monoclonal 
antibody RV202 (lanes 3). 
Immunoprecipitated vimen-
tin was stained by anti-MC 
antibodies (upper panel), 
anti-Sa serum (middle 
panel), and polyclonal anti-
vimentin antibodies (lower 
panel) indicating that Sa is 
citrullinated vimentin. An 
immunoprecipitation with 
an isotype-matched mono-
clonal control antibody 
4G3 (lanes 4) served as a 
negative control. Lanes 1 
contain in vitro citrullinated 
human recombinant vimen-
tin (50 ng) as a positive 
control. 10% input is shown 
in lanes 2. Molecular weight 
markers are indicated on 
the left.
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score positive for anti-Sa. This observation is in agreement 
with the difference in sensitivities of both assays (70-80% 
for anti-CCP2, 30-40% for anti-Sa) [66,185]. Other assays 
that detect anti-citrullinated protein antibodies by immu-
noblotting (using ﬁlaggrin as the antigen) have sensitivities 
(~40%) comparable to the sensitivity of the anti-Sa assay 
[93,94,96]. 
The presence of antibodies to citrullinated proteins is 
correlated with more severe disease outcome, especially 
when high titers of the antibody are present (reviewed 
in [185]). In an early RA cohort study, anti-Sa antibodies 
appear to be slightly more correlated with erosive disease 
outcome than anti-CCP [219], which is in agreement with 
the idea that the Sa antigen is recognized by patients with 
high titers of anti-citrullinated protein antibodies. 
To actually prove that the placental Sa antigen is citrul-
linated vimentin, we performed western blotting and IP 
experiments. Sa was recognized by anti-MC antibodies, 
showing that it does contain citrulline residues. Further-
more, anti-Sa serum was reactive with in vitro citrullinated 
vimentin but not with unmodiﬁed vimentin, showing that 
citrulline is essential for antigenicity. Finally, antigenic Sa 
protein could be immunoprecipitated from semi-puriﬁed 
placental extracts by anti-vimentin antibodies, showing 
that the antigenic citrulline residues are indeed carried by 
vimentin. Taken together, our results show that the placen-
tal Sa antigen is citrullinated vimentin. Therefore, anti-Sa 
antibodies are member of the expanding family of anti-
citrullinated protein antibodies (reviewed in [185]), which 
includes anti-perinuclear factor [70], anti-‘keratin’ anti-
bodies [74], anti-ﬁlaggrin antibodies [76,77] and anti-CCP 
antibodies [85,98]. Their common antigenic determinant is 
the nonstandard amino acid citrulline; the name of the anti-
body is simply determined by the antigen used to detect 
them. Not every citrulline residue in a protein will provide 
a good epitope, however, because the amino acids ﬂanking 
the citrulline residue are important for the presentation of 
the antigenic citrulline residue. Therefore, proteins with 
high arginine content, i.e. ﬁlaggrin, ﬁbrinogen, vimentin, 
histones, or myelin basic protein, are more likely to contain 
reactive epitopes upon citrullination, than proteins with 
low arginine content, i.e. albumin [220]. In fact, most of the 
in vitro citrullinated arginine rich proteins mentioned here 
have been used in diagnostic assays to detect the RA spe-
ciﬁc anti-citrullinated protein antibodies (ﬁlaggrin [96,97], 
ﬁbrinogen [221], myelin basic protein [220]). Because each 
antigen and each test format (immunoﬂuorescence, immu-
noblot or ELISA) will show different values for sensitivity 
and speciﬁcity for RA, care should be taken in using the 
proper nomenclature and standardization. 
The commercially available anti-CCP2 test has a reported 
sensitivity of almost 80% and a speciﬁcity of 98% [35,104]. 
Interestingly, some (2 out of 46) of the anti-Sa positive RA 
patients tested negative for anti-CCP. Vimentin contains 43 
arginine residues (see Figure 2). Each of them can poten-
tially be citrullinated by PAD, resulting in a large variety 
of citrullinated epitopes. In contrast, in the anti-CCP2 test 
only a few epitopes are presented. It had been previously 
established that RA sera show a remarkable variety in the 
reactivity pattern towards different citrulline-contain-
ing peptides, indicating as previously mentioned that the 
amino acids ﬂanking the citrulline residue are important 
for the antigenicity of the epitope and that anti-citrulli-
nated protein reactivity is a strongly polyclonal response 
[85]. It follows that anti-Sa positive/anti-CCP negative sera 
are most likely directed to citrullinated epitopes that are 
only present on the Sa antigen.
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Conclusion
The placental Sa antigen, speciﬁcally recognized by 
antibodies in serum from RA patients has been identiﬁed 
as citrullinated vimentin. Anti-Sa antibodies are therefore 
member of the family of anti-citrullinated protein antibod-
ies. The Sa antigen is present in the rheumatoid pannus 
[62]. We recently observed that vimentin is citrullinated in 
dying human macrophages [69]. Furthermore, it has been 
described that vimentin-derived citrullinated peptides 
were able to bind to HLA-DR4 shared epitope much more 
efﬁciently than non-citrullinated peptides [159]. These 
ﬁndings, together with our identiﬁcation of the Sa anti-
gen, make citrullinated vimentin an interesting candidate 
autoantigen in RA and may provide new insights on the 
potential role of citrullinated synovial antigens and the 
antibodies directed to them in the pathophysiology of RA.
Materials and Methods
Patient sera and antibodies
In this study we used 87 serum samples from patients attend-
ing the Rheumatic Diseases Unit, Faculté de Medicine, Université 
de Sherbrooke, Sherbrooke, QC, Canada. Sixty-one sera were from 
RA patients satisfying the 1987 ACR criteria for RA [26]: 46 were 
anti-Sa positive and 15 anti-Sa negative. The 26 non-RA sera (8 
osteoarthritis patients, 14 systemic lupus erythematosus patients, 
2 psoriatic arthritis patients and 2 healthy individuals) were all 
anti-Sa negative. Experiments were approved by the local ethics 
committee.
Rabbit antibodies directed against chemically modiﬁed 
citrulline (anti-MC) were described previously [189,190]. Mouse 
monoclonal antibodies (RV202) [222] and afﬁnity-puriﬁed rabbit 
polyclonal antibodies against vimentin were a kind gift of Dr. F. 
Ramaekers (Maastricht, The Netherlands).
Preparation of placental Sa antigen
Semi-puriﬁed placental extracts were prepared as described 
previously [62,63]. Brieﬂy, fresh human placenta was homogenized 
in a low salt Tris buffer (50 mM Tris·HCl pH 7.4, 120 mM NaCl, 
0.02% NaN
3
, 1 mM dithiotreitol (DTT), 1.5 mM phenylmethyl-
sulphonylﬂuoride (PMSF) and chemostatin, leupeptin, antipain, 
and pepstatin, 0.5 µg/ml each). The soluble fraction was separated 
by anion exchange chromatography. Sa proteins were eluted with 
300 mM of NaCl and subsequently desalted and lyophilized for 
storage at –80°C.
Characterization of placental Sa antigen
To prepare Sa for amino acid sequencing, a three step puriﬁca-
tion procedure was performed essentially as described by Liang et 
al. [223]. In the ﬁrst step, 1 mg of the semi-puriﬁed Sa (prepared 
as described above) was resolved on a preparative 10% SDS-PAGE 
gel. Vertical strips were cut from each side of the gel and were 
blotted onto nitrocellulose membrane. The blotted strips were 
incubated with anti-Sa reference serum and served to determine 
the exact position of the Sa bands. 
In the second step of the procedure, the Sa-rich horizontal 
strip was cut out of the preparative gel and washed extensively in 
a freshly prepared, ﬁltered and pre-warmed (37°C) wash solution 
(2 mM Tris·HCl pH 8.0, 8 M of deionized urea, and 1% Nonidet-
P40 (NP-40)). The washed gel strip was then loaded on an iso-
electric focusing (IEF) gel (6 M urea, 1% NP-40, 6% acrylamide 
(39:1), 2% carrier ampholytes (Bio-Rad; pH range 3-10), and 
0.067% riboﬂavin). IEF was performed as described by Bouffard 
et al. [224]. IEF standards for pH range 3.6-6.6 (Sigma) were used 
to estimate the pI of the proteins. Immediately after migration, 
the gel was ﬁxed in 20% trichloroacetic acid (TCA) for 20 min and 
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then colored with Coomassie Brilliant Blue. Each individual band 
was cut out and frozen at –20°C.
The third step of the procedure was to load excised bands on 
a second preparative 10% SDS-PAGE gel. Each band from the IEF 
gel was divided over two lanes; one was used for western blotting 
with anti-Sa reference serum to determine the exact position of 
the Sa antigen, the other lane was stained with Coomassie. The 
bands that matched the Sa antigen were excised from the Coo-
massie stained gel and washed twice with 50% acetonitrile before 
being frozen and sent out for microsequencing at the Harvard 
microchemistry facility (Harvard University, Cambridge, MA) 
[225]. Peptides, generated by in gel digestion with trypsin were 
separated by liquid chromatography followed by double mass 
spectrometry (LC/MS/MS) and ﬁnally sequenced by Edman deg-
radation. The obtained peptide sequences were used to identify 
the puriﬁed Sa antigen using the NCBI non-redundant protein 
database.
Detection of autoantibodies
Presence of anti-Sa antibodies was determined by immunoblot-
ting as described previously [62,63]. Brieﬂy, semi-puriﬁed Sa was 
loaded on 15% SDS-PAGE slab gels (0.1-0.2 mg of total protein 
per cm of gel width). Following migration, proteins were blotted 
onto nitrocellulose membranes. Sera were diluted 1:40 and tested 
for IgG anti-Sa. Immunoblots were scored independently by two 
individuals.
Anti-CCP (cyclic citrullinated peptide) autoantibodies were 
detected using the Rapscan RA mk2 kit (CCP2; Euro-Diagnostica, 
Arnhem, The Netherlands) according to the instructions of the 
manufacturer.
Immunoprecipitation
Immunoprecipitations (IPs) were performed essentially as 
described elsewhere [226]. Brieﬂy, 2.5 mg of semi-puriﬁed Sa was 
dissolved by heating to 95°C for 1 min in 250 µl buffer containing 
20 mM Tris·HCl pH 7.4, 20 mM ethylene glycol bis(β-aminoethyl-
ether) N,N’-tetraacetic acid (EGTA), 1 mM dithioerythritol (DTE), 
and 2% SDS. Insoluble proteins were removed by centrifuga-
tion for 5 min at 13,000 g. The supernatant was diluted with IP 
buffer (IPB: 50 mM Tris-HCl pH 7.2, 150 mM NaCl, 0.25% Na-
deoxycholate, 1% Triton X-100, and Complete protease inhibitor 
cocktail (Roche)) to a ﬁnal concentration of 0.1% SDS. The diluted 
solution was centrifuged another 5 min at 13,000 g to remove 
insoluble proteins. Protein G agarose beads (150 µl 50% slurry) 
were washed 3 times with IPB-SDS (IPB containing 0.1% SDS). 
RV202 monoclonal anti-vimentin antibodies (150 µl) were incu-
bated with the beads in IPB-SDS for 4 hours at room temperature. 
After removal of unbound antibody by 3 washes with IPB-SDS, 
500 µg Sa (1 ml of diluted solution) was incubated with the beads 
overnight at 4°C. After extensive washing (3 washes with IPB-
SDS, 1 wash with IPB-SDS supplemented with 100 mM KCl and 
a last wash with IPB-SDS) bound proteins were eluted by boiling 
in SDS-sample buffer (250 mM Tris·HCl pH 6.8, 2% SDS, 5% β-
mercaptoethanol). The immunoprecipitate was divided over three 
13% SDS-PAGE gels and transferred to Hybond-C Extra (Amer-
sham) membranes. The blots were stained with either anti-MC 
antibodies, anti-Sa reference serum or polyclonal anti-vimentin 
antibodies as described below. As a negative control, an IP was 
performed with an isotype-matched unrelated control antibody 
(4G3 directed to U2 snRNP B’’ protein [227]).
Citrullination of vimentin
Human recombinant vimentin (Research Diagnostics Inc., 
Flanders, NJ) was citrullinated in vitro by rabbit muscle PAD 
(Sigma; 40 U of PAD per mg of vimentin) for 3 hours at 55°C in a 
buffer containing 0.1 M Tris·HCl pH 7.6, 10 mM CaCl
2
 and 5 mM 
DTE. The reaction was stopped by adding EGTA (pH 8.0) to a 
ﬁnal concentration of 50 mM. The extent of the citrullination was 
estimated by immunoblotting with anti-MC antibodies (described 
below). 
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Western blotting
Blots were incubated in blocking buffer (PBS containing 5% 
non-fat dried milk and 0.1% NP-40) for 1 hour at room tempera-
ture and 1-3 hours with the antibody of interest diluted in block-
ing buffer. After washing with blocking buffer, bound antibodies 
were detected by incubation with HRP-conjugated secondary 
antibodies, followed by chemiluminescence. For the detection 
of citrullinated proteins, blots were chemically treated prior to 
immunostaining with anti-MC antibodies as described previously 
[189]. 
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Peptidylarginine deiminase (PAD; EC 3.5.3.15) enzymes 
catalyze the conversion of arginine residues to citrulline 
residues in proteins (Figure 1). Citrulline is a nonstandard 
amino acid, as it is not incorporated into proteins during 
translation. Indications that citrulline residues occur in 
proteins date as far back as 1939 [228] and evidence that 
citrulline is part of the backbone of certain proteins came 
with the development of amino acid sequencing techniques 
[229]. Because no citrulline tRNA exists, the presence of 
citrulline residues in proteins has to be the result of post-
translational modiﬁcation. The enzyme responsible for this 
modiﬁcation, PAD, was ﬁrst described in 1977 [230].
At the moment it is believed that at least four, strongly 
related isoforms of PAD enzymes exist in mammals and pos-
sibly also in other vertebrates (one chicken PAD has been 
described). In this review, we will focus on the sequence 
homology and genomic organization of the known PAD 
P
 eptidylarginine deiminase (PAD, EC 3.5.3.15) enzymes catalyze the conversion 
of protein-bound arginine to citrulline. This posttranslational modiﬁcation 
may have a big impact on the structure and function of the target protein. In 
this chapter we will discuss the effects of citrullination and its involvement in 
several human diseases, including rheumatoid arthritis and multiple sclerosis.
So far, four isotypes of PAD have been described in mammals. We describe the 
existence of PAD in non-mammalian vertebrates and the existence of a ﬁfth 
mammalian PAD. Furthermore, tissue-speciﬁc expression, genomic organization 
and evolutionary conservation of the different PAD isotypes will be discussed 
in detail.
enzymes and provide evidence for the existence of novel 
PADs, both in mammalian and non-mammalian species. 
We will also discuss the involvement of PAD enzymes and 
their products (citrullinated proteins) in human disease.
PAD by PAD, isotypes 
and features
To date, four isotypes of PAD have been cloned from 
mouse, rat and human. Furthermore a sheep and a chicken 
enzyme have been cloned. In addition, evidence for PAD 
activity in cow, rabbit and guinea pig has been published. 
All these enzymes rely strongly on the presence of Ca2+ for 
activity (Figure 1) and are unable to convert free L-arginine 
into L-citrulline [149]. Free L-arginine can be converted to 
free L-citrulline by nitric oxide synthase (EC 1.14.13.39) in 
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eukaryotes or by arginine deiminase (EC 3.5.3.6) in bacte-
ria. Both enzymes are not dependent on Ca2+ for activity 
and the former produce NO instead of NH
3
 as a byproduct 
of citrullination. Although the chemical reaction catalyzed 
by PAD enzymes is ofﬁcially called peptidylarginine deimi-
nation, throughout the text we will use the term citrullina-
tion, since a peptidylcitrulline is formed.
To date only a single prokaryotic enzyme that can 
citrullinate proteins has been identiﬁed, in Porphyromonas 
gingivalis [231]. This enzyme (AAF06719), however, is not 
evolutionarily related to the vertebrate PAD enzymes, can 
convert both peptidylarginine and free L-arginine, is not 
dependent on Ca2+, and shares sequence homology with 
several arginine deiminases [232]. Therefore, this enzyme 
will not be discussed further in this review.
Data mining in EST and genomic databases revealed the 
existence of a ﬁfth PAD enzyme in mammals and the exis-
tence of PAD enzymes in non-mammalian vertebrates. All 
isotypes of PAD display extensive mutual sequence homol-
ogies, as will be discussed in detail below. The most notice-
able difference between the isotypes is their tissue-speciﬁc 
expression. Not much is known about the speciﬁcity of 
PAD towards protein substrates. It appears that all isotypes 
can citrullinate most proteins with accessible arginines in 
vitro [233], although certain proteins are citrullinated more 
rapidly than others by individual PADs [234]. Also, studies 
with peptides indicate that certain amino acids ﬂanking the 
Arg inﬂuence its susceptibility to citrullination by PAD (e.g. 
Arg sandwiched between two Pro residues in not citrulli-
nated at all) [235]. For the in vivo situation, we expect that 
the subcellular localization of the enzyme, its microenvi-
ronment (e.g. local Ca2+ concentrations) and physiochemical 
features of the target protein (e.g. like structure, charge, 
size, and ﬂexibility) are important for substrate selection.
PAD1
PAD1 is mainly expressed in epidermis and uterus 
[132,233,236,237], although RT-PCR [135,238] and EST 
data suggest a broader tissue distribution (Table 1). PAD1 
is encoded by a 3.8 kb mRNA containing a 3’UTR of 1600-
1700 nt. Regarding human PAD1, a 3846 (AK023211) and 
2711 (NM_013358) nt cDNA have been described [135], but 
considering the presence of an A-rich stretch in the 3’UTR 
just downstream of where the 2711 nt sequence stops, this 
sequence is most likely the result of aspeciﬁc annealing 
of oligo-dT primers during cDNA synthesis. In mouse the 
3.8 kb transcript size has been conﬁrmed by northern blot-
ting [132].
During terminal differentiation of keratinocytes, kera-
tins (K1 and K10), and the keratin-associated protein ﬁlag-
grin are citrullinated [190,196,206,239]. In general, citrul-
lination decreases the net positive charge of the protein, 
causing loss of potential ionic bonds and interference with 
H-bonds. These changes affect intramolecular bonds, lead-
ing to partial unfolding of the protein, but also intermo-
lecular interactions with other molecules can be altered 
(Figure 2) [92]. As a consequence, it is believed that the 
ﬂexibility of the keratin cytoskeleton is reduced upon 
citrullination, stimulating the corniﬁcation of the epidermis 
[207]. Filaggrin (ﬁlament aggregating protein) cross-links 
keratin ﬁlaments in order to form very rigid structures. It 
is synthesized as a large, heavily phosphorylated precursor 
Figure 1. Citrullination 
(deimination) of peptidy-
larginine by PAD. The gua-
nidino group of arginine is 
hydrolyzed yielding a ureido 
group and ammonia.
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protein, consisting of 10-12 ﬁlaggrin subunits [78]. In the 
ﬁnal stages of keratinocyte differentiation, pro-ﬁlaggrin 
maturates via a multi-step process, which includes dephos-
phorylation, citrullination and cleavage into separate ﬁlag-
grin subunits. Although the exact mechanisms involved are 
not completely understood, we believe that citrullination of 
pro-ﬁlaggrin opens up the structure of the protein, render-
ing it susceptible to cleavage by proteases [79] including 
calpain I [80]. Finally, the mature ﬁlaggrin subunits bind 
to and aggregate keratin ﬁlaments via ionic interactions 
to form dense macroﬁbrils that protect the keratins from 
proteolytic cleavage [81,82]. Furthermore, ﬁlaggrin can be 
covalently cross-linked to the keratin ﬁlaments and the 
corniﬁed cell envelope by transglutaminase 1, enhancing 
the physical resistance of the epidermis [207,240].
Although other PADs are also expressed in epidermis 
(at least at the mRNA level), it appears that in vivo keratin 
is a substrate of mainly PAD1, because isolated keratin K1 
is citrullinated much more rapid by PAD1 than by other 
isotypes of PAD [234].
PAD2
PAD2 is the most widely expressed type of PAD (Table 1). 
The most abundant expression is observed in skeletal mus-
cle, brain, spleen and secretory glands [136,137,236,241-
245]. When investigating PAD2 expression it is important 
to note that PAD2 expression is regulated both at the tran-
scriptional and the translational level [69,156]. The 4.5 kb 
mRNA [237,241] contains a very long 3’UTR (> 2 kb) which 
is probably important for translational regulation. An 
example of this is the expression of PAD2 in monocytes. 
Although the mRNA is expressed in comparable amounts 
in monocytes and monocyte-derived macrophages, PAD2 
protein is only detectable in macrophages [69]. Thus far, 
Figure 2. Possible effects 
of protein citrullination. 
Target proteins are un-
folded by citrullination. The 
positive charge of arginine 
residues is lost causing 
the disruption of intra-
molecular (ionic) interac-
tions. The unfolding of the 
protein may have several 
consequences, like loss of 
intermolecular interactions 
(e.g. MBP-lipid interactions 
or disintegration of vimen-
tin ﬁlaments). On the other 
hand, the new structure of 
the citrullinated protein 
may enable the formation 
of de novo intermolecular 
interactions (e.g. keratin 
aggregation by ﬁlaggrin). 
The less ordered structure 
of the citrullinated protein 
makes it more vulnerable to 
proteolytic degradation (e.g. 
cleavage of pro-ﬁlaggrin 
by calpain or MBP degrada-
tion by cathepsin). Shown 
is a hypothetical protein 
motif with some positively 
charged arginines (green 
circles), negatively charged 
residues (red circles) and 
citrullines (purple circles). 
Although citrullination also 
induces conformational 
changes to the secondary 
structure, only changes to 
the tertiary structure of the 
protein are drawn in this 
schematic picture.
64 Chapte r 5
two natural substrates for PAD2 are known: myelin basic 
protein (in the central nervous system) and vimentin (in 
skeletal muscle and macrophages). 
Macrophages express PAD2 both at the RNA and the 
protein level [69], but the cytosolic Ca2+ concentration 
(approximately 10–7 M) is too low for activity of the enzyme 
[68,69]. The minimum Ca2+ concentration required for 
PAD2 activity is approximately 100 fold higher than the 
normal cytosolic Ca2+ concentration. Half-maximal activity 
is obtained at 40-60 mM Ca2+ [149]. In vivo activation of 
PAD enzymes can be accomplished by artiﬁcially raising 
the cytosolic Ca2+ concentration with a calcium ionophore. 
Macrophages treated with calcium ionophores become apop-
totic and show selective citrullination of vimentin [68,69]. 
The vimentin cytoskeleton in healthy cells is a highly 
dynamic structure, as polymerization and depolymeriza-
tion of the ﬁlaments are involved in various biological func-
tions. Under physiological conditions, these processes are 
regulated by reversible phosphorylation at speciﬁc sites in 
the amino terminal head domain of the vimentin molecules 
[205]. Citrullination of this head domain by PAD induces 
disassembly of the vimentin ﬁlaments [214], probably caus-
ing the collapse of the vimentin cytoskeleton that is often 
observed in apoptotic or necrotic cells in which intracel-
lular Ca2+ levels are raised.
PAD2 is also expressed throughout the nervous system. 
Expression is highest in the grey matter and hypothalamus, 
while cerebellum contains relatively low amounts of PAD2 
[246]. Myelin basic protein (MBP) is the major protein 
component of the myelin sheath that covers the axons of 
mRNA       Unigene Expression
Isotype Species Accession nr. Length (nts) Accession nr. Protein (references) mRNA / EST
PAD1
H.sapiens AK026652 3846 Hs.392972
epidermis, uterus [135,233,236]
brain, colon, embryonic stem cells, eye 
(retina), inner ear, kidney, muscle, nerve, 
placenta, skin, thymus, uterus, vagina
M.musculus NM_011059 3755 Mm.20854
R.norvegicus AB010998 3740 Rn.30030
PAD2
H.sapiens AB023211 4343 Hs.33455 brain, spinal cord (glial cells), uterus, sali-
vary gland, macrophages, pituitary gland, 
sweat gland, spleen, pancreas, bone marrow, 
oligodendrocytes, yolk-sac (leucocytes), 
skin (ambiguous)  [68,136-138,236,237,243-
246,248,249,251,252,255,278-280]
aorta, brain, breast, bone (marrow), cervix, 
colon, embryo, epididymus, eye (retina), 
inner ear, kidney, leukocyte, lung, lymph 
node, macrophage, muscle, ovary, pancreas, 
placenta, prostate, salivary gland, skin, 
spleen, thymus, uterus   
M.musculus NM_008812 4689 Mm.2296
R.norvegicus NM_017226 4507 Rn.37619
PAD3
H.sapiens NM_016233 3183 Hs.149195
hair follicles [134,236,256,257] muscle, skin, thymusM.musculus NM_011060 3068 Mm.20851
R.norvegicus NM_017230 3100 Rn.32094
PAD4
H.sapiens NM_012387 2263 Hs.397050
eosinophils, neutrophils, granulocytes 
[140,141]
brain, bone (marrow), eye, fetal liver/spleen, 
inner ear, kidney, leukocyte, macrophage, 
placenta, prostate, skin, thymus  
M.musculus NM_011061 2276 Mm.20874
R.norvegicus NM_017227 2258 Rn.11155
PAD6
H.sapiens NM_207421 2110 Hs.531598
egg, ovary, early embryo, leukocytes 
[142,332]
embryo, ovary (egg), thymus, leukocytesM.musculus NM_153106 2336 Mm.271661
R.norvegicus XM_233601 2070 —
  
Table 1. Overview of PAD 
expression.
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nerve cells. In healthy individuals, approximately 18% of 
MBP molecules contain 6 citrullines (out of 19 arginines). 
The proportion of citrulline-containing MBP is increased 
in patients with multiple sclerosis (MS) [247]. The conse-
quences of MBP citrullination will be addressed in detail 
in the discussion of MS below. MBP is produced by mature 
oligodendrocytes in the central nervous system (CNS) and 
in the peripheral nervous system by Schwann cells. In 
rat, PAD2 has been found in oligodendrocytes, but not in 
astrocytes [248]. Citrullinated proteins, like MBP and glial 
ﬁbrillary acidic protein (GFAP), could only be detected in 
rat brain extracts after incubation of the extracts at 37°C. 
This indicates that intracellular Ca2+ levels were too low for 
in situ PAD activity and that PAD enzymes became only 
activated after post lytic contact with Ca2+ from intracellu-
lar Ca2+ stores or from the extracellular space [248]. GFAP is 
an astrocyte-speciﬁc intermediate ﬁlament protein. If oligo-
dendrocytes are the only PAD2 producing cells in brain, it 
would be unlikely that GFAP is citrullinated in vivo. Other 
studies, however, report PAD2 expression mainly in astro-
cytes and microglial cells in rat brain and spinal cord but 
not in oligodendrocytes [191,249]. Again, citrullinated pro-
teins (both GFAP and MBP) were only detectable if extracts 
were incubated at 37°C to facilitate post lytic activation of 
PAD2 [191]. The occurrence of citrullinated MBP in normal 
brain and spinal cord is an established phenomenon, ﬁrst 
described in 1971 [250]. Since PAD2 is the only type of PAD 
expressed in the brain, one would expect its expression in 
MBP producing cells: oligodendrocytes and Schwann cells. 
The reported astrocyte-speciﬁc expression of PAD2, mainly 
based on cell morphology and partial colocalization with 
GFAP, should therefore be interpreted with caution.
PAD2 levels appear to be (partly) regulated by hormones. 
The PAD2 levels in pituitary gland are higher in female rats 
and mice than in males. Following ovarectomy of these 
animals, the PAD2 levels in uterus and pituitary gland 
dropped considerably, but levels could be restored by injec-
tion of 17β-estradiol [243,251]. In uterus, PAD2 protein lev-
els showed estrogen-related changes during the menstrual 
cycle; expression being 3 to 4 fold higher during estrous 
stage compared to diestrous stage [237,252]. On the mRNA 
level, menstrual cycle related changes of PAD2 expression 
show much stronger ﬂuctuations (50 fold or more) [253]. 
During pregnancy, PAD2 expression in uterus and pituitary 
gland is elevated after an initial decline [254,255]. Other tis-
sues do not show a clear estrogen-dependent PAD2 expres-
sion [252]. All these data suggest a tissue speciﬁc hormonal 
regulation of PAD2 expression.
PAD3
Next to the three species from which all PAD isotypes 
have been cloned (rat, mouse and human), the cDNA of 
PAD3 from sheep has been cloned as well. Its expression 
is restricted to hair/wool follicles [134,236,256,257]. The 
enzyme is encoded by a 3.1 kb mRNA (Table 1) [132]. For 
sheep PAD3 only the coding sequence was determined, 
although northern blotting indicates that the mRNA is also 
in the 3 kb range [257]. PAD3 shows co-expression and co-
localization with its natural substrate, trichohyalin, which 
is a major structural protein of inner root sheath cells of 
hair follicles [133,257]. Like ﬁlaggrin, trichohyalin mediates 
aggregation of keratin ﬁlaments. Citrullination of tricho-
hyalin opens its α-helical structure and renders it available 
for efﬁcient cross-linking to keratin ﬁlaments by transglu-
taminase 3 [92,258]. The solid matrix that is formed in this 
manner acts as a ﬁrm tube to guide the directional growth 
of the hair ﬁber. Trichohyalin is also expressed in tongue 
and nail, where it functions in the formation of the ﬁliform 
papillae and of the nail fold, respectively [259]. PAD and 
transglutaminase both are Ca2+ dependent enzymes, while 
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trichohyalin and proﬁlaggrin  are both Ca2+ binding pro-
teins [260,261]. This suggests a putative functional rela-
tionship in which the substrate proteins present Ca2+ to the 
enzymes by which they are modiﬁed [257]. In such a way 
local enrichment of Ca2+ levels could activate PAD locally.
PAD4/PAD5
PAD5 is the human homolog of mouse and rat PAD4. The 
human enzyme shows slightly different reaction kinetics 
towards artiﬁcial substrates [139]. This is why the human 
enzyme was ﬁrst believed to be a novel PAD, hence its name 
PAD5. Sequence data, expression data and the genomic 
organization of the PAD genes (Figures 3-5, see below), 
however, all indicate that human PAD5 corresponds to 
the rodent PAD4 [140,141]. Our suggestion to rename the 
human PAD5 to PAD4 was approved by the HUGO Gene 
Nomenclature Committee (HGNC).
PAD4 is expressed mainly in white blood cells (granulo-
cytes [140,141,153] and monocytes [69,139]), and can there-
fore be detected in a variety of tissues [242,262]. It is the 
only type of PAD that resides in the cell nucleus [141]. A 
putative monopartite NLS motif, depicted in dark blue in 
Figure 3, was recently shown to be essential for the nuclear 
localization of human PAD4 [141].
Analogous to experiments with PAD2 [69], stimulation 
of PAD4 expressing granulocytes with a calcium ionophore 
induced the citrullination of proteins. Histones and nucleo-
phosmin/B23, both nuclear proteins, were targeted by 
PAD4 [141,153]. No data exists on the function of histone 
citrullination, but one might speculate on a role in apopto-
sis. Granulocytes are constantly produced in large amounts 
in the bone marrow and since they only have a lifespan of 
about three days, they die by apoptosis in equally large 
numbers. Their high arginine content (> 10%) gives the 
histones a strong net positive charge, which is important 
for their interaction with the negatively charged DNA 
backbone. Both the conformation and the net charge of the 
histones are altered by citrullination, potentially causing 
the nucleosomes to open up, which makes the DNA more 
susceptible to degradation. DNA fragmentation is one of the 
hallmarks of apoptosis. As described for PAD1 and PAD3, 
citrullination is often observed during terminal differentia-
tion, a process closely related to apoptosis.
PAD6
Searching in EST and genomic databases with a consen-
sus sequence derived from all mammalian PADs revealed 
the existence of a novel PAD isotype. Very recently, PAD6 
was cloned from mouse and designated ePAD because of its 
expression in egg cells and embryo [142]. It is the ﬁfth iso-
type in mammals, but to avoid confusion with the human 
PAD4/5 enzyme and yet to stay in conﬁrmation with the 
existing PAD nomenclature, we suggest to designate this 
novel enzyme as PAD6. This annotation was agreed upon 
by the HGNC. PAD6 is localized to egg cytoplasmic sheets. 
These keratin-containing intermediate ﬁlament structures 
are only found in mammalian egg cells and early embryos 
and are known to undergo reorganization in early stages of 
development [142]. Although, the presence of citrullinated 
proteins in the egg cytoplasmic sheets has not been inves-
tigated yet, it seems likely that citrullination could play a 
role in the reorganization of these structures.
All vertebrate PAD enzymes 
are highly conserved
Strong conservation of the proteins of the PAD family 
has been described in various studies. Inter-isotype conser-
vation within one species is approximately 50-55% (identi-
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cal amino acids). The conservation of each isotype among 
mammals is very high (70-95% identical amino acids). In 
literature, sequence comparisons have been reported either 
for single PAD isotypes from different organisms or for dif-
ferent isotypes in a single organism [134,135,138,262]. An 
overview of the sequence conservation among all known 
PAD enzymes has, however, never been published.
Using the ClustalW program, we constructed an amino 
acid sequence alignment of all the available PAD enzymes 
(Figure 3: available as a separate foldable leaf in this the-
sis). Partial PAD sequences, derived from EST and genomic 
databases, were added manually. Full length sequences of 
all 5 isotypes were available from human (Homo sapiens, 
Hs), mouse (Mus musculus, Mm), and rat (Rattus norvegi-
cus, Rn) and of single isotypes from chicken (Gallus gallus, 
Gg), and sheep (Ovis aries, Oa; PAD3). Partial sequences of 
other mammalian PADs were derived from sequence data-
bases for cow (Bos taurus, Bt; PAD1-4), dog (Canis familia-
ris, Cf; PAD3), pig (Sus scrofa, Ss; PAD3 and 6), and rabbit 
(Oryctolagus cuniculus, Oc; PAD2). In addition non-mam-
malian PAD sequences were found for African clawed frog 
(Xenopus laevis, Xl), zebraﬁsh (Danio rerio, Dr), rainbow 
trout (Oncorhynchus mykiss, Om), and Japanese pufferﬁsh 
(Takifugu rubripes, Tr). The alignment demonstrates that the 
highest level of conservation exists in the C-terminal part 
of these proteins, although the N-terminal part also shows 
profound amino acid homology. Overall 118 residues (18%) 
are fully conserved in all PADs; in the C-terminal half of 
the proteins (position 390 and up in the alignment), 25% of 
amino acids are fully conserved. The calculated pI values of 
the enzymes is quite low (average of 5.8 for human PADs), 
because of a surplus of acidic residues. The resulting net 
negative charge under physiological conditions (on average 
–14 for human PADs) is important for the interaction with 
positively charged arginines of the substrates. Moreover, 
negatively charged residues are important for the binding 
of Ca2+, the essential cofactor for PAD enzyme activity.
Mouse PAD2 uses a start-codon 8 residues upstream of 
the conserved start site (M
9
 in the MmPAD2 sequence). 
Various EST sequences support the presence of this aberrant 
upstream start codon. Acetylation of M
1
 in mouse PAD2 
has been reported [237]. Acetylation of proteins with Gln 
as the penultimate residue is, however, very uncommon. 
Normally, Met-Gln- proteins (or Met-Leu-, the other PAD2 
enzymes) are not N-terminally acetylated, while Met-Ala- 
(PAD1 and 4) and Met-Ser- (PAD3 and 6) are predicted to 
be processed by methionine aminopeptidase and Na-acetyl 
Figure 3 (provided as a separate leaf). Multiple alignment of all available PAD protein sequences. 
Gaps (-) are introduced for optimal alignment. Accession numbers (NCBI) of full length sequences are 
given at the end of the alignment. Incomplete sequences are indicated by “~”. Conserved residues 
that are identical in more than 50% of PAD sequences are shaded in black; fully conserved residues 
are shaded in light blue. Conserved charged residues are also indicated: shaded light grey. Possible 
amino acid modiﬁcations (putative acetylation and putative citrullination sites [237]) are shaded in 
yellow. In the consensus sequence highly conserved residues are shown in capitals. Absolutely con-
served residues are also in bold. Conserved positive residues are shown in red in the consensus line 
(Arg and Lys), negatives (Asp and Glu) in green. Additionally, prolines (shaded grey) and cysteines 
(shaded yellow) are indicated. Exon-boundaries, based on PAD1 sequences, are annotated above the 
alignment (┌). Double overlined is the stretch of a.a. resembling the Ca2+-binding site of ICaBP [241]. 
The monopartite NLS in PAD4 is shaded in dark blue; conserved NLS residues bold [141]. Putative 
catalytic residues are indicated with asterisk’s above the alignment (blue [242], red and black [232]). 
Residues deemed to function as the catalytic site (indicated by asterisk’s) or in Ca2+-binding (amino 
acid side chain interaction with Ca2+ indicated by +; amino acid main chain interaction with Ca2+ 
indicated by ^) based upon the recently described crystal structure of HsPAD4 [331] are indicated in 
yellow below the alignment and shaded in purple.
Accession numbers (NCBI) of partial PAD sequences (refer to text for abbreviation of species): 
<1> CfPAD3 based on gb: Z97755 (130 aa); <2> SsPAD3 based on gb: BM484610 (174 aa); <3> BtPAD4 
based on gb: BG364988 (120 aa), and BM287180 (105 aa); <4> BtPAD2 based on gb: AW357435 
(56 aa); <5> OcPAD2 based on own sequence data (162 & 59 aa); <6> TrPAD based on gb: CA589487, 
CA588558, and ENSEMBLE accession SINFRUP00000025953 (438 aa); <7> BtPAD1 based on gb: 
BF602225 (45 aa); <8> BtPAD3 based on gb: BM483261, CB425399 (119 aa); <9> HsPAD6 based 
on AAR38850 with I623M and T686A based on own sequence data and gb: XM_372767, and 
HSA549502; <10> SsPAD6 based on contig from gb: BI342160, BF078403, and BF078404 (190 aa); 
<11> HsPAD2 based on NP_031391 with L661W based on BAA76838; <12> DrPAD based on own 
sequence data (675 aa); <13> OmPAD based on gb: CA385723 (144 aa).
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transferase to Ac-Ala- or Ac-Ser-, respectively [263]. A pos-
sible (auto)citrullination of the conserved R
352
 (position 387 
in the alignment) in mouse PAD2 has also been reported 
[237].
PAD enzymes depend on Ca2+ for activity; all the PAD 
(Swissprot) database entries list a putative Ca2+-binding 
EF-hand domain. This region (indicated “=” above the 
alignment, position 550-561), however, shows very little 
homology with the consensus EF-hand sequence (Prosite: 
PDOC00018). The reported putative EF-hand is based on an 
alignment of rat PAD2 with the calcium binding domain of 
several ICaBPs [241]. This alignment, however, shows not 
enough sequence homology with the modiﬁed EF-hand of 
the S100/ICaBP proteins (Prosite: PDOC00275) to be recog-
nized by Prosite searches. Furthermore, the kinetics of Ca2+ 
binding to PAD2 indicate that 3 molecules of Ca2+ can bind 
per molecule of PAD [149]. This suggests that PAD enzymes 
contain 3 low-afﬁnity Ca2+ binding domains (40-60 mM 
Ca2+ is required for half-maximal PAD activity). Many Ca2+ 
binding domains consist of 2 helices separated by a loop 
containing negatively charged residues. A few of such ele-
ments can be discerned in the highly conserved C-terminal 
part of PAD. In conclusion, the evidence that the reported 
putative Ca2+ binding region of PAD indeed acts as a genu-
ine Ca2+ binding site is very poor. Experimental data is 
needed to map the actual Ca2+ binding site(s) of PADs.
Two residues, His
475
 and Cys
655
, have been suggested to 
be important for catalytic activity of murine PAD2 (Figure 3: 
blue asterisks above the alignment at positions 512 and 708) 
[242]. This is in agreement with the absolute conservation 
of these residues in all PADs (Figure 3). Interestingly, the 
catalytic sites of bacterial arginine deiminases, Porphy-
romonas gingivalis PAD and bacterial amidinotransferases 
(convert: L-Arg + Gly  L-ornithine + guanidinoacetic 
acid) contain conserved His and Cys residues, separated by 
100-130 amino acids. In these enzymes two Asp residues at 
position –100 and +2 relative to the His are important in 
binding free arginine via their carboxyl groups [232]. The 
+2 Asp residue is also conserved in all PADs (Figure 3: red 
asterisk at position 514). Moreover, four fully conserved 
Asp residues are located between position –170 and –70 
relative to His
475 
(black asterisks at positions 324, 391, 410, 
and 446), which could fulﬁll the binding function of the 
–100 Asp (of the bacterial arginine deiminases).
PAD4 is the only isotype that localizes to the nucleus. Its 
NLS, located near the N-terminus (around position 70 in the 
alignment; shaded in dark blue), was shown to be essential 
and sufﬁcient for nuclear localization; critical amino acids 
are shown in bold [141].
Phylogeny of PAD
From the ClustalW multiple alignment of the complete 
PAD amino acid sequences a phylogenetic tree (Figure 4) 
was constructed using Treeview. The tree conﬁrms that the 
human PAD5 is the human ortholog of murine PAD4. PAD1 
Figure 4. Phylogenetic 
tree of PAD enzymes. 
Phylogenetic tree con-
structed from all available 
full length PAD sequences 
using ClustalX. The PAD1 
and PAD3 enzymes and the 
PAD4 and PAD6 enzymes 
are slightly more closely 
related to each other than 
to the other PADs. Analysis 
of complete and partial 
sequences of non-mamma-
lian PADs (shown in grey are 
PAD from zebraﬁsh (DrPAD), 
clawed frog (XlPAD), and 
chicken (GgPAD)) shows 
strongest conservation with 
PAD2. The bar represents 1 
amino acid substitution per 
10 positions.
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and PAD3 enzymes are more related to each other than to 
the other PADs, as is the case for PAD4 and PAD6.
The chicken enzyme appears to be slightly more related 
to the mammalian PAD2 than to the other isotypes. Phy-
logenetic analysis with parts of the sequence, however, 
showed that only the middle part (position 200-400 in the 
alignment) of the chicken enzyme is most strongly related 
to PAD2, whereas the N-terminal and C-terminal parts are 
more closely related to PAD1/3 and PAD4, respectively 
(data not shown). The chicken enzyme can therefore not 
be isotyped. Based on the available sequence data, it seems 
possible that non-mammalian vertebrates contain only a 
single PAD gene and that these single PAD genes are more 
conserved to each other than to any of the ﬁve mammalian 
Figure 5. Genomic or-
ganization of PAD gene 
clusters. Ideograms of  hu-
man chromosome 1, mouse 
chromosome 4, and rat 
chromosome 5 showing the 
location and orientation 
of the PAD gene clusters. 
Lengths of genes and 
intergene spaces are given 
in kb. PAD2 is oriented in 
the opposite direction as 
the other 4 PAD genes. The 
area of human chromosome 
1 that is homologous to the 
distal part of the shown 
mouse and rat chromosomes 
is indicated. 
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isotypes. All known parts of the ﬁsh and frog sequences are 
most closely related to PAD2. Based on these observations 
and on the fact that PAD2 is the isotype with the broad-
est tissue distribution, it can be speculated that the other 
PAD isotypes arose via gene duplication around the time of 
divergence of mammalian and non-mammalian vertebrates. 
Due to mutations both in promoter region and open read-
ing frame, these isotypes then could have adopted sequence 
variations and more restricted expression patterns.
Genomic organization
By comparing genomic and mRNA sequences using Blat 
searches, the individual exons of all human, rat and mouse 
PADs could be mapped. The exon/intron-boundaries we 
found were in concordance with the exon organization 
reported for rat PAD2 [264] and human PAD1 [135] and 
PAD2 genes [138]. The positions of the exon/exon-bound-
aries in the amino acid sequences are highly conserved in 
all mammalian PADs (indicated in Figure 3). The size of the 
introns and the total gene length (indicated in kb in Fig-
ure 5) are moderately conserved; PAD2 is the largest gene, 
PAD6 the smallest.
The chromosomal localization of the PAD genes was 
determined by combining results from Blat searches with 
the NCBI Mapview utility. Figure 5 shows the position and 
orientation of the genes on chromosomal ideograms. All 
ﬁve mammalian isotypes are located in a single gene clus-
ter. The human PAD gene cluster spans a 334.7 kb region 
on chromosome 1p36.1. In mouse and rat, the PAD gene 
cluster is located on chromosome 4E1 (71.0 cM) and 5q36, 
respectively (Figure 5). These distal parts of mouse chro-
mosome 4, rat chromosome 5 and human chromosome 1p 
are known regions of syntheny (mouse genome informatics 
(MGI 2.9), The Jackson Laboratory, indicated in Figure 5). 
The clusters show the same gene arrangement: the order 
and direction of the genes as well as the relative spacings 
are conserved. 
The high sequence homology within each PAD isotype, 
the conserved exon structure, and the conservation of the 
total gene cluster all indicate that the 5 mammalian PAD 
enzymes are the result of a series of gene duplications that 
occurred before divergence of the mammalian species.
PAD in human disease
PAD enzymes and their products, citrullinated proteins, 
are known to play a role in several human diseases. In this 
review we will discuss the role of PAD in psoriasis, rheu-
matoid arthritis (RA) and multiple sclerosis (MS).
Psoriasis
The word psoriasis is derived from the Greek word psora, 
meaning “itch”. Psoriasis is a chronic skin disease char-
acterized by inﬂamed lesions covered with silvery-white 
scabs of dead skin. In psoriasis, keratinocytes proliferate 
very rapidly and travel from the basal layer to the surface 
in only about four days. This process normally takes about 
a month. The skin can not shed these cells quickly enough 
so they accumulate in thick, dry patches, or plaques. In 
normal keratinocytes, keratin K1 is citrullinated by PAD1 
during terminal differentiation. This process causes the ker-
atin ﬁlaments to become more compact, which is essential 
for the normal corniﬁcation process of the epidermis. The 
keratinocytes in the psoriatic hyperproliferative plaques do 
not contain citrullinated keratin K1 [265]. In this “chicken 
and egg” situation it is not clear whether the increased cell 
proliferation prevents adequate citrullination by PAD or 
that inactivity of PAD allows hyperproliferation and accu-
mulation of keratinocytes. Whether the absence of citrul-
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lination is associated with a defective PAD1, is unknown. 
The ductal epithelium of the sweat glands, in which PAD2 
is expressed, is, however, not affected [245,252,265]. Thus, 
although the mechanism is unknown, aberrant citrullina-
tion in psoriatic epidermis obviously is related to PAD1.
Rheumatoid Arthritis
RA is a common human autoimmune disease with a 
prevalence of about 1%. The disease is characterized by a 
chronic inﬂammation of the synovial joints and inﬁltration 
of blood-derived cells, mainly activated macrophages. Like 
many autoimmune diseases, RA occurs more frequently in 
women than in men (3:1 ratio), suggesting a role for sex 
hormones. Although the etiology of the disease is still 
unknown, several risk factors (genetic and environmental) 
have been identiﬁed [148].
The blood of RA patients contains large numbers of circu-
lating antibodies directed against a variety of autoantigens, 
including the well known rheumatoid factor (reviewed in 
[37]). The most speciﬁc family of RA autoantibodies are the 
antibodies directed against citrullinated proteins (reviewed 
in [40]). These antibodies can be detected in almost 80% of 
RA sera with a speciﬁcity of 99% [35]. Besides being very 
speciﬁc for RA, anti-citrullinated protein antibodies can 
be detected very early in the disease and appear to predict 
clinical disease outcome [29,126,128], making them a very 
useful diagnostic tool for the rheumatologist.
The anti-citrullinated protein antibodies are produced 
locally in the inﬂamed synovium [88-90]. This suggests 
the presence of citrullinated proteins in the RA synovium 
causing an antigen-driven maturation of anti-peptidyl-
citrulline speciﬁc B cells at the site of inﬂammation in RA. 
An example of citrullinated proteins present in inﬂamed 
RA joints is extravascular citrullinated ﬁbrin [144]. In 
inﬂamed RA synovia the oxygen metabolism is in dis-
equilibrium, which leads to sites with oxygen excess (and 
subsequent generation of reactive oxygen species) and 
on the other hand to sites of hypoxia, which can cause 
synovial tissue micro-infarctions. At these sites, plaques of 
extravascular ﬁbrin can be found. The inﬂamed synovium 
also contains many PAD2 expressing macrophages and 
sometimes PAD4 containing granulocytes. Normally, PAD 
enzymes are present intracellularly (either in the cytosol 
or, in the case of PAD4, in the nucleoplasm). However, 
when the cells are dying, e.g. as a result of extensive oxida-
tive stress in the inﬂamed synovium, PAD enzymes might 
leak out of the cells, become activated (the extracellular 
Ca2+ concentration is ~10–3 M, sufﬁcient for PAD activity) 
and induce the citrullination of extracellular proteins, like 
ﬁbrin.
The occurrence of both citrullinated proteins and anti-
bodies against them will lead to the formation of immune 
complexes, which can contribute to the chronicity of the 
joint inﬂammation.
Multiple sclerosis
MS is a chronic inﬂammatory disorder of the CNS, 
characterized by destruction of the myelin sheath. Patho-
logic ﬁndings include multiple sharply demarcated areas 
of demyelination throughout the white matter of the CNS. 
The myelin sheath is formed by a single layer of cells that 
cover the axons of neurons. These cells, oligodendrocytes 
in the CNS and Schwann cells in the peripheral nervous 
system, provide electrical insulation to the neuron, which 
is important for adequate conduction of nerve impulses. 
Demyelination causes loss of nerve signals, which in turn 
results in many different clinical manifestations (e.g. visual 
loss, extra-ocular movement disorders, paresthesias, loss 
of sensation, weakness, dysarthria, spasticity, ataxia, and 
bladder dysfunction).
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The cells of the myelin sheath form a multibilayer 
structure around the axons consisting of lipid-protein 
complexes in a ratio of about 3:1. Two major proteins, MBP 
and lipophilin, account for 85% of the protein fraction. 
MBP is a highly cationic protein, capable of forming strong 
interactions with negatively charged phospholipids such 
as phosphatidylserine [266]. In approximately 18% of the 
MBP molecules of healthy adult humans 6 (out of 19) argi-
nines are citrullinated (MBP-cit
6
: R
25
, R
31
, R
122
, R
130
, R
159
, 
R
169
 [267]) [268]. The remaining MBP molecules do not con-
tain citrulline. In MS patients the proportion of MBP-cit
6
 
is increased to 45% of total MBP [268]. The decreased net 
positive charge of MBP-cit
6
 causes partial unfolding of MBP 
molecules and weakens their interaction with the phospho-
lipids [266,269]. Although MBP-cit
6
 is capable of forming 
lipid complexes more rapidly than non-citrullinated MBP, 
the complexes that are formed are not as densely packed 
as those formed with non-citrullinated MBP [266,270]. In 
children up to the age of 2 years, almost all MBP is of the 
MBP-cit
6
 type [247]. The ability to rapidly form myelin 
structures is important in young children with a develop-
ing nervous system, while good electric insulation of the 
axons is less important, because of the smaller distances 
that have to be bridged. The amount of MBP-cit
6
 drops rap-
idly from almost 100% to 18% between 2 and 4 years of age 
[247]. Interestingly, this is the infant phase associated with 
the greatest motorneuronal development. 
Citrullination of MBP not only alters the lipid-complex 
forming ability of MBP, it also unfolds the structure of 
MBP, making the protein more susceptible to degradation 
by cathepsin D [269]. MBP-cit
6
 is degraded 4 times more 
rapidly by cathepsin D than non-citrullinated MBP [271]. 
In a rare case of acute fulminating MS (Marburg type), 
80% of the MBP molecules are heavily citrullinated (MBP-
cit
18
) [268]. This highly citrullinated form of MBP is not 
capable of forming lipid complexes [266,270]. The severely 
unfolded MBP-cit
18
 is degraded 45 times more rapidly by 
cathepsin D than normal MBP [271].
Transgenic mice bearing high copy numbers of a trans-
gene coding for DM-20 (a myelin proteolipid protein) 
spontaneously develop a pathology with much similarity 
to MS [272]. The amount of citrullinated MBP in these 
mice is increased 2-3 fold compared to control animals 
[273]. The onset of symptoms is preceded by an increase 
in the amount of myelin-associated PAD2 protein [274]. 
Of interest, phosphatidylserine, one of the major lipid 
components of myelin enhances the velocity of the reac-
tion catalyzed by PAD2 and reduces the Ca2+ requirement 
of PAD2 [149]. Currently clinical trials with paclitaxel, 
the active component of the anti-cancer drug taxol, are 
in progress [275]. Low doses of paclitaxel can inhibit 
citrullination of MBP by PAD2 in vitro [276]. Treatment 
with paclitaxel attenuates clinical symptoms and induces 
remyelination of damaged sheaths [277], underlining the 
possible importance of PAD as a candidate factor in demy-
elinating disease [274].
Concluding remarks
In mammals, ﬁve isotypes of PAD exist. The available 
data indicate that non-mammalian vertebrates have only a 
single PAD enzyme. The human PAD previously designated 
PAD5 in fact is a PAD4 enzyme, as indicated by its tissue 
distribution, nuclear localization, sequence conservation 
and genomic organization. We therefore propose to use the 
name human PAD4 for this enzyme. The conservation of 
the mammalian PAD gene cluster indicates that the ﬁve iso-
types have developed through a series of gene duplications 
in a common ancestor.
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All known natural substrates of PAD enzymes (like 
intermediate ﬁlaments or ﬁlament associated proteins) are 
proteins that have an important structural function. As 
illustrated in Figure 2, citrullination may have serious con-
sequences for intra- and intermolecular interactions of the 
target protein. Intracellular calcium levels under normal 
physiological conditions are insufﬁcient for PAD activity. 
This indicates a relation between PAD activity and termi-
nal differentiation or death of cells when control of calcium 
homeostasis is lost [150]. The citrullination of ﬁlaggrin and 
keratin during terminal differentiation of keratinocytes 
and the citrullination of vimentin and histones during 
apoptosis support this idea.
The PAD enzymes and their products are involved in 
several human diseases. Investigating the regulation and 
the catalytic mechanisms of these enzymes will provide 
new insights in the etiology of these diseases and may con-
tribute to the development of PAD inhibiting drugs.
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The blood of rheumatoid arthritis (RA) patients contains 
large numbers of circulating antibodies directed against a 
variety of autoantigens. The most widely known is the rheu-
matoid factor (RF), antibodies directed against the Fc part 
of IgG molecules (reviewed in [37]). RF can be detected in 
roughly 75% of RA patients, but is also present in patients 
with other rheumatic or inﬂammatory diseases and even in 
A
 ntibodies directed to proteins containing the nonstandard amino acid 
citrulline, are extremely speciﬁc for rheumatoid arthritis (RA). Peptidyl-
citrulline can be generated by posttranslational conversion of arginine 
residues. This process, citrullination, is catalyzed by a group of calcium 
dependent peptidylarginine deiminase (PAD) enzymes. In the present study, we 
investigated the expression and activity of four isotypes of PAD in peripheral 
blood and synovial ﬂuid cells of RA patients.
The data presented here show that citrullination of proteins by PAD enzymes 
is a process regulated at three levels: transcription – in peripheral blood PAD2 
and PAD4 mRNAs are expressed predominantly in monocytes; PAD4 mRNA is not 
detectable in macrophages, translation – translation of PAD2 mRNA is subject 
to differentiation-stage speciﬁc regulation by its 3’ UTR, and activation – the 
PAD proteins are only activated when sufﬁcient Ca2+ is available. Such high 
Ca2+ concentrations are normally not present in living cells. These results 
indicate that PAD2 and PAD4 are the PAD isotypes most likely involved in 
the citrullination of synovial proteins in RA. In macrophages, which are very 
abundant in the inﬂamed RA synovium, vimentin is speciﬁcally citrullinated 
after Ca2+ inﬂux. Citrullinated vimentin can, therefore, be considered a 
candidate autoantigen in RA.
a substantial percentage of the healthy (elderly) population 
[38]. Its speciﬁcity for RA is thus limited. 
Autoantibodies directed against citrullinated proteins 
have a much higher speciﬁcity for RA (reviewed in [40]). 
This family of autoantibodies comprises the anti-peri-
nuclear factor (APF) [70], the so-called anti-‘keratin’ anti-
bodies (AKA) [74], anti-ﬁlaggrin antibodies (AFA) [76,77], 
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and anti-cyclic citrullinated peptide (anti-CCP) antibodies 
[85,98]. These autoantibodies all recognize epitopes con-
taining the nonstandard amino acid citrulline; the naming 
of the antibody is simply determined by the method used 
to detect them. With the most sensitive assay (CCP2), anti-
citrullinated protein antibodies can be detected in almost 
80% of RA sera with a speciﬁcity of 98% [35,40,98,104]. 
Besides being very speciﬁc for RA [35,39,98,102], anti-CCP 
antibodies can be detected very early in the disease and can 
predict clinical disease outcome [29,126-128], making them 
a very useful tool for the clinician.
The relative amounts of anti-citrullinated protein anti-
bodies in synovial ﬂuid and in extracts of synovial tissue of 
RA patients is 1.4 and 7.5 fold higher, respectively, than in 
sera of the same patients [88,89]. Furthermore, anti-citrul-
linated protein antibody secreting cells are found in the 
inﬂamed RA synovia [88,90]. These data suggest the pres-
ence of citrullinated proteins in the RA synovium causing 
an antigen-driven maturation of CCP-speciﬁc B cells at the 
site of inﬂammation. Indeed, the presence of citrullinated 
proteins in the RA synovium (e.g. ﬁbrin) has already been 
reported [144].
Because citrulline is a nonstandard amino acid, it is 
not incorporated into proteins during translation. It can, 
however, be generated by posttranslational enzymatic 
deimination (citrullination) of arginine residues [281]. 
This conversion is catalyzed by the enzyme peptidylargi-
nine deiminase (PAD, EC 3.5.3.15). Therefore, when citrul-
linated proteins are present in the inﬂamed RA synovium 
[144] also PAD enzymes must be present. Several isotypes 
of PAD exist, each with a different tissue distribution 
(reviewed in [86]). PAD1 and PAD3 are mainly found in 
epidermis and hair follicles [132-135]. PAD2 is expressed 
in a variety of tissues, including muscle, brain and hemo-
poietic cells [136-138], while the human PAD4 (formerly 
known as PAD5) is found primarily in hemopoietic cells 
[139-141].
The RA synovial membrane contains large numbers of 
activated macrophages [14]; cells that have been described 
to express PAD enzymes and, under certain conditions, to 
contain citrullinated proteins [68,152]. This makes them 
good candidates for the generation of synovial citrullinated 
antigens.
Here we describe the mRNA and protein expression of 
PAD enzymes in monocytes and macrophages, as well as in 
synovial ﬂuid mononuclear cells. Possible mechanisms for 
regulation of PAD expression and activity are discussed.
Results
PAD2 and PAD4 mRNAs are expressed 
in CD14 positive cells
Mononuclear leukocytes are important actors in the 
pathology of RA. We investigated the expression of four 
isotypes of PAD in mononuclear blood cells. Total PBMCs 
were isolated from a healthy individual by Ficoll density 
gradient centrifugation. Subsequently cells were subdivided 
with antibody-coated magnetic beads in T cell (CD3+), B cell 
(CD19+), monocyte (CD14+) and NK cell (CD56+) fractions. 
Total RNA was isolated from the cells and each isotype of 
PAD was ampliﬁed by RT-PCR using PAD isotype-speciﬁc 
primers. Human PAD1 is mainly expressed in epidermis and 
uterus [132,133,135]; PAD3 expression is restricted to hair 
follicles [134]. It is therefore not surprising that PAD1 and 
PAD3 were undetectable in the PBMCs (Figure 1). Human 
PAD2 is expressed in a broad range of tissues, including 
skeletal muscle, uterus, brain, salivary glands and pancreas 
[86]. Human PAD4 is found in hemopoietic cells [86]. PAD2 
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and PAD4 mRNA could both be detected in the PBMCs. 
The vast majority of the expression was found in the CD3–, 
CD19–, CD56–, and CD14+ fractions. PAD2 and PAD4 
mRNA are thus predominantly expressed by CD14 positive 
cells (Figure 1, indicated by white squares).
Differential expression of PAD during mono-
cyte to macrophage differentiation
To investigate the PAD2 and PAD4 expression by CD14+ 
cells in more detail, peripheral blood monocytes were dif-
ferentiated into macrophages. Total PBMCs were isolated 
from the peripheral blood of RA patients and healthy con-
trols by Ficoll density gradient centrifugation. Monocytes 
were isolated by adherence to plastic 6 well culture plates. 
After removal of non-adherent cells, the monocytes were 
differentiated into macrophages in 7 days. PAD mRNA 
expression was evaluated by RT-PCR. Human PAD2 mRNA 
could be detected in equal amounts in monocytes and in 
macrophages (Figure 2). No signiﬁcant up or down regula-
tion was observed during monocyte differentiation. PAD4 
mRNA, however, could only be observed in the monocytes. 
The PAD4 mRNA expression was lost during differentia-
tion (Figure 2). Cells from RA patients and healthy controls 
showed identical expression patterns.
The same cells were also tested for PAD protein expres-
sion. Protein extracts were analyzed by immunoblotting 
using PAD isotype-speciﬁc antibodies. Surprisingly, PAD2 
protein was only present in macrophages. Although PAD2 
mRNA was equally expressed in monocytes and macro-
phages, very little (if any) PAD2 protein could be detected 
in the monocytes (Figure 3). These results indicate that the 
differential expression of PAD2 is regulated at the trans-
lational level. PAD4 protein was detected at similar levels 
in monocytes and macrophages (Figure 3). It appears that, 
although the message for PAD4 is gradually lost during 
the differentiation, the PAD4 protein level remains stable 
during the 7 days of differentiation. Again, cells from RA 
patients and healthy controls showed identical patterns of 
expression.
Differential expression of PAD during 
monocyte infiltration into the joint
The macrophages used in the previous experiments were 
differentiated ex vivo from circulating monocytes. Mono-
cytes that inﬁltrate the synovium during inﬂammation will 
also differentiate into macrophages, albeit in an inﬂamma-
tory environment. The differences between ex vivo and in 
vivo environments could induce subtle differences in the 
resulting phenotype of the macrophages. We therefore 
compared PAD expression in PMBCs and synovial ﬂuid 
mononuclear cells (SFMCs) of RA patients. Mononuclear 
cells were isolated by Ficoll density gradient centrifugation 
from paired PB and SF samples. Total RNA was isolated for 
-actin
PAD1
PAD2
PAD3
PAD4
CD3 CD14 CD19 CD56 control Figure 1. Messenger 
RNA expression of PAD 
isotypes in peripheral 
blood mononuclear cells. 
Total PBMCs from a healthy 
individual were fractionated 
with MACS magnetic beads 
coated with either anti-CD3 
(T cells), anti-CD14 (mono-
cytes), anti-CD19 (B cells), 
or anti-CD56 (NK cells) for 
RNA isolation. Expression of 
PAD was analyzed by RT-PCR. 
PAD1 and PAD3 were not de-
tectable in any of the PBMC 
fractions. For PAD2 and 
PAD4, speciﬁc PCR products 
were produced in all frac-
tions. In the case of CD3, 
CD19, and CD56, the cells 
that did not bind to the 
beads (CD3–, CD19–, CD56–) 
showed higher expression 
than the cells that did bind 
(CD3+, CD19+, CD56+). In 
contrast, the cells that 
were bound by the anti-
CD14 coated beads (CD14+, 
monocytes) showed higher 
PAD2 and PAD4 expression 
compared to the cells that 
did not bind the anti-CD14 
coated beads (CD14–, all but 
the monocytes) as indicated 
by white squares. β-actin 
served as a control for 
mRNA input. Cloned cDNAs 
served as positive PCR con-
trols (no positive control 
included for β-actin), PCR 
without template as nega-
tive control.
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amounts in the PBMC and SFMC fractions (Figure 5B). The 
PAD4 mRNA is thus gradually lost during synovial inﬁltra-
tion and subsequent macrophage differentiation; notwith-
standing that the PAD4 protein levels remain unchanged. 
These results show again that the PAD4 protein that is 
already present in the peripheral blood monocytes is not 
degraded during monocyte inﬁltration and differentiation 
in the synovium.
PAD2 translation is regulated by its 3’ UTR
Although monocytes contained comparable amounts of 
PAD2 mRNA as macrophages or SFMCs, they contained 
little, if any, PAD2 protein. It thus appears that the PAD2 
mRNA is not translated in monocytes and that translation 
is initiated sometime during macrophage differentiation. 
PAD2 is encoded by a 4.5 kb transcript (AB023211) [237,241] 
which contains a very long 3’ UTR (> 2 kb). To investigate 
if this 3’ UTR could be involved in regulation of PAD2 
expression at the translational level, we cloned the PAD2 
3’UTR behind a luciferase reporter gene. Constructs con-
taining ﬁreﬂy luciferase with or without PAD2 3’ UTR were 
Figure 2 (). PAD4 mRNA 
is only expressed in mono-
cytes, not in macrophages. 
RNA expression of PAD2 and 
PAD4 in freshly isolated 
monocytes (mono) from pe-
ripheral blood and in ex vivo 
differentiated macrophages 
(macro) of RA patients (RA1 
– RA3) and healthy controls 
(HC1 – HC3) was analyzed 
by RT-PCR. β-actin served 
as a control for mRNA input, 
α-2-macroglobulin (α-2-m) 
expression was analyzed as 
a control for macrophage 
differentiation. Cloned 
cDNAs served as positive 
PCR controls, (no positive 
control included for β-ac-
tin), PCR without template 
as negative control. 
Figure 3 (). PAD2 
protein is only expressed 
in macrophages. Protein 
expression of PAD2 and 
PAD4 in freshly isolated 
monocytes (mono) from pe-
ripheral blood and in ex vivo 
differentiated macrophages 
(macro) of RA patients (RA1 
– RA3) and healthy controls 
(HC1 – HC3) was analyzed by 
western blotting. Recombi-
nant PAD2 or PAD4 proteins 
are included as controls. 
Molecular weight markers 
(kDa) are indicated on the 
left.
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RT-PCR analysis, protein extracts were prepared for immu-
noblotting analysis. 
PAD2 mRNA could be detected in equal amounts in 
PBMCs and SFMCs (Figure 4) whereas PAD2 protein could 
only be detected in signiﬁcant amounts in the SFMCs (Fig-
ure 4). These patterns of expression are thus identical to the 
patterns observed in ex vivo differentiated cells (Figures 2 
and 3). PAD2 mRNA expression remains unaltered during 
inﬁltration of circulating monocytes into the synovium and 
subsequent differentiation into macrophages. Since PAD2 
protein is only expressed in the cells from the synovial ﬂuid 
it appears that translation of its messenger RNA is initiated 
during macrophage differentiation.
The situation for PAD4 is also identical to the observa-
tions made with the ex vivo differentiated cells (Figures 2 
and 3). PAD4 mRNA could only be detected in the PBMCs 
(Figure 4). PAD4 protein could be detected in similar 
81PAD enz ymes in monoc y te s and mac rophages
transfected into COS-1 cells. A plasmid containing renilla 
luciferase was cotransfected as a transfection control. 
Mean luciferase activity (ratio of ﬁreﬂy versus renilla 
luciferase activity) without PAD2 3’ UTR was set to 100% 
(± 10.3). Addition of the PAD2 3’ UTR caused a 6 fold 
reduction of luciferase activity (16.3% ± 2.0). This and 
the observed expression patterns, indicate that the 3’ UTR 
sequence is important in regulating PAD2 protein expres-
sion at the translational level.
Citrullinated proteins are only generated 
after calcium influx
For detection of citrullinated proteins in protein extracts 
or ﬁxed cells, Senshu and coworkers developed a method in 
which the citrulline side-chain is speciﬁcally modiﬁed into 
an artiﬁcial amino acid side chain that is so bulky, that the 
inﬂuence of ﬂanking amino acids for epitope recognition 
becomes negligible [189-191]. We used these anti-modiﬁed 
citrulline (anti-MC) antibodies to detect citrullinated pro-
teins in freshly isolated monocytes and ex vivo differenti-
ated macrophages. As shown in ﬁgure 6 (lanes indicated 
with 0), no citrullinated proteins could be detected in 
either the monocytes or the macrophages.
It thus appears that the mere presence of PAD enzymes 
in both monocytes (PAD4) and macrophages (PAD2 and 
PAD4) is not sufﬁcient for the citrullination of intracel-
lular proteins. It is, however, known that calcium ions, 
and possibly other factors, are required for activity of the 
PAD enzymes. The threshold Ca2+ concentration for PAD 
activity is approximately 10–5 M (S. Nijenhuis, Nijmegen, 
The Netherlands, personal communication) [149]; the cyto-
solic calcium concentration in normal cells is much lower 
(10–7 M). The cytosolic calcium concentration can be arti-
ﬁcially raised by addition of various agents like ionomycin 
or thapsigargin. Ionomycin is a calcium ionophore which 
facilitates the sustained inﬂux of extracellular calcium. 
Thapsigargin is an inhibitor of the ubiquitous sarco-endo-
plasmic reticulum Ca2+-ATPases (SERCA) causing release of 
calcium from the intracellular Ca2+ stores into the cytosol 
[282]. Monocytes and ex vivo differentiated macrophages 
were therefore treated with 1 µM ionomycin or 1 µM thap-
sigargin in the presence of 2 mM extracellular calcium for 
different periods of time (15 min, 60 min, or overnight).
As expected, proteins are citrullinated upon ionomycin 
treatment (Figure 6). In macrophages (Figure 6B), several 
distinct bands of citrullinated proteins could be detected. 
After overnight (~18 hours) treatment with ionomycin, 
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RA1 RA2 RA3 Figure 4 (). PAD4 
mRNA is only present in 
peripheral blood cells, not 
in synovial ﬂuid mono-
nuclear cells. Mononuclear 
cells were isolated from 
peripheral blood (PB) and 
synovial ﬂuid (SF) samples 
of RA patients. RNA expres-
sion of PAD2 and PAD4 was 
analyzed by RT-PCR. β-actin 
served as a control for 
mRNA input. Cloned cDNAs 
served as positive PCR con-
trols, (no positive control 
included for β-actin), PCR 
without template as nega-
tive control. 
Figure 5 (). PAD2 pro-
tein is only expressed in 
synovial ﬂuid mononuclear 
cells. Protein expression of 
PAD2 and PAD4 in mono-
nuclear cells isolated from 
peripheral blood (PB) and 
synovial ﬂuid (SF) samples 
of RA patients was analyzed 
by western blotting. Re-
combinant PAD2 and PAD4 
proteins are included as 
controls. Molecular weight 
markers (kDa) are indicated 
on the left.
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the intensity of the staining decreased and the bands 
appeared to shift to a lower molecular weight, indicating 
that the citrullinated proteins are degraded. In monocytes 
(Figure 6A), proteins are citrullinated more slowly than in 
macrophages (Figure 6B). Also different proteins appear to 
be citrullinated. No differences could be observed between 
cells from RA patients and healthy controls. Citrullination 
of intracellular proteins was also observed after treatment 
with thapsigargin (data not shown).
Citrullinated proteins can be immunopre-
cipitated by anti-vimentin antibodies
The four bands that are detectable in the macrophages 
after 60 min of ionomycin treatment are in the molecular 
weight range of the intermediate ﬁlament protein vimen-
tin and the observed banding pattern resembles the 
banding pattern observed with anti-vimentin (RV202) 
monoclonal antibodies (data not shown). Speciﬁc citrul-
lination of vimentin during calcium ionophore-induced 
apoptosis in mouse peritoneal macrophages has been 
reported previously [68]. To investigate if indeed vimen-
tin is the citrullinated protein observed after ionomy-
cin treatment, we immunoprecipitated vimentin from 
ionomycin-treated cell extracts. Immunoblots contain-
ing immunoprecipitated vimentin were subsequently 
stained with anti-MC antibodies (Figure 7). No citrul-
linated vimentin could be detected in untreated cells 
(lanes labeled 0). In monocytes (Figure 7A), citrullinated 
vimentin or its degradation products are detectable after 
overnight treatment with ionomycin. In contrast, citrul-
linated vimentin is already detectable in macrophages 
after 15 min of ionomycin treatment (Figure 7B). In the 
macrophages that were treated overnight, only degrada-
tion products of citrullinated vimentin could be detected. 
Analysis of cells from RA patients and healthy controls 
gave identical results.
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Figure 6 (). Citrul-
linated proteins are only 
generated after calcium 
inﬂux. Monocytes (A) and 
macrophages (B) from a 
healthy control (HC) and an 
RA patient (RA) were treat-
ed for 0, 15 min, 60 min, or 
overnight (o/n) with 1 mM 
ionomycin in the presence 
of 2 mM CaCl2. Extracts were 
analyzed for the presence 
of citrullinated proteins 
by western blotting with 
anti-MC antibodies. In vitro 
citrullinated human ﬁbrino-
gen (25 ng) is included as a 
positive control. Molecular 
weight markers (kDa) are 
indicated on the left. 
Figure 7 (). Vimentin 
is speciﬁcally citrullinated 
in calcium stimulated 
macrophages. Immuno-
precipitated vimentin 
from monocytes (A) and 
macrophages (B) from a 
healthy control (HC) and 
an RA patient (RA), treated 
for 0, 15 min, 60 min, or 
overnight (o/n) with 1 mM 
ionomycin in the presence 
of 2 mM CaCl2, was stained 
with anti-MC antibodies. In 
vitro citrullinated human ﬁ-
brinogen (25 ng) is included 
on the western blot as a 
positive control. Molecular 
weight markers (kDa) are 
indicated on the left.
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Discussion
We investigated the expression of four PAD isotypes 
in PBMCs: PAD1 to PAD4. The human PAD4 was previ-
ously known as PAD5 because it showed slightly different 
reaction kinetics towards artiﬁcial substrates compared to 
the rodent PAD4 enzymes [139]. Sequence data, expression 
data, intracellular localization, and the genomic organi-
zation of the PAD genes [86], however, all indicate that 
human PAD5 corresponds to the rodent PAD4 [140,141]. 
Our suggestion to rename the human PAD5 to PAD4 was 
recently approved by the HUGO Gene Nomenclature Com-
mittee [86].
The most noticeable difference between the different 
PAD isotypes is their tissue-speciﬁc expression (reviewed 
in [86]). PAD1 and PAD3 are expressed mainly in epidermis 
and hair follicles [86,132-135]. It is therefore not surprising 
that their respective mRNAs were undetectable in PBMCs. 
Expression of PAD2 and PAD4 has been reported in a vari-
ety of tissues, including hemopoietic cells [86,136-141]. In 
the PMBCs, both PAD2 and PAD4 mRNA were predomi-
nantly expressed in the monocytes (CD14+, CD3–, CD19–, 
CD56– cells).
Differentiation of the monocytes into macrophages (both 
ex and in vivo) has several consequences for PAD expression 
(summarized in Figure 8). The mRNA expression of PAD4 
is lost during differentiation. Nevertheless, the PAD4 pro-
tein levels remain unchanged, indicating that the enzyme 
is stable and not degraded. In contrast, PAD2 mRNA levels 
remain unchanged, while PAD2 protein levels signiﬁcantly 
increase during differentiation. It appears that the trans-
lation of PAD2 mRNA is blocked in the monocytes. This 
apparent discrepancy has previously been described in epi-
dermis: although the PAD2 mRNA was found in epidermis 
[238], PAD2 protein was absent [245]. 
Expression of many proteins is regulated post-transcrip-
tionally by 5’ and 3’ UTR motifs. The 5’ UTR of PAD2 is 
only 64 nts in length, in contrast, the 3’ UTR measures 
2.3 kb. PAD4, in contrast, contains a much shorter 3’UTR 
of 245 nts. By cloning the very long 3’ UTR of PAD2 behind 
a luciferase reporter gene, we showed that the 3’ UTR is 
responsible for inhibition of translation, as luciferase acti-
vity was reduced over 6 fold by the PAD2 3’ UTR. Most, if 
not all, mRNAs regulated by 3’ UTR motifs are subjected 
to regulation during early embryonic development or dur-
ing differentiation (reviewed in [283]). Examples of such 
differentially regulated mRNAs are protamines in devel-
oping sperm cells [284] and 15-lipoxygenase during ery-
throid differentiation [285,286]. A general mechanism for 
post-transcriptional regulation by 3’ motifs is the binding 
of regulatory proteins to speciﬁc differentiation control 
elements in the 3’ UTR region of the mRNA [283]. These 
regulatory proteins interact with the 5’ end of the mRNA 
by forming a loop structure. In this way they prevent the 
binding of initiation factors to the mRNA [287]. Which 
parts of the 3’ UTR of PAD2 and which regulatory proteins 
are involved in the observed cell-stage speciﬁc inhibition of 
translation, is currently under investigation.
Although PAD enzymes were present in monocytes 
(PAD4) and macrophages (PAD2 and PAD4), they appar-
ently were not active, because no citrullinated proteins 
were detectable. The cytosolic and nucleoplasmic Ca2+-con-
centration under normal physiological conditions is much 
too low (approximately 100 fold) for PAD activity [149]. 
Raising the cytosolic and nucleoplasmic calcium concentra-
tion by treatment with either ionomycin or thapsigargin 
induced activation of PAD and subsequent citrullination 
of intracellular proteins. As shown in Figure 6, monocytes 
and macrophages showed different banding patterns of 
citrullinated proteins. PAD activation by treatment with 
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a calcium-ionophore has been described previously for 
mouse macrophages [68], rat keratinocytes [152], and 
human HL-60 granulocytes [141,153]. Elevation of cytosolic 
Ca2+ levels is important for induction of apoptosis [151,288]. 
During apoptosis (or necrosis), the plasma membrane Ca2+ 
pump (PMCA) is cleaved by caspases, so that inﬂuxing cal-
cium can no longer be efﬁciently cleared by PMCA, which 
results in Ca2+ overload [150]. This could explain why 
citrullination in vivo takes place during death or terminal 
differentiation of cells (e.g. citrullination of ﬁlaggrin and 
keratin during terminal differentiation of keratinocytes 
[190,196,206]), when control of calcium homeostasis is lost.
Vimentin is speciﬁcally citrullinated in the macrophages 
after Ca2+ inﬂux. This observation has previously been 
reported for mouse peritoneal macrophages [68], although 
no suggestions were made at that time which PAD isotype 
is responsible for vimentin citrullination. We show here 
that macrophages contain both PAD2 and PAD4, the former 
is located in the cytosol, the latter locates to the nucleus 
[141]. Vimentin is an intermediate ﬁlament protein and thus 
is located in the cytosol. This makes PAD2 the most likely 
candidate for vimentin citrullination. The high cytosolic 
Ca2+ levels in the ionomycin-treated monocytes and mac-
rophages induce cell death [68,151], which leads to nuclear 
fragmentation and subsequent release of PAD4 into the 
cytosol. This may explain why vimentin is citrullinated 
much more slowly in monocytes, which only contain PAD4 
protein (Figure 7). 
After overnight exposure to high cytosolic Ca2+, citrulli-
nated vimentin was shown to be degraded. In healthy cells, 
the vimentin cytoskeleton is a highly dynamic structure, as 
polymerization and depolymerization of the ﬁlaments are 
involved in various biological functions. Under physiologi-
cal conditions, these processes are regulated by reversible 
phosphorylation at speciﬁc sites in the amino terminal head 
domain of the vimentin molecules [205]. In apoptotic cells, 
the network of vimentin ﬁlaments is disrupted; it collapses 
into perinuclear aggregates. Two processes may contribute 
to this collapse. Citrullination of the amino terminal head 
Figure 8. Model for synovial PAD inﬁltration. Many leucocytes inﬁltrate the inﬂamed synovium 
in RA. When monocytes from the peripheral blood enter the synovium, they will differentiate into 
macrophages. This differentiation process has several consequences for PAD expression: the mRNA 
expression of PAD4 is lost during differentiation, but the PAD4 protein levels remain unchanged, in-
dicating that the enzyme is not rapidly degraded. For PAD2, the situation is different: the mRNA lev-
els remain more or less equal, but the mRNA is only translated into PAD2 protein in the macrophages. 
The patterns of PAD expression are identical in RA patients and healthy controls, but because of 
the large numbers of macrophages that can be found in the RA (and not in healthy) synovium, the 
amount of PAD enzyme in the RA synovium will be much higher than in healthy synovium. During 
apoptosis or necrosis of the PAD-containing macrophages, free intracellular Ca2+ levels are increased, 
resulting in activation of the PAD enzymes and citrullination of cellular proteins. In the macrophages, 
vimentin is speciﬁcally citrullinated after increase of cytoplasmic Ca2+. Furthermore, PAD enzymes 
may leak out of necrotic cells, causing the citrullination of extracellular proteins (like ﬁbrin [144]).
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domain by PAD induces disassembly of the vimentin ﬁla-
ments [214]. Furthermore, vimentin is subjected to cleavage 
by caspases early in apoptosis [289-291]. Although no data 
exist on a possible correlation between these two processes 
in this speciﬁc case, in general, citrullination of proteins 
causes protein unfolding, which makes them more suscep-
tible to proteolysis [80,86,92,271].
A schematic representation of the events that may lead 
to the production of citrullinated vimentin in the inﬂamed 
synovium is shown in Figure 8. Monocytes are recruited to 
the inﬂamed synovium by various chemoattractant factors. 
Following inﬁltration of the synovium, monocytes will dif-
ferentiate into macrophages, which causes upregulation of 
PAD2 protein and downregulation of PAD4 mRNA expres-
sion. 
The macrophages that are abundantly present in the RA 
synovial tissue (in RA 80-100% of synovial lining cells 
are macrophage-like cells, compared to 20-30% in nor-
mal synovium [14]) show signs of activation [148]. Short-
term activated macrophages are protected from apoptosis, 
whereas long-term (>24 hours) activated macrophages are 
very prone to cell death [154]. Calcium inﬂux in the dying 
macrophages triggers activation of PAD and subsequent 
citrullination of vimentin. Furthermore, PAD enzymes may 
leak out of dead cells enabling them to citrullinate extracel-
lular proteins, like ﬁbrin [144,156]. The likely presence of 
citrullinated vimentin in the rheumatoid synovium, makes 
it a potential autoantigen in RA. Interestingly, antibodies 
directed to the Sa-antigen (citrullinated vimentin [66,186]) 
are highly speciﬁc for RA and can be detected in about 
50% of RA patients [62].
In conclusion, our data show that citrullination of pro-
teins by PAD enzymes is a process regulated at three levels: 
transcription, translation and activation (by Ca2+ inﬂux). 
Vimentin is speciﬁcally citrullinated by macrophages 
after Ca2+ inﬂux and citrullinated vimentin is a candidate 
autoantigen in RA. PAD2 and PAD4 are the most likely 
candidate PAD isotypes for the citrullination of synovial 
proteins in RA.
Materials and Methods
Patients and controls
Blood samples from patients matching the ACR criteria for RA 
[26] were collected with informed consent from the Department 
of Rheumatology of the University Medical Center St. Radboud 
in Nijmegen. Paired samples of synovial ﬂuid (SF) and periph-
eral blood (PB) from patients matching the ACR criteria for RA 
[26] were collected with informed consent from the Department 
of Rheumatology of the St. Maartenskliniek in Nijmegen. Blood 
samples from healthy individuals were collected from volunteer-
ing blood donors. All blood and synovial ﬂuid samples were pro-
cessed immediately to ensure optimal cell preparations.
Cell isolation, culture and calcium treatment
Heparinized blood (15 ml) was diluted 1:1 with PBS-citrate 
(PBS containing 0.455% Na
3
-citrate) and layered over a 15 ml 
Ficoll cushion. After centrifugation for 20 min at 500 g, the PBMC 
containing interphase was collected and washed two times with 
PBS-citrate. From here on PBMCs were fractionated either by plas-
tic adherence, or with MACS magnetic beads (Miltenyi Biotec). 
For MACS fractionation, beads coated with either anti-CD3, anti-
CD14, anti-CD19 or anti-CD56 antibodies were used according to 
the manufacturer’s instructions. For plastic adherence, PBMCs 
were cultured for 60 min in RPMI-1640 medium (with glutamax-I, 
Dutch modiﬁcation, Gibco BRL) containing 10% pooled human 
serum, 1 mM pyruvate, and 50 µg/ml gentamicin (Gibco BRL) in 
6 well culture plates, allowing monocytes to adhere to the plastic. 
The nonadherent lymphocytes were removed by washing the cul-
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ture plates with PBS, after which the adherent monocytes were 
either harvested directly or allowed to differentiate into mac-
rophages in 7 days. This combined Ficoll centrifugation/plastic 
adherence protocol allow for >90% pure cell preparations [292]. 
Mononuclear cells from synovial ﬂuid were isolated by the same 
procedure. To increase cytosolic Ca2+ concentrations, cells were 
treated with either 1 µM ionomycine (Sigma) or 1 µM thapsigar-
gin (Sigma) in Locke’s solution (150 mM NaCl, 5 mM KCl, 10 mM 
Hepes·KOH pH 7.3, 0.1% glucose) in the presence of 2 mM extra-
cellular calcium for 15 min up to 18 hours.
Reverse transcriptase–polymerase 
chain reaction (RT-PCR)
RNA was isolated from cells using Trizol reagent (Gibco BRL) 
according to the manufacturer’s instructions. Synthesis of cDNA 
from 1 µg of RNA was performed using the Reverse Transcription 
System (Promega) with 500 ng of random primers. The reaction 
mixture was incubated for 10 min at room temperature, fol-
lowed by 90 min at 42°C. After incubation, cDNA samples were 
diluted with distilled water to 100 µl. For RT-PCR 10 µl cDNA 
was added to 40 µl mastermix containing 75 mM Tris·Cl pH 
8.8, 20 mM (NH
4
)
2
SO
4
, 0.01% (v/v) Tween-20, 2 mM MgCl
2
, 0.2 
mM dNTPs, 0.5 µM forward and reverse primer, and 1 U Red 
Hot DNA polymerase (ABGene). PCR was performed using a T3 
thermocycler (Biometra): 2 min 94°C, 25-35 cycles of (30 s, 94°C; 
30 s, 56-60°C; 15-30 s, 72°C), 2 min 72°C. 15 µl PCR product was 
analyzed on a 1.5% agarose gel using the Geldoc (Biorad) system. 
The following primer pairs were used (the size of the amplicon is 
given in parentheses): β-actin (239 bp) 5’-ACTCCATCATGAAGT-
GTGACG-3’ and 5’-CATACTCCTGCTTGCTGATCC-3’; PAD1 
(458 bp) 5’-CCACAGCTGGCTGATG-3’ and 5’-TCTCATTGGAGC-
CATGAG-3’; PAD2 (173 bp) 5’-CATGTCCCAGATGATCCTGC-3’ 
and 5’-CATGGTAGAGCTTCCGCC-3’; PAD3 (314 bp) 5’-CTGT-
GAGGGAAGGCAGG-3’ and 5’-CATGCCTATAGGCCTCACAC-3’; 
PAD4 (377 bp) 5’-GGACTGCGAGGATGATG-3’ and 5’-GCT-
GTCTTGGAACACCAC-3’; α2-macroglobulin (147 bp), 5’-CAG-
CAGCAACCATGTCTTG-3’ and 5’-TGCAAACTCATCCGTCTCG-3’. 
Cloned cDNAs served as positive control.
Antibodies
Rabbit antibodies directed against chemically modiﬁed 
citrulline (anti-MC) were a kind gift of Dr. T. Senshu (Tokyo, 
Japan). Mouse monoclonal antibodies against vimentin (RV202) 
were a kind gift of Dr. F. Ramaekers (Maastricht, The Nether-
lands).
Isotype-speciﬁc antibodies directed against PAD type 2 or 4 
were produced by immunization of rabbits with PAD isotype-
speciﬁc peptides (PAD2: aa 3-8 and aa 516-531; PAD4: aa 210-
225 and aa 517-531) (Eurogentec, Seraing, Belgium).
To afﬁnity purify the anti-PAD antisera, 1 mg of each 2 pep-
tides was conjugated to 8 mg BSA in the presence of 0.05% glu-
taraldehyde. After 1 hour at room temperature the reaction was 
stopped by adding 0.1 volume of 1 M glycine·NaOH pH 7.2. The 
mixture was dialyzed against coupling buffer (0.1 M NaHCO
3
 
pH 8.3, 500 mM NaCl) and then coupled to 0.5 g CNBr-activated 
Sepharose-4B (Amersham-Pharmacia) according to the manu-
facturer’s instructions. The column was equilibrated in wash-
ing buffer (PBS pH 7.4 supplemented with 350 mM NaCl, and 
0.05% Nonidet-P40 (NP-40)) before serum was added. Unbound 
antibodies were removed by extensive washing. Anti-PAD anti-
bodies were eluted with elution buffer (100 mM glycine·HCl 
pH 2.5, 500 mM NaCl, 0.05% NP-40). Collected fractions were 
neutralized with 1 M Tris (~pH 11).
Western blot analysis
Cells were washed with PBS and subsequently scraped in 
ice-cold 50 mM Tris·HCl pH 7.4, 100 mM KCl, 20 mM ethylene 
glycol bis(β-aminoethylether) N,N’-tetraacetic acid (EGTA), 1 
mM dithioerythritol (DTE), 1% NP-40, 0.5 mM phenylmeth-
ylsulfonyl ﬂuoride (PMSF), and Complete protease inhibitor 
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cocktail (Roche). Extracts were soniﬁed 3 times for 15 s with 
a microtip soniﬁer (Branson) at 20% output. For detection of 
PAD enzymes, extracts were centrifuged at 12,000 g for 15 
min. Soluble proteins were separated by SDS-PAGE (10%) and 
transferred to nitrocellulose membranes. For detection of citrul-
linated proteins, extracts were concentrated by acetone precipi-
tation prior to separation by SDS-PAGE (13%) and transferred 
to Hybond-C extra (Amersham) membranes. Blots used to detect 
citrullinated proteins were chemically modiﬁed prior to immu-
nostaining with anti-MC antibodies as described by Senshu et 
al. [189] Blots were blocked in blocking buffer (PBS contain-
ing 5% non-fat dried milk and 0.1% NP-40) for 1 hour at room 
temperature and incubated for 1-3 hours with the antibody of 
interest diluted in blocking buffer. After washing with block-
ing buffer, bound antibodies were detected by incubation with 
HRP-conjugated swine anti-rabbit IgG antibodies (DAKO), fol-
lowed by chemiluminescence. Puriﬁed recombinant His-tagged 
human PAD2 or PAD4 (a gift of S. Nijenhuis, Nijmegen, The 
Netherlands) or in vitro citrullinated human ﬁbrinogen served 
as a positive control.
Immunoprecipitations of citrullinated vimentin
For each immunoprecipitation 85 µl mouse anti-vimentin 
(RV202) was coupled to 20 µl of a 50% suspension of protein G-
agarose beads in IPP
500
 (500 mM NaCl, 10 mM Tris·Cl pH 8.0, 
0.05% NP-40) for 2 hour at room temperature. Beads were 
washed three times with IPP
500
 and once with ice-cold IPP
150
 
(150 mM NaCl, 10 mM Tris·Cl pH 8.0, 0.05% NP-40). Extracts 
of ex vivo differentiated macrophages (prepared as described 
above) were added and the mixture was incubated for 2 hours 
at 4°C. After three washes with IPP
150
, bound proteins were 
eluted with SDS-sample buffer, separated by SDS-PAGE (13%) 
and transferred to Hybond-C extra (Amersham) membranes. 
The blots were stained with anti-MC antibodies to reveal the 
presence of citrullinated vimentin.
UTR reporter study
Human PAD2 cDNA (KIAA0994, AB023211, described in [293]) 
was obtained from Kazusa DNA Research Institute, Japan. The 3’ 
UTR sequence was subcloned by PCR into the XbaI site of the 
pGL3-Promotor Vector (Promega). In 6 well culture plates, 0.4·106 
COS-1 cells were seeded per well and transfected with 1 µg of both 
plasmids, pGL3-Promotor (either with or without PAD2 3’ UTR 
sequence) plasmid DNA and pG5luc reporter vector (Promega), 
using 5 µl Fugene Transfection Reagent (Roche), as described 
by the manufacturer. After 40-48 hours of growth, cells were 
harvested using 500 µl Passive Lysis Buffer (PLB; Promega) and 
the activity of both the ﬁreﬂy luciferase and the control renilla 
luciferase were determined using the Dual Luciferase Reporter 
Assay System (Promega) on a Berthold Lumat LB 9507 Luminom-
eter. In brief, 100 µl of ﬁreﬂy luciferase substrate solution was 
added to 20 µl of cell extract and the luminescence was measured 
to determine the efﬁciency of the interaction. Next, 100 µl of 
renilla luciferase substrate solution (containing a quencher for the 
ﬁreﬂy luciferase activity) was added and again the luminescence 
was determined to monitor the transfection efﬁciency. Results are 
expressed as the ratio of ﬁreﬂy versus renilla luciferase activity 
(mean ± SD).
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Citrullination of synovial 
proteins in murine models 
of rheumatoid arthritis
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Abbreviations:
AFA anti-ﬁlaggrin antibodies
AKA ‘anti-keratin’ antibodies
APC antigen presenting cell
APF antiperinuclear
CCP cyclic citrullinated peptide
CIA collagen type II induced arthritis 
CII collagen type II
ELISA enzyme linked immunosorbent assay
HLA human leukocyte antigen
PAD peptidylarginine deiminase
PMN polymorphonuclear neutrophil
RA rheumatoid arthritis
RF rheumatoid factor
SCW streptococcal cell wall
SF synovial ﬂuid
91C i t r u l l ina ted p rote ins in mur ine mode l s o f  RA
Rheumatoid arthritis (RA) is the most prevalent sys-
temic rheumatic disorder, affecting about 1% of the world 
population. It is characterized by chronic inﬂammation of 
the joints eventually causing irreversible joint damage that 
can lead to severe disability. The inﬂamed joints are inﬁl-
A
 ntibodies directed to citrulline-containing proteins are highly speciﬁc for 
rheumatoid arthritis (RA) and can be detected in up to 80% of RA patients. 
Citrulline is an nonstandard amino acid that can only be incorporated into 
proteins by posttranslational modiﬁcation of arginine by peptidylarginine 
deiminase (PAD) enzymes. We investigated the presence of anti-citrulline 
antibodies, PAD enzymes and citrullinated antigens in an acute and a chronic 
destructive mouse model for arthritis: streptococcal cell wall arthritis and 
collagen-induced arthritis.
In both mouse models, PAD2 mRNA is present in the synovium but not 
translated into PAD2 protein. In contrast, PAD4 mRNA, although absent from 
healthy synovia, is readily transcribed and translated by polymorphonuclear 
neutrophils inﬁltrating the synovial tissue during inﬂammation. As a conse-
quence, several synovial proteins are subjected to citrullination. One of these 
proteins was identiﬁed as ﬁbrin, which has been reported to be citrullinated 
also in the synovia of RA patients. Although the generation of citrullinated 
antigens during synovial inﬂammation in the mice was eminent, no anti-CCP 
antibodies could be detected. In conclusion, the citrullination of synovial 
antigens is an active process during joint inﬂammation both in mouse and 
man, but the induction of autoantibodies directed to these proteins is a more 
speciﬁc phenomenon only detectable in RA patients.
trated by large numbers of activated mononuclear cells that 
contribute to the destruction of articular cartilage.
One of the major features of RA is that many circulat-
ing autoantibodies directed to self-antigens can be found 
in the patient sera, including the well known rheumatoid 
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factor (RF) antibodies (reviewed in [37]). The most speciﬁc 
autoantibody system for RA is the family of autoantibod-
ies directed to citrulline-containing proteins (reviewed in 
[40]), including APF [73], AKA [76], AFA [87], anti-Sa [66] 
and anti-CCP [87,98]. The essential part of the antigenic 
determinant recognized by these antibodies is the unnatu-
ral amino acid citrulline [85,98]. Citrulline can be generated 
by posttranslational modiﬁcation of the guanido group of 
arginine into a ureido group (Figure 1). This modiﬁcation 
is catalyzed by peptidylarginine deiminase (PAD) enzymes, 
of which 4 mammalian isotypes have been described [132]. 
Antibodies to citrullinated proteins can be detected in up 
to 80% of RA patients with more than 98% speciﬁcity 
[35,40].
Many murine models of arthritis exist and two such 
models were studied here. Collagen type II induced arthritis 
(CIA) is a widely used model of arthritis, based on autoreac-
tivity against cartilage collagen type II (CII). Immunization 
of susceptible strains of mice with foreign CII consequently 
leads to cross-reactivity of the T-cell response and an anti-
body mediated immune reaction to homologous CII. After a 
delayed onset (approximately 4 weeks), arthritis will enter 
a chronic stage, characterized by severe cartilage and bone 
erosions [294,295]. Streptococcal cell wall (SCW) arthritis 
can be induced in mice by intra-articular injection of bac-
terial fragments. An acute, macrophage-initiated inﬂam-
mation is induced with severe joint swelling accompanied 
by the release of chemokines leading to rapid inﬁltration 
of predominantly polymorphonuclear neutrophils (PMNs) 
and macrophages into the joint. This acute and local inﬂam-
mation does not lead to a chronic or polyarticular arthritis; 
non-injected joints remain unaffected [296,297].
In animal models RF has only been reported in MRL/lpr 
mice [298] and recently in Interleukin-1 receptor antagonist-
deﬁcient [299] and HLA-DQ8 transgenic CIA mice [300]. No 
reports exist on the presence of antibodies to citrullinated 
proteins or the presence of citrullinated synovial antigens 
in mouse models. This is the ﬁrst report on the synovial 
expression of PAD enzymes and the presence of citrulli-
nated proteins in CIA and SCW-induced arthritis.
Results
Absence of antibodies to citrullinated proteins 
in serum and synovial fluid of mice with 
experimental arthritis and control mice
Autoantibodies to citrullinated proteins are very speciﬁc 
markers for RA and can be detected, by the CCP2 test, in 
up to 80% of all RA patients [35,104]. The antibodies con-
stitute a higher proportion of IgG in SF compared to serum 
(our unpublished results, [66,89]) which is indicative of a 
local antibody production in the inﬂamed synovium. This 
production demands local presence of citrullinated anti-
gens. One such antigen, citrullinated ﬁbrin, is speciﬁcally 
present in actively inﬂamed synovial tissue of RA patients 
[144]. It has been suggested that other proteins might also 
be citrullinated in the inﬂamed synovium [66,88].
Since no reports exist on the presence of antibodies to 
citrullinated proteins in animal models of arthritis, we 
investigated whether these antibodies can be detected in 
the serum and synovial ﬂuid of CIA and SCW mice by two 
methods: the CCP2 test and an in house ELISA with in vitro 
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Figure 1. Citrullination or 
deimination: enzymatic con-
version of peptidylarginine 
to peptidylcitrulline by PAD 
in the presence of Ca2+.
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citrullinated ﬁbrinogen. All serum (n=50) and synovial 
ﬂuid (n=10) samples from arthritis affected CIA and SCW 
mice as well as from control animals (n=20) tested negative, 
suggesting that antibodies to citrullinated proteins are not 
produced during the course of disease in these models of 
experimental arthritis. Serum from CIA affected mice 70 
days post-immunization (n=5) also tested negative.
Expression of PAD enzymes in synovial tissue
Although anti-CCP antibodies could not be detected in 
the examined mouse models, it has been shown that PAD 
enzymes, which catalyze the formation of peptidylcitrulline 
(Figure 1), are expressed in leukocytes [137,301]. The joints 
of the arthritis-affected mice are inﬁltrated by large num-
bers of these cells. We, therefore, investigated the expres-
sion of PAD enzymes in the inﬂamed mouse synovia.
First, the mRNA expression of PAD enzymes was inves-
tigated. The four mammalian PAD enzymes are highly 
conserved. To be able to distinguish between each type of 
PAD mRNA, isotype-speciﬁc PCR primer sets were devel-
oped. Total RNA was isolated from synovial biopsies of CIA 
and SCW mice and each isotype of PAD was ampliﬁed by 
RT-PCR using the isotype-speciﬁc primers. Mouse PAD1 is 
normally only expressed in epidermis and uterus [132,236], 
while PAD3 expression is restricted to hair follicles [133]. 
It is therefore not surprising that mRNAs coding for PAD1 
and PAD3 were undetectable in the mouse synovia (Fig-
ure 2). Mouse PAD2 is expressed in a broad range of tissues, 
including skeletal muscle, uterus, brain, salivary glands, 
and pancreas [236,241]. As shown in Figure 2, PAD2 mRNA 
is readily expressed in the mouse synovial tissue and its 
expression level remains essentially unchanged during the 
inﬂammation process. PAD4 is also expressed in a wide 
variety of tissues, including spleen, pancreas, ovary, and 
granulocytes [132,140,242]. In uninﬂamed mouse synovia, 
however, it was undetectable (Figure 2, lanes 1 and 4). 
Interestingly, mRNA expression of PAD4 was observed in 
the inﬂamed mouse synovia (Figure 2, lanes 2, 3, 5, and 
6) and mRNA expression levels appeared to correlate with 
the degree of inﬂammation (data not shown). These results 
indicate that normally only the mRNA encoding for PAD2 
is present in mouse synovia. After induction of synovial 
inﬂammation, however, large numbers of activated leuko-
cytes enter the joint and PAD4 mRNA expression can be 
detected.
Secondly, the protein expression of the PAD enzymes 
was investigated. Since no mRNA of PAD1 or PAD3 could be 
detected, we focussed on PAD2 and PAD4. Protein extracts 
were prepared from biopsies of synovial tissue and ana-
lyzed by immunoblotting. Furthermore, sections of syno-
vial tissue were analyzed by immunohistochemistry. Using 
the PAD2 isotype-speciﬁc antibodies, PAD2 protein could 
be detected on blot neither in naive nor in inﬂamed mouse 
Figure 2. Messenger RNA 
expression of PAD en-
zymes in mouse synovial 
tissue. Total RNA, isolated 
from synovial biopsies, was 
analyzed by RT-PCR with 
isotype-speciﬁc primers. 
PAD1 and PAD3 mRNAs were 
undetectable. Expression of 
PAD2 mRNA was observed 
in comparable amounts in 
both naive and arthritic 
mice, whereas PAD4 expres-
sion could only be detected 
in arthritis affected mice 
(lane 2, CIA day 35, average 
inﬂammation score 1.4; 
lane 3, CIA day 42, average 
inﬂammation score 1.8; 
lane 5, SCW arthritis day 1, 
average inﬂammation score 
1.5; lane 6, SCW arthritis 
day 2, average inﬂamma-
tion score 1.7). β-actin was 
used as a control for RNA 
input. Cloned cDNAs served 
as positive controls (lane 8). 
As a negative control, 
reverse transcription was 
performed without template 
RNA (lane 7).
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synovia (Figure 3A). Also synovial tissue sections of CIA 
affected (Figure 4A), SCW affected and control mice (data 
not shown) were negative for PAD2 protein. As expected, 
abundant PAD2 staining was observed in the muscle tissue 
adjacent to the synovium (Figure 4B) [241,302]. From these 
experiments we conclude that although the mRNA encod-
ing PAD2 is present, it is not translated into protein neither 
in control mice, nor in CIA or SCW affected mice.
The situation for PAD4 was found to be completely dif-
ferent. Using the PAD4 isotype-speciﬁc antibodies, PAD4 
protein could be detected in inﬂamed (CIA as well as SCW 
arthritis), but not in naive synovial tissue (Figure 3B). The 
amount of PAD4 protein appeared to correlate with the 
degree of inﬂammation (data not shown). To identify which 
cells were expressing PAD4 we proceeded with immu-
nolocalizations on synovial tissue sections. In sections of 
naive control mice, no PAD4 staining could be seen (Figure 
5A) while in inﬂamed synovia a staining of the leukocyte 
inﬁltrate was observed (Figure 5B and E). Serial sections 
stained for monocytes/macrophages (F4/80, Figure 5C and 
F) and PMNs (NIMP/R14, Figure 5D and G) revealed a clear 
colocalization of PAD4 expression with PMNs but not with 
monocytes/macrophages. These results indicate that during 
inﬂammation PAD4 protein is expressed by PMNs inﬁltrat-
ing the mouse synovium.
Presence of citrullinated proteins 
in inflamed synovial tissue
The presence of PAD enzymes not necessarily means 
that citrullinated proteins –the products of these enzymes– 
are also present, since calcium and possibly other factors 
are needed for activation of the enzymes. For detection 
of citrullinated proteins in protein extracts or tissue sec-
tions, Senshu and coworkers developed a method in which 
the citrulline side-chain is speciﬁcally modiﬁed into an 
Figure 4 (). Immunolocalization showing that PAD2 protein 
is absent from the synovial tissue. Sections of mouse synovial 
tissue were stained for PAD2. No PAD2 protein could be detected in 
synovium from mice with CIA (A), naive mice, or mice with SCW ar-
thritis (not shown). Sections of mouse skeletal muscle (B) served 
as positive control. Puriﬁed IgG from pre-immune serum (insets) 
was used as a negative control. Sections were counterstained with 
hematoxylin to reveal tissue morphology. Bars represent 100 µm.
Figure 3 (). Mouse 
PAD4 protein can only be 
detected in tissue extracts 
from inﬂamed synovium. 
Protein extracts from 
mouse synovial tissue were 
analyzed by immunoblot-
ting using isotype-speciﬁc 
anti-PAD antisera. A. Im-
munoblot stained for PAD2. 
No PAD2 protein could be 
observed in either naive 
(lane 3), mice with CIA 
(lane 4), or SCW mice (lane 
5). Puriﬁed recombinant 
PAD2 (lane 1) served as a 
positive control, puriﬁed 
recombinant PAD4 (lane 2) 
as a negative control. B. 
Identical immunoblot 
stained for PAD4. PAD4 pro-
tein expression could only 
be observed in inﬂamed 
synovial tissue (lanes 4 and 
5) and was undetectable in 
naive mice (lane 3). Puriﬁed 
recombinant PAD4 (lane 2) 
served as a positive control, 
puriﬁed recombinant PAD2 
(lane 1) as a negative 
control.
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Figure 5. Immunolocalization of PAD4 in naive and inﬂamed 
synovium. No PAD4 staining was observed in sections of naive 
mouse synovium (A). In contrast, PAD4 could be detected in the 
leukocyte inﬁltrate in mice with CIA (B; day 42, inﬂammation 
score 2) and SCW arthritis (E; day 2, inﬂammation score 2). The 
site of strongest PAD4 expression is indicated by a white ellipse. 
Serial sections stained for monocytes/macrophages (F4/80; C and 
F) and PMNs (NIMP/R14; D and G) indicate a colocalization of 
PAD4 expression with PMNs but not with monocytes/macrophages. 
Puriﬁed IgG from pre-immune serum (insets) was used as a nega-
tive control. Sections were counterstained with hematoxylin (A) or 
methylene green (B-G) to reveal tissue morphology. Bars represent 
100 µm.
Figure 6. Immunolocalization of citrullinated proteins in naive 
and inﬂamed mouse synovium. No citrullinated protein could be 
detected in the synovial tissue of naive mice (A). In the synovial 
tissue of arthritis affected mice, however, citrullinated protein 
could be detected in the leukocyte inﬁltrated areas (B: CIA day 
42, inﬂammation score 2; C: SCW day 2, inﬂammation score 2). 
Serial section stained for ﬁbrin(ogen) revealed a colocalization 
of ﬁbrin(ogen) and citrullinated proteins (E: CIA; F: SCW). No 
ﬁbrin(ogen) could be detected in the synovial tissue of naive 
mice (D); only staining in blood vessels and bone marrow could be 
observed. Citrullinated proteins were detected with anti-modiﬁed 
citrulline antibodies. Non-modiﬁed sections were used as a nega-
tive control for citrulline staining (insets). For ﬁbrin(ogen) stain-
ing, puriﬁed IgG from normal rabbit serum was used as a negative 
control (insets). Sections were counterstained with hematoxylin to 
reveal tissue morphology. Bars represent 100 µm.
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artiﬁcial amino acid side chain that is so bulky, that the 
inﬂuence of ﬂanking amino acids for epitope recognition 
becomes negligible [189-191]. Noncitrullinated proteins 
cannot be modiﬁed by the chemical treatment and are thus 
not recognized by the speciﬁc antibodies. This method has 
been used successfully for the speciﬁc detection of citrul-
linated proteins in various studies (e.g. [68,139,141,144,189-
191,196,206,303]). We used these anti-modiﬁed citrulline 
(anti-MC) antibodies to investigate the presence of citrul-
linated proteins in the mouse synovia. 
Staining of tissue sections revealed that citrullinated 
proteins could be detected in the synovial leukocyte inﬁl-
trate of both CIA and SCW affected mice (Figure 6B and 
C). Synovia of naive control mice were completely negative 
(Figure 6A). In the inﬂamed synovium oxygen metabolism 
is in disequilibrium which leads to sites with oxygen excess 
(and subsequent generation of reactive oxygen species) and 
on the other hand to sites of hypoxia, which can cause 
synovial tissue micro-infarctions. At these sites, plaques 
of extravascular ﬁbrin can be found. Masson-Bessière et al. 
have described that in RA some of this ﬁbrin is citrulli-
nated [144]. To investigate if the citrullinated protein mass 
observed in the sections of inﬂamed mouse synovial tis-
sue could contain ﬁbrin, sequential sections were stained 
for ﬁbrin(ogen). No extravascular ﬁbrin(ogen) could be 
detected in the healthy control synovia (Figure 6D). In the 
arthritis affected synovia, however, large plaques of extra-
vascular ﬁbrin could be observed, which showed –at least 
partly– colocalization with the citrullinated proteins (Fig-
ure 6E-F). These results strongly suggest that extravascular 
ﬁbrin and probably other proteins are citrullinated during 
inﬂammation of the mouse synovium.
For a biochemical analysis of citrullinated proteins, 
biopsies of synovial tissue were grinded to powder in liquid 
nitrogen and extracts from this powder were analyzed by 
Figure 7. Immunoblots of 
synovial tissue extracts, 
revealing the presence 
of citrullinated proteins 
in inﬂamed synovium. A. 
No citrullinated proteins 
were detectable in extracts 
from naive mice (lane 3, 
aqueous extract ; lane 
6, guanidine extract). In 
arthritis affected synovial 
tissue, multiple bands of 
citrullinated proteins are 
stained (lane 4, CIA, aque-
ous extract; lane 5, SCW, 
aqueous extract; lane 7, 
CIA, guanidine extract; lane 
8, SCW, guanidine extract). 
Citrullinated proteins were 
detected with anti-modi-
ﬁed citrulline antibodies. 
Arrows indicate citrullinated 
ﬁbrinolytic fragments that 
react with anti-ﬁbrin(ogen) 
antibodies. In vitro citrul-
linated human ﬁbrinogen 
(25 ng, lane 1) served as a 
positive control. Non citrul-
linated human ﬁbronogen 
(25 ng, lane 2) was included 
as a speciﬁcity control. The 
ﬁbrinogen-subunits (Aα, Bβ and γ) are indicated. The γ-subunit cannot be citrullinated because it 
contains no arginines. B. Identical immunoblot stained for ﬁbrin(ogen). The amount of ﬁbrin(ogen) 
present is strongly elevated in inﬂamed synovial tissue, due to the occurence of plaques of extra-
vascular ﬁbrin. Several ﬁbrinolytic fragments are present in the extracts of inﬂamed synovial tissue. 
Arrows indicate citrullinated ﬁbrinolytic fragments that are recognized by anti-modiﬁed citrulline 
antibodies. A number of these bands can be recognized in the citrulline immunoblot (indicated by 
arrows). Human ﬁbrinogen (citrullinated and non citrullinated, both 25 ng) is included as a positive 
control.
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immunoblotting. Naive mice tested negative, as expected, 
while the extracts of arthritis affected mice contained 
several citrullinated proteins (Figure 7A). Several citrulli-
nated protein bands could be detected in the aqueous, and 
guanidine extracts (compare lanes 4 and 5 with 7 and 8). 
Some bands were also decorated by anti-ﬁbrin(ogen) anti-
bodies of an identical immunoblot (indicated by arrows). 
From these experiments we conclude that citrullination of 
synovial ﬁbrinolytic fragments and also of other synovial 
proteins is induced during the inﬂammatory processes in 
CIA and SCW arthritis models.
Discussion
In both an acute and a chronic mouse model of arthritis, 
PAD2 mRNA is present in the synovium but not translated 
into PAD2 protein. In contrast, PAD4 mRNA although 
absent from naive synovia, is readily transcribed and 
translated in PMNs inﬁltrating the synovial tissue during 
inﬂammation. As a consequence, several synovial proteins 
are subjected to citrullination. One of these proteins was 
identiﬁed as ﬁbrin, which has been reported to be citrulli-
nated also in the synovia of RA patients. Although the gen-
eration of citrullinated antigens during synovial inﬂamma-
tion in the mice was evident, no anti-citrullinated protein 
antibodies could be detected. 
Mouse PAD2 mRNA expression was substantial in both 
naive and arthritis affected mice. The primers used to 
amplify PAD2 are selected on separate exons, so there is no 
risk of possible artifacts by the presence of genomic DNA 
in the RNA isolates. Nevertheless, PAD2 protein could 
not be detected in the synovial tissue, neither by western 
blotting nor by immunohistochemistry. In contrast, PAD2 
protein was abundantly present in the muscle tissue sur-
rounding the synovium. These observations strongly indi-
cate that the synthesis of PAD2 protein in synovial cells 
is strictly regulated at the translational level. We assume 
that additional, as yet unknown, factors are needed for the 
translation of PAD2 mRNA. The exact nature of such fac-
tors is not clear at present but the results presented here 
indicate that PAD2 protein is not involved in the citrul-
lination of synovial proteins in these mouse models of 
arthritis.
In the synovia of naive mice, no PAD4 expression could 
be detected, whereas in the inﬂamed synovium PAD4 was 
found at both the RNA and the protein level. The amount of 
PAD4 present in the synovium was on par with the degree 
of inﬂammation: weak expression in mildly inﬂamed 
synovium, stronger expression in severely inﬂamed 
synovium. The immunolocalizations showed a clear over-
lap of PAD4 expression with PMNs, not with monocytes 
or macrophages. 
Expression of the human homolog of rodent PAD4 has 
been reported in human PMNs [140,141]. This human 
homolog was previously known as PAD5. The human 
enzyme shows slightly different reaction kinetics towards 
artiﬁcial substrates [139]. This is why the human enzyme 
was ﬁrst believed to be a novel PAD, hence its name PAD5. 
Recent data (reviewed in [86]), however, all indicate that 
human PAD5 corresponds to the rodent PAD4 [140,141]. 
Sequence data show that human PAD4/5 is more strongly 
conserved to rodent PAD4 (71% identical aa) than to other 
PAD isotypes (~50% identical aa). Its position within the 
PAD gene cluster (all PADs are encoded on human chromo-
some 1p36, mouse 4E1, rat 5q36) is conserved. Furthermore, 
PAD4/5 contains a conserved NLS motif, which has been 
shown to be required and sufﬁcient for nuclear localization, 
whereas all other PAD isotypes are located in the cytosol 
[141]. Based on these data, our suggestion to rename the 
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human PAD5 to PAD4 was recently approved by the HUGO 
Gene Nomenclature Committee (for details, see [86]).
PAD4 expressed has been observed in human and mouse 
peripheral blood granulocytes ([140,153], our unpublished 
observations) and in HL60-derived granulocytes-like cells 
[139]. In both mouse models inﬁltration of PMNs into the 
synovium is a crucial step in the onset of joint inﬂamma-
tion. These results strongly suggest that the inﬁltrating 
PMNs are responsible for the synovial expression of PAD4 
protein.
For the activation of PAD4 protein Ca2+, and possibly 
other factors, are needed. PAD enzymes are present in the 
cytosol or nucleoplasm [141,252], where the Ca2+ concentra-
tion usually is very low (~10–7 M) and strictly regulated. 
The threshold Ca2+ concentration for PAD activation is 
approximately 10–5 M (our unpublished observations and 
[149]); the cytosolic Ca2+ concentration is thus too low for 
activation of PAD. Several publications have shown that 
PAD enzymes can be activated by stimulation of PAD-con-
taining cells with a calcium ionophore [68,141,152,153]. Also 
in human buccal mucosa cells (which contain the APF-anti-
gen ﬁlaggrin [73]), PAD enzymes are only activated very 
late in the terminal differentiation of the cells [196,207]. By 
that time the integrity of the plasma membrane of the cells 
is compromised, causing inﬂux of Ca2+ from the extracellu-
lar space and subsequent activation of PAD. In the inﬂamed 
synovium many cells undergo apoptosis or necrosis. Espe-
cially PMNs have a very short life span estimated to be 
only a couple of days. When the membrane integrity is lost 
during the death of these cells, Ca2+ can freely enter the 
cell and activate PAD enzymes that are already present. An 
alternative possibility is that PAD enzymes could leak out 
of the dying cells, become activated (the extracellular Ca2+ 
concentration is ~10–3 M) and induce the citrullination of 
extracellular proteins, like ﬁbrin.
Citrullinated proteins could be detected in the leukocyte 
inﬁltrate in the inﬂamed synovium (Figure 6). This area 
contains large numbers of PAD4 positive PMNs, which cor-
roborates the idea that PAD4 is responsible for the citrul-
lination of synovial proteins during inﬂammation.
In the tissue sections of inﬂamed synovial tissue large 
deposits of extravascular ﬁbrin can be seen (Figure 6E-F). 
These ﬁber-like structures can be visualized with antibod-
ies against ﬁbrin(ogen), but are known to contain other 
proteins (like ﬁbronectin and collagen) as well [147,304]. 
These ﬁber-like structures are also intensively decorated 
with anti-MC antibodies, indicating that they contain 
citrullinated proteins. Western blots conﬁrm that ﬁbrin 
is one of these citrullinated proteins (Figure 7), although 
other citrullinated proteins appear to be present as well. 
The identity of these proteins is the subject of our further 
investigations.
Our ﬁnding that extravascular ﬁbrin is citrullinated dur-
ing joint inﬂammation in mouse models of arthritis is very 
interesting, because the presence of citrullinated ﬁbrin has 
also been reported in RA [144]. It therefore appears that the 
generation of citrullinated ﬁbrin in both mouse and human 
is the result of synovial inﬂammation and not a particularly 
RA-speciﬁc phenomenon.
Although citrullinated proteins were present during 
synovial inﬂammation in mice, no antibodies directed to 
them could be detected, neither in the serum nor in the 
synovial ﬂuid. In fact none of the many animal models 
of arthritis tested (including rodent, canine, and primate 
models) appears to be positive for anti-CCP (unpublished 
observations and Chapter 8). There are two likely expla-
nations for this phenomenon.
Time factor – there is a huge difference in the duration of 
the human disease as compared to the mouse models. In the 
SCW model, joint inﬂammation is induced within 24 hours, 
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in the CIA model onset of inﬂammation is a matter of a 
few weeks. The development of RA takes many years, pos-
sibly over a decade. Two independent studies have recently 
shown that former blood donors who later developed RA 
became RF and anti-CCP positive years before appearance 
of the ﬁrst clinical symptoms of RA [30,31]. Anti-CCP pro-
duction and, consequently citrullination as well, are clearly 
very early processes in the development of RA. Neverthe-
less, it could take many months or even years before anti-
CCP autoimmunity develops. The duration of the animal 
models, in the case of the CIA model a maximum of 10 
weeks, may well be too short for the evolution of anti-CCP 
antibodies.
Genetic factors – the role of genetic factors, e.g. HLA 
alleles as a risk factor of RA, have been known for over 
25 years. Especially the HLA-DR4 (HLA-DRB1*0401 and 
*0404) phenotypes are are important in this respect [11]. 
Recent molecular modeling data indicate that peptides con-
taining citrulline, but not arginine, can be bound by *0401 
MHC molecules [305]. This citrulline-speciﬁc interaction 
might be the basis of a citrulline-speciﬁc immune response. 
T cell proliferation assays with HLA-DRB1*0401 transgenic 
mice showed that stimulation with citrullinated peptides, 
not with arginine peptides, induced proliferation and acti-
vation of T cells [306]. These data suggest that the speciﬁc 
structure of HLA-DR4 molecules plays an important role 
in the induction of autoimmunity to citrullinated proteins. 
The mice used in the CIA (DBA-1) and SCW arthritis (C57/
Bl6) models do not have the arthritis-prone alleles. Their 
respective HLA haplotypes, H2(q) and H2(b), are not asso-
ciated with a risk of developing RA. 
These factors together are compatible with the danger-
model hypothesis [168]. An initial small inﬂammation 
caused by an external pathogen can cause the death of 
inﬂammatory cells and consequently induce the citrullina-
tion of synovial proteins. In a certain genetic environment, 
this may lead to presentation of citrullinated peptides by 
APCs and consequently to an activation of T cells. Given the 
right conditions, this initial immune response can snowball 
into a systemic disease that is manifested many years later.
Conclusion
Citrullination of synovial proteins is not a process 
speciﬁc for RA. In both the acute and chronic models of 
arthritis, several synovial proteins, including ﬁbrin, are 
subjected to citrullination during inﬂammation. Although 
these mouse models can be very useful in understand-
ing the arthritic process, they do not exactly mimic RA 
(especially not the SCW model, which is a model of acute 
arthritis). The humoral response that is so characteristic for 
RA is absent in these mice. We conclude that the genera-
tion of citrullinated antigens is an inﬂammation-associated 
process, but that the antibody response to citrullinated 
proteins is highly speciﬁc for RA and possibly involved in 
the perpetuation of the human disease.
Materials & methods
Animals
For CIA, male DBA-1 mice were obtained from Bomhold-
gård, Rye, Denmark. For SCW arthritis, male C57/Bl6 mice were 
obtained from Charles River, Sulzfeld, Germany. The mice were 
housed in ﬁlter top cages, and water and food were provided ad 
libitum. The mice were used at the age of 10-12 weeks.
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Collagen arthritis induction
Mice were immunized at the base of the tail with 100 µg 
bovine type II collagen in complete Freunds adjuvant, enriched 
with Mycobacterium Tuberculosis H37Ra (4 mg/ml). Bovine col-
lagen was isolated as described elsewhere [294]. The mice were 
boostered intraperitoneally with 100 µg collagen diluted in phos-
phate buffered saline (PBS) at day 21. Mice were sacriﬁced, in 
groups of at least 5 animals, at 14, 21, 28, 35 and 42 days post-
immunization.
SCW preparation and induction of SCW arthritis 
Streptococcus pyogenes T12 were cultured overnight in Todd-
Hewitt broth. Cell walls were prepared as described previously 
[307]. The resulting 10,000 g supernatant was used for arthritis 
induction. Unilateral arthritis was induced by intra-articular 
injection of 25 µg SCW in 5 µl PBS into the right knee joint of 
naive mice. As a control, PBS was injected into the left knee joint. 
Mice were sacriﬁced, in groups of at least 5 animals, after 1 or 2 
days.
Assessment of arthritis
Mice were carefully examined and scores for disease activity 
were given as previously described [308,309]. The clinical sever-
ity of arthritis was graded on a scale of 0-2 for each paw, according 
to changes in redness and swelling; 0: no changes; 0.5: signiﬁcant; 
1.0: moderate; 1.5: marked; 2.0 maximal swelling and redness and 
later on ankylosis. After removal of the skin around the knee 
joint, the inﬂammation of the knee joints was rated according to 
the same scoring-system. The total arthritis score was expressed 
as a mean ± SD for all paws and knee joints.
Collection of mouse tissue samples
Following orbita punction to collect blood for serum analysis, 
mice were killed by cervical dislocation. The patella with adja-
cent synovium was immediately dissected. Two biopsies with a 
diameter of 3 mm were punched out using a biopsy punch (Stiefel, 
Wachtersbach, Germany): one from the lateral and one from the 
medial side. The synovium punches were immediately frozen in 
liquid nitrogen and stored at –80°C. For immunohistochemical 
analysis, total knee joints were ﬁxed for 4 days in 4% formalde-
hyde. After decalciﬁcation in 5% formic acid the specimens were 
processed for parafﬁn embedding.
Measurement of antibodies to citrullinated proteins
The presence of antibodies to citrullinated proteins in mouse 
serum and synovial ﬂuid was investigated by two ELISAs: the 
Rapscan RA mk2 kit (CCP2 test; Euro-Diagnostica b.v., Arnhem, 
The Netherlands) and an ELISA with citrullinated ﬁbrinogen. 
The CCP2 test was performed according to the manufacturer’s 
instructions. For the ELISA with citrullinated ﬁbrinogen, human 
ﬁbrinogen (1 mg; Sigma) was citrullinated in vitro with 2 U rabbit 
PAD2 (Sigma) in 0.1 M Tris-HCl pH 7.6, 10 mM CaCl
2
 and 5 mM 
DTE for 2 hours at 37°C. Progression of the citrullination was 
followed by immunoblotting with anti-MC antibodies (described 
below). ELISA was performed as described previously [310]; 
0.5 µg of citrullinated ﬁbrinogen was coated per well. Unmodiﬁed 
ﬁbrinogen was coated as a negative control. Sera from RA patients 
(positive controls) were tested in a 200 fold, mouse serum in a 
10 fold and mouse synovial ﬂuid in a 5 fold dilution.
Antibodies
Rabbit antibodies directed against chemically modiﬁed citrul-
line (anti-MC antibodies) have been described previously [189,190]. 
Monoclonal antibodies NIMP-R14 and F4/80 were obtained from 
Serotec (Kidlington, UK). Antibodies against mouse ﬁbrin(ogen) 
were obtained from DAKO. Isotype-speciﬁc antibodies directed 
against PAD type 2 or 4 were produced by immunization of rab-
bits with PAD isotype-speciﬁc peptides (PAD2: aa 3-8 and aa 
516-531; PAD4: aa 210-225 and aa 517-531) (Eurogentec, Seraing, 
Belgium).
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To afﬁnity purify the anti-PAD antisera, 1 mg of each 2 
peptides was conjugated to 8 mg BSA in the presence of 0.05% 
glutaraldehyde. After 1 hour at room temperature the reaction 
was stopped by adding 0.1 volume of 1 M glycine·NaOH pH 
7.2. The mixture was dialyzed against coupling buffer (0.1 M 
NaHCO
3
 pH 8.3, 500 mM NaCl) and then coupled to 0.5 g CNBr-
activated Separose-4B (Amersham-Pharmacia) according to the 
manufacturer’s instructions. The column was equilibrated in 
washing buffer (PBS pH 7.4 supplemented with 350 mM NaCl, 
and 0.05% NP-40) before serum was added. Unbound antibodies 
were removed by extensive washing. Anti-PAD antibodies were 
eluted with elution buffer (100 mM glycine·Cl pH 2.5, 500 mM 
NaCl, 0.05% NP-40). Collected fractions were neutralized with 1 
M Tris (~pH 11).
Preparation of synovial tissue protein extracts
Frozen synovium biopsies (10 biopsies from 5 mice per time-
point) were ground to a ﬁne powder using a micro-dismembra-
tor II (B. Braun, Melsungen, Germany). Proteins were extracted 
by resuspending the powder in lysis buffer (50 mM Tris·Cl pH 7.4, 
100 mM KCl, 20 mM ethylene glycol bis(β-aminoethylether) N,N’-
tetraacetic acid (EGTA), 1 mM dithioerythritol (DTE), 1% Non-
idet-P40 (NP-40), 0.5 mM phenylmethylsulfonyl ﬂuoride (PMSF)) 
followed by soniﬁcation using a Branson microtip. Insoluble 
material was removed from the aqueous extract by centrifuga-
tion (12,000 g, 15 min) and extracted with guanidine buffer (6 M 
guadinine·HCl, 20 mM EGTA, 10 mM DTE, 0.02% NaN
3
, 1 mM 
PMSF). After precipitation with 4 volumes of acetone, the gua-
nidine extracted proteins were redissolved in SDS sample buffer 
(250 mM Tris pH 6.8, 2% SDS, 5% β-mercaptoethanol).
Western blotting
Proteins were separated on 10% or 13% SDS-polyacrylamide 
gels and transferred onto nitrocellulose membranes by electro-
blotting. Blots used to detect citrullinated proteins were chemi-
cally modiﬁed prior to immunostaining as described by Senshu 
et al. [189]. Blots were blocked in blotting buffer (PBS contain-
ing 4% non-fat dried milk and 0.1% NP-40) for 2 hours at room 
temperature and incubated for 1-3 hours with the antibody of 
interest diluted in blotting buffer. After washing with blotting 
buffer, bound antibodies were detected by incubation with HRP-
conjugated swine anti-rabbit IgG antibodies (DAKO), followed by 
chemiluminiscence.
RNA isolation and reverse transcriptase-
polymerase chain reaction (RT-PCR)
Total RNA was isolated from the powder with 1 ml Trizol 
reagent (Gibco BRL) according to the manufacturer’s instructions. 
Synthesis of cDNA from 1 µg of RNA was performed using the 
Reverse Transcription System (Promega) with 500 ng of random 
primers according to the manufacturer’s instructions. The reaction 
mixture was incubated for 10 min at room temperature, followed 
by 90 min at 42°C. After incubation, cDNA samples were diluted 
with water to 100 µl. For RT-PCR 10 µl cDNA was added to 40 µl 
mastermix containing 75 mM Tris·Cl pH 8.8, 20 mM (NH
4
)
2
SO
4
, 
0.01% (v/v) Tween-20, 2 mM MgCl
2
, 0.2 mM dNTPs, 0.5 µM 
forward and reverse primer, and 1 U Red Hot DNA polymerase 
(ABGene). PCR was performed using a T3 thermocycler (Biometra): 
2 min 94°C, 25-35 cycles of (30 s, 94°C; 30 s, 60°C; 15 s, 72°C), 2 min 
72°C. 15 µl PCR product was analyzed on a 1.5% agarose gel using 
the Geldoc (Biorad) system. The following primer pairs were used 
(the size of the amplicon is given in parentheses): β-actin (239 bp) 
5’-ATTCCATCATGAAGTGTGACG-3’ and 5’-CGTACTCCTGCTT-
GCTGATCC-3’; PAD1 (460 bp) 5’-TGCTAACCATTTGAAG-3’ and 
5’-CTTGTCATTGCGGCCGTGG-3’; PAD2 (173 bp) 5’-CATGTCT-
CAGATGATCCT-3’ and 5’-GCTGGTAGAGCTTCTGCC-3’; PAD3 
(315 bp) 5’-CTGTGCGGACCGGCAGG-3’ and 5’-CACACTTATAG-
GCCTCACAG-3’; PAD4 (373 bp) 5’-ATGGACTTTGAGGATGAC-3’ 
and 5’-TGTCTTGGAACACACGGG-3’. Cloned cDNAs served as 
positive controls.
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Immunolocalization
For the immunolocalization of PAD enzymes, deparafﬁnized 
sections (7 µm) were treated for 15 min with 3% H
2
O
2
 in methanol, 
washed with PBS and incubated for 60 min at room temperature 
with the puriﬁed rabbit anti-PAD2 or anti-PAD4 primary anti-
body. After washing the sections were incubated for 30 min at 
room temperature with biotinylated swine anti-rabbit secondary 
antibody (DAKO E0431) diluted 1:200 in PBS plus 1% BSA. After 
another wash, the samples were incubated for 30 min at room tem-
perature with 4 µg/ml horse radish peroxidase-conjugated strep-
tavidin (DAKO P0397). The sections were developed for 10 min at 
room temperature with 0.5 mg/ml diaminobenzidine in 50 mM 
Tris pH 7.6 and 0.02% H
2
O
2
 and counterstained with either hema-
toxyline or methylene green (to facilitate the detection of nuclear 
staining of PAD4). The sections were embedded in Permount and 
evaluated using a Leica DM-R microscope. Puriﬁed pre-immune 
IgG from the same rabbits was used as a negative control.
PMN’s and mononuclear cells were detected by staining with 
the mAb NIMP-R14 and F4/80, respectively, as described previ-
ously [311,312]. 
Citrullinated proteins were detected as described by Asaga 
and Senshu [191]. Prior to incubation with the primary antibody, 
sections were treated for 3 hours at 37°C in modiﬁcation solution 
consisting of 2 parts solution A (0.025% (w/v) FeCl
3
, 4.6 M H
2
SO
4
, 
3.0 M H
3
PO
4
), 1 part solution B (1% diacetyl monoxime, 0.5% 
antipyrine, 1 M acetic acid) and 1 part H
2
O. Control sections were 
incubated in a mixture of 2 parts solution A and 2 parts H
2
O. 
After extensive washing with PBS, slides were subsequently incu-
bated with 3% H
2
O
2
 in methanol (15 min), with 5% normal swine 
serum (DAKO X0901) and 1% BSA in PBS (30 min). Samples were 
incubated overnight at room temperature with 0.125 µg/ml anti-
modiﬁed citrulline (anti-MC) in PBS plus 1% BSA. After washing 
the sections were incubated for 30 min at room temperature with 
biotinylated swine anti-rabbit secondary antibody (DAKO E0431) 
diluted 1:200 in PBS plus 1% BSA. Finally the slides were incu-
bated for 30 min with Vectastain ABC reagent (Vector Labs) and 
subsequently developed as described above.
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Absence of citrulline-speciﬁc 
autoantibodies in animal 
models of autoimmunity
Arthritis & Rheumatism 2004, 50: 2370-2372
Abbreviations:
CCP cyclic citrullinated peptide
COI cutoff index
HLA human leukocyte antigen
RA rheumatoid arthritis
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Autoantibodies directed to citrullinated proteins (e.g. 
anti-CCP; reviewed in [185]) are highly speciﬁc markers of 
rheumatoid arthritis (RA) and can be detected in approxi-
mately 80% of the RA patients. The antibodies recognize 
proteins containing the nonstandard amino acid citrulline, 
which is the product of posttranslational modiﬁcation of 
arginine residues by peptidylarginine deiminase enzymes 
(PAD, reviewed in [86]).
Presence of citrullinated proteins in the synovium of 
RA patients has been described [144]. One of these citrul-
linated proteins could be identiﬁed as ﬁbrin [144] which is 
efﬁciently recognized by the anti-CCP antibodies. Recently, 
we described the presence of citrullinated proteins (includ-
ing citrullinated ﬁbrin) in the inﬂamed synovium of mice 
with collagen induced arthritis or streptococcal cell wall-
induced arthritis [156]. The occurrence of synovial citrul-
linated proteins is therefore not speciﬁc for RA, rather their 
presence appears to be associated with inﬂammatory pro-
cesses. Although these mice express synovial citrullinated 
proteins they do not produce citrulline-speciﬁc autoanti-
bodies [156]. 
A recent paper in Arthritis and Rheumatism [313] 
described the putative presence of anti-CCP antibod-
ies in MRL-lpr/lpr and (NZW × B6)F
1
-hbcl-2 transgenic 
mice that exhibited defects in regulation of lymphocyte 
apoptosis. MRL-lpr/lpr mice, which do not express the 
Fas antigen, develop an autoimmune syndrome similar to 
human systemic lupus erythematosus [314,315]. The disease 
is characterized by the production of a large spectrum of 
autoantibodies, including anti-DNA and rheumatoid factor 
autoantibodies, and by the development of lymphadenopa-
thy, glomerulonephritis and arthritis. Similarly, (NZW × 
B6)F
1
-hbcl-2 transgenic mice overexpressing human Bcl-2 
in B cells, also develop an autoimmune lupus-like disease 
but do not show signs of arthritis (Merino R. et al., in 
preparation).
In the past, we investigated the presence of anti-CCP 
antibodies in numerous animal models of arthritis. Some 
C
 itrulline-speciﬁc autoantibodies are highly speciﬁc for rheumatoid arthritis 
and have, thus far, not been described in animal models of arthritis. A recent 
report by Lopez-Hoyos et al. [313] describes that such autoantibodies may 
be present in mice with defects in the regulation of lymphocyte apoptosis. 
Our current study describes, however, that these antibodies appeared to be 
also reactive with a non-citrullinated control peptide and are therefore not 
citrulline-speciﬁc. These observations stress the importance of performing the 
proper control experiments when surveying the presence of these antibodies in 
animals.
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animals indeed showed antibody reactivity against the 
citrullinated peptide cfc1-cyc (the CCP1 peptide), but these 
animals also showed reactivity against the non-citrulli-
nated control peptide cf0-cyc (Figure 1; peptides described 
in [98]). The antibodies in these mice are therefore not 
citrulline-speciﬁc, but rather directed against other parts 
of the peptide. To investigate if the antibodies detected in 
the MRL-lpr/lpr and (NZW × B6)F
1
-hbcl-2 transgenic mice 
[313] were indeed citrulline-speciﬁc as was suggested in 
this study, we measured antibody reactivity in these mice 
against the citrullinated cfc1-cyc and the non-citrullinated 
cf0-cyc peptide. Results, expressed as cutoff indexes (COIs; 
cutoff deﬁned as 3 SD above mean of control sera) are 
shown in Figure 1. 
Sera of MRL-lpr/lpr mice reacted both with the citrul-
linated (3.4 [2.3-10.0]; median COI [interquartile range]) 
and the non-citrullinated peptide (5.6 [2.7-10.7]). There 
was a strong correlation between the degree of reactivity 
to both peptides (r = 0.972, P<0.0001), indicating that the 
antibodies are directed to a part of the peptide other than 
the citrulline moiety (lanes 1 X and R). Similar reactivity 
patterns were observed in (NZW × B6)F
1
-hbcl-2 mice (cfc1-
cyc: 2.4 [1.0-3.5]; cf0-cyc: 2.2 [1.6-4.0]). In all the other 
mice studied, no signiﬁcant levels of antibodies to either 
the citrullinated or the non-citrullinated peptide could be 
observed (median < 1.0), despite the presence of active 
autoimmune disease in the MRL/++ and (NZW × NZB)F
1
 
mice. Only rabbits with methylated-BSA induced arthritis 
[316] produced moderate levels of autoantibodies to peptides 
(cfc1-cyc: 1.5 [1.1-1.7]; cf0-cyc: 1.6 [1.2-1.7]; lanes 7 X and 
R). But again, the reactivity was not citrulline-speciﬁc.
We also measured antibody levels to both peptides in 
a selected group of 182 RA patients. Sixty-ﬁve patients 
reacted positive with the citrullinated peptide (cfc1-cyc: 
1.8 [1.3-3.1]), but none of the patients reacted with the 
non-citrullinated peptide (cf0-cyc: 0.5 [0.4-0.6]). Of the 
117 patients that were unreactive with the citrullinated 
peptide, only one was slightly reactive (COI = 1.1) with the 
non-citrullinated peptide. These results are in concordance 
with our initial report on citrulline-speciﬁc autoantibodies 
in RA [85]. At that time, it was shown that substitution 
of the citrulline residue by another amino acid (alanine, 
glutamic acid, glutamine or ornithine) completely abolished 
reactivity with patient serum.
Our data thus show that citrulline-speciﬁc autoantibod-
ies are only present in RA patients and not in animal mod-
els of autoimmune disease. Many known autoantibodies 
are directed against proteins that become modiﬁed during 
cell death and in particular during apoptosis (reviewed 
in [162,213]). When these modiﬁed self proteins are inef-
ﬁciently cleared, they may be presented to the immune sys-
tem and might not be recognized as ‘self’ [167]. In the pres-
ence of sufﬁcient ‘danger signals’ (like in an inﬂammatory 
environment) this can lead to an immune response against 
the modiﬁcation [167,168]. In most cases autoimmune 
patients also have generated autoantibodies to the unmodi-
ﬁed antigen as a result of epitope spreading. In the case of 
citrullination, which is known to occur during terminal 
differentiation or cell death [69], the antibodies are only 
directed to the modiﬁcation. This raises the question what 
mechanisms are underlying this speciﬁcity. Some clues may 
be obtained from recent studies on HLA alleles. Several 
HLA alleles are known to be associated with RA, especially 
HLA-DR4 (HLA-DRB1*0401 and *0404) [11]. Recently it 
was shown that citrullinated peptides were able to bind to 
HLA-DR4 shared epitope much more efﬁciently than non-
citrullinated peptides and, in HLA-DR4 transgenic mice, 
T cells were readily activated by citrullinated antigens, 
but not by unmodiﬁed antigens [159]. Although there is 
no absolute requirement for HLA-DR4 in order to develop 
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anti-CCP antibodies, there is a strong correlation between 
HLA-DR4 status and anti-CCP positivity in RA patients 
[160]. It thus seems likely that the genetic background is an 
important factor in the decision whether citrulline-speciﬁc 
antibodies are made (as in most RA patients) or not (as in 
the mouse models). 
Although the production of cross reactive antibodies to 
citrullinated cfc1-cyc and non-citrullinated cf0-cyc peptide 
in (NZW × B6)F
1
-hbcl-2 Tg and MRL-lpr/lpr mice is clearly 
associated with alterations in the mechanisms that regu-
late B lymphocyte survival in these animals, the nature of 
the antigenic determinant recognized by these antibodies 
is unknown, because the animals produce antibodies to a 
multitude of antigens (modiﬁed or not).
Our results indicate that care should be taken when 
measuring antibodies to citrullinated proteins in animals. 
Reactivity to the non-citrullinated antigen should always 
be measured as an essential control. In fact, this control 
appears to be also essential when using citrullinated pro-
teins (e.g. citrullinated ﬁbrinogen) instead of peptides for 
the detection of anti-citrullinated proteins antibodies in 
RA patients, because circulating antibodies directed to the 
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Figure 1. Serum levels of IgG antibodies to citrullinated pep-
tide cfc1-cyc (black dots, lanes X) and non-citrullinated control 
peptide cf0-cyc (gray dots, lanes R) in various animal models of 
autoimmune disease and RA patients. Values are expressed as 
cutoff indexes (COI; cutoff deﬁned as 3 SD above mean of control 
sera); median values are indicated by a black line. 1. 3 month old 
MRL-lpr/lpr (n = 8, described in [313]); 2. 8 month old MRL/++ (n 
= 11, described in [313]); 3. 7-8 month old (NZW x B6)F1-hbcl-2 Tg 
(n = 7, described in [313]); 4. 7-8 month old (NZW x B6)F1 non-Tg 
(n = 10, described in [313]); 5. 8 month old (NZW x NZB)F1 (n = 23, 
described in [313]); 6. 8 month old B6 hbcl-2 Tg (n = 6, described 
in [313]); 7. Rabbits with methylated BSA induced arthritis (n = 
57; kindly provided by Dr. Janet Dawson, Novartis Pharma, Basel, 
Switzerland; described in [316]); 8. TNFα transgenic mice (n = 
25, kindly provided by Dr. Günther Steiner, University of Vienna, 
Vienna, Austria; described in [317]); 9. Mice with Staphylococcus 
aureus induced arthritis (n = 17; kindly provided by Dr. Margareta 
Verdrengh, University of Göteborg, Göteborg, Sweden; described 
in [318]); 10. Mice with pristane-induced arthritis (n = 23; kindly 
provided by Dr. Westley Reeves, University of Florida, Gainesville, 
FL; described in [319]); 11. Mice with proteoglycan (aggrecan)-
induced arthritis (n = 10; kindly provided by Dr. Alison Finnegan, 
Rush University, Chicago, IL; described in [320]); 12. CCP1-posi-
tive RA patients (n = 65 ; only in RA patients, reactivity to the 
citrullinated peptide was signiﬁcantly higher (paired t test: 
P<0.0001) compared to the non-citrullinated control peptide). 13. 
CCP1-negative RA patients (n = 117).
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non-citrullinated protein may lead to false-positive results. 
This problem is less of a concern when using synthetic 
citrullinated peptides as the antigen, because peptides that 
give false positive results (some peptides are reactive with 
human sera even when citrulline is replaced by arginine, 
our unpublished observations) can be selectively left out. 
The peptides in the CCP assay have been optimized for not 
giving such false-positive results with human sera.
In conclusion, our present study demonstrates that 
autoantibodies to citrullinated antigens are highly speciﬁc 
for human patients with RA and have (thus far) not been 
observed in autoimmune animals. In addition, our results 
indicate that it is crucial to always use the corresponding 
non-citrullinated antigen as a negative control when sur-
veying anti-citrullinated protein antibodies.
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Various pieces of evidence suggest that anti-CCP auto-
antibodies are very important in RA and that they may 
play a role in the pathophysiology of the disease. Much 
of this data is reviewed in Chapter 2, but to freshen up 
the memory a small summary is provided here. The ﬁrst 
piece of evidence for an important role of anti-CCP in RA 
is the high speciﬁcity of the antibodies. Speciﬁcity can be 
looked at from two perspectives: “a highly speciﬁc antibody 
is not present in people with other diseases,” or, perhaps 
more interestingly, “everybody that has the antibody has the 
disease.” For anti-CCP it appears that everybody that has 
the antibody either already has RA or will develop it in the 
future. The latter point of view pushes us on towards the 
second piece of evidence: the antibodies are present early 
in the disease. In fact they are often detectable before the 
ﬁrst clinical symptoms of the disease are noticeable. This 
implicates that the antibodies may be directly involved in 
the process of developing the disease and thus disfavors 
the possibility that the antibodies are an epiphenomenon. 
The third piece of evidence is the fact that the presence 
S
 ince the discovery that the RA-speciﬁc APF and AKA autoantibodies are 
directed to citrulline-containing epitopes, ﬁrst described in 1998, much 
progress has been made in understanding the molecular properties of the 
antibodies, the antigens and PAD enzymes (Figure 1).
Nevertheless, a key question remains as yet unanswered: “Are these antibodies 
active players in the pathogenesis of RA or merely an epiphenomenon.” This 
chapter will try to shed some light on the pathogenic signiﬁcance of anti-CCP 
antibodies.
of anti-CCP antibodies is associated with erosive disease. 
A fourth piece of evidence is the local production of the 
anti-CCP antibodies at the site of inﬂammation. In Chap-
ter 3 we showed that anti-CCP antibodies constitute a 
1.4 fold higher proportion of total IgG in synovial ﬂuid 
Figure 1. The number of 
publications about citrul-
lination in the context of 
rheumatoid arthritis has 
strongly increased over the 
last few years. The National 
Center for Biotechnology 
Information (NCBI) PubMed 
database was searched with 
the following query (citrul-
lin* AND arthritis). Results 
were then ﬁltered manually. 
The number of publications 
in 2004 is estimated by 
extrapolating the number 
of publications in the ﬁrst 
quarter of 2004.
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than in serum, which is consistent with the idea of a local 
production of the antibodies. Furthermore, Masson-Bes-
sière et al. showed that the antibodies constitute a 7.5 fold 
higher proportion of IgG in synovial tissue compared to 
serum [88]. These ﬁndings suggest diffusion of the locally 
produced antibodies from the synovium to the circulation. 
The presence of anti-CCP producing plasma cells in the 
synovium is indicative of an antigen-driven maturation 
of CCP-speciﬁc B cells at the site of inﬂammation in RA 
[88,90]. In agreement with this, the presence of citrul-
linated proteins in the inﬂamed RA synovium has been 
demonstrated. This raises several questions that will be 
addressed ﬁrst.
When does citrullination occur?
Citrullination is the posttranslational conversion of 
arginine residues to citrulline residues by PAD enzymes 
(Chapter 5 describes our current knowledge of these 
enzymes and of the physiological functions of citrullina-
tion). Of the ﬁve PAD isotypes that have been described 
in mammals, PAD2 and PAD4 are most relevant for RA 
because they are expressed in leukocytes which can be 
found in large numbers in the inﬂamed joints. As described 
in Chapter 6, PADs are normally present in the cytosol or 
nucleoplasm as inactive enzymes because the local calcium 
ion concentration is lower than what is required for their 
activation. During cell death, however, the integrity of the 
plasma membrane is lost [150,151], resulting in an inﬂux 
of Ca2+ from the extracellular space (the extracellular 
Ca2+ concentration is ~10–3 M, sufﬁcient for PAD activ-
ity [149]) and subsequent activation of intracellular PAD 
[68,69,141,152,153]. Alternatively or simultaneously, PAD 
enzymes may leak out of the dying cells, become activated 
[149] and catalyze the citrullination of extracellular pro-
teins. 
Which citrullinated proteins are likely 
to be found in the RA synovium?
Many cells in the inﬂamed synovium have fragmented 
DNA, which is generally considered a hallmark of apop-
tosis. Nevertheless, these cells lack an apoptosis-speciﬁc 
morphology and the presence of large numbers of apoptotic 
cells in the inﬂamed synovium is therefore still debated 
[321]. This discrepancy could be explained by the possible 
occurrence of impaired apoptosis. It may be that the apop-
totic process is halted or that apoptotic cells switch to necro-
sis. In both cases, PAD enzymes may become activated by 
raised intracellular calcium levels, as probably is the case 
during the terminal differentiation of keratinocytes [196], 
a process that shows many parallels with halted apoptosis. 
In Chapter 6, we described that vimentin is citrullinated 
in dying human macrophages. Because macrophages are 
very abundant in the RA synovium, it is not surprising that 
citrullinated vimentin is present in the synovium as well. 
Indeed, the Sa antigen, which was identiﬁed as citrullinated 
vimentin in Chapter 4, can be detected in rheumatoid 
synovial tissue [62]. The Sa antigen is speciﬁcally targeted 
by autoantibodies in RA sera (reviewed in [66]).
In the inﬂamed synovium, the oxygen metabolism is 
in disequilibrium. This leads to sites with oxygen excess 
(and the subsequent generation of reactive oxygen spe-
cies) and on the other hand to sites of hypoxia, which can 
cause synovial tissue micro-infarctions [146,147]. At these 
sites, plaques containing extravascular ﬁbrin are com-
monly found. Masson-Bèssiere et al. [144] have shown that 
such deposits contain citrullinated proteins. One of these 
proteins could be identiﬁed as citrullinated ﬁbrin, which 
is efﬁciently recognized by autoantibodies present in RA 
sera.
Although the presence of citrullinated histones in the 
inﬂamed synovium has not (yet) been reported, it is not 
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unlikely that they are present. Citrullination of histones 
has been described ex vivo during calcium-ionophore 
induced apoptosis of granulocytes [141,153]. Large num-
bers of granulocytes are present in the inﬂamed synovium, 
especially in the synovial ﬂuid. Because granulocytes only 
have a lifespan of about three days, they will die in large 
numbers at the site of inﬂammation, which may trigger his-
tone citrullination.
In summary, although many different citrullinated pro-
teins may be present in the RA synovium, three proteins 
can be considered currently as candidate autoantigen in 
RA: citrullinated ﬁbrin, citrullinated vimentin, and citrul-
linated histones.
Is the occurrence of citrullinated proteins in 
the synovium a phenomenon specific to RA?
As postulated in Chapter 3, two possible explanations 
may be considered for the high speciﬁcity of autoantibod-
ies directed to citrullinated antigens for RA. One explana-
tion might be that there is an RA-speciﬁc overexpression 
of citrullinated antigens in the rheumatoid synovium that 
leads to an immune response. Alternatively, the presence 
of citrullinated proteins may be a common phenomenon in 
any inﬂamed (synovial) tissue but RA patients may develop 
an abnormal humoral response to them.
The ﬁrst possibility may be supported by the ﬁnding 
of genetic polymorphisms in the PAD4 gene [143]. Suzuki 
et al. investigated the existence of RA-associated genetic 
polymorphisms in the PAD genes, which -in Chapter 5- 
were shown to be located in a single gene cluster on chro-
mosome 1p36, a region known to contain a susceptibility 
locus for RA [322,323]. Eight of the 17 single nucleotide 
polymorphisms (SNPs) that were identiﬁed in the PAD4 
gene were strongly associated (P<0.001) with RA, whereas 
SNPs in the other PAD genes were not. Because the SNPs 
within the PAD4 gene are in strong linkage disequilibrium, 
they segregate together in distinct haplotypes. The two 
most frequent haplotypes account for more than 85% of all 
individuals. One of these two haplotypes (referred to as the 
susceptible haplotype) was more frequent in Japanese RA 
patients than in controls (case : control ratio = 1.28; vs. 0.87 
for the non-susceptible haplotype).
Although three of the SNPs that were described by 
Suzuki et al. result in amino acid substitutions, possible 
consequences for the function and activity of the PAD4 
enzyme were not analyzed [143]. Based on a comparison 
with other PAD sequences [197] it is, however, unlikely that 
there will be important differences in enzymatic function 
between the enzyme encoded by the susceptible haplo-
type and that encoded by the non-susceptible haplotype. 
Alternatively, the SNPs could inﬂuence mRNA stability 
or maturation (the SNPs most strongly associated with RA 
in this Japanese population were located in introns of the 
PAD4 gene). Suzuki et al. determined mRNA stability in 
vitro and showed that indeed the stability of susceptible 
gene transcripts is higher (approximately 3 fold) than that 
of non-susceptible gene transcripts. In this study, however, 
it was not investigated whether there are differences in 
PAD4 mRNA and proteins levels between individuals with 
the susceptible haplotype versus the non-susceptible haplo-
type. Nevertheless, it was hypothesized that the increased 
stability of the PAD4 mRNA may lead to more PAD4 
enzyme being produced and subsequently to an increased 
production of citrullinated proteins that serve as autoan-
tigens. This hypothesis is supported by the observation 
that RA patients that are homozygous for the susceptible 
haplotype have signiﬁcantly more frequently antibodies to 
citrullinated proteins (87% vs. 67%; P<0.05) compared to 
heterozygous or homozygous non-susceptible RA patients. 
Although the increased presence of citrullinated proteins 
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was not investigated in this study, these data strongly 
suggest that PAD4 SNPs have functional effects in vivo. 
It should be mentioned here, however, that these ﬁndings 
might be speciﬁc for a Japanese population since Barton and 
colleagues [324] could not conﬁrm the association between 
these SNPs and RA in a British population. Nevertheless, 
the existence of polymorphisms in exons and in 5’ and 3’ 
regions of PAD4 has also been reported by Caponi et al. 
[325]. One haplotype was more frequent in European RA 
patients compared to controls (38% vs. 17%, P<0.007) and 
appeared to be associated with the presence of antibodies to 
citrullinated proteins (AKA) in the serum of these patients 
[325].
Some studies dealing with the second explanation for 
the high speciﬁcity of anti-citrullinated protein antibodies 
have recently been published. Masson-Bèssiere et al. [144] 
showed that various citrullinated proteins are present in 
the synovial tissue of RA patients. They could be detected 
in the cytoplasm of various mononuclear cells as well as 
in deposits of extravascular ﬁbrin (as described above). 
Although originally no synovial tissue specimens of non-
RA patients were investigated, a recent follow-up of this 
study showed that citrullinated ﬁbrin may also be pres-
ent in synovial tissue of patients with other forms of joint 
inﬂammation [326]. In addition, data presented in Chap-
ter 3, obtained using several types of anti-citrullinated 
protein antibodies suggest that citrullinated proteins can 
be detected in RA patients, but also in controls (such as 
osteoarthritis and reactive arthritis patients). The presence 
of citrullinated antigens in synovial tissue was not associ-
ated with the presence of anti-CCP autoantibodies in serum 
or synovial ﬂuid. These results thus suggest that the pres-
ence of citrullinated proteins in the synovium is not speciﬁc 
for RA, which is supported by the observations described 
in Chapter 7, where it was shown that also in mouse mod-
els of arthritis, various synovial proteins are citrullinated 
during inﬂammation (summarized in Figure 2). 
Having considered these issues, I will resume the discus-
sion of a possible role of anti-CCP antibodies in the patho-
physiology of RA. As mentioned above, it was recently 
reported that anti-CCP antibodies are present very early in 
the disease, and that their presence predicts future progres-
sion to RA [119]. Importantly, the antibodies can be detected 
in serum many years before the appearance of the ﬁrst 
symptoms of arthritis [30,31]. Although the initial events 
that lead to the immune response against citrullinated pro-
teins are unknown, it can be postulated that in principle 
every trauma or infection that causes death of PAD express-
ing cells may result in citrullination of proteins (explained 
Figure 2. Schematic repre-
sentation of the processes 
that may lead to the citrul-
lination of proteins (left 
panel) and the immune 
response to these proteins 
(right panel).
As discussed in the text, 
PAD-containing inﬂamma-
tory cells inﬁltrate a site of 
inﬂammation. At the onset 
of death of these cells, the 
intracellular calcium con-
centration is raised, thereby 
causing activation of PAD 
enzymes and consequently 
citrullination of proteins. 
This process is not speciﬁc 
for RA. A combination of 
impaired clearance of dy-
ing cells, ‘danger signals’ 
and genetic factors may 
blend into a susceptible 
environment in which the 
presence of citrullinated 
proteins leads to an immune 
response. As the result of 
this RA-speciﬁc immune 
response, the RA-speciﬁc 
anti-CCP antibodies are 
produced.
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above). Only in certain susceptible individuals and only 
under certain conditions [168], the presence of these citrul-
linated proteins will lead to an immune response and to the 
generation of anti-CCP antibodies. Several genetic factors 
may be important in creating the required conditions for 
this response. As mentioned in Chapter 1, genetic factors 
are believed to make a major contribution to the etiology 
of RA [11,12]. Although many susceptibility loci have been 
found [322], well deﬁned functional effects of such RA-
associated genetic factors have only been described very 
recently. The model depicted in Figure 3 shows how several 
independently described genetic risk factors for (severe) 
RA might be functionally linked to either the production 
or the effects of anti-CCP antibodies.
A. SNPs in the gene for PAD4 cause increased 
mRNA stability of the susceptible transcript as described 
above. This might lead to increased levels of PAD4. Ca2+ 
is needed for the enzymatic activity of PAD and because 
normal intracellular Ca2+ levels are much too low (required: 
>10–5 M, intracellular concentration: ~10–7 M), PAD 
enzymes are normally inactive. Only when the control of 
calcium homeostasis is lost (e.g. during cell death or ter-
minal differentiation), the PAD enzymes become activated 
as described above. Increased amounts of PAD may lead to 
increased citrullination of proteins [143]. When dying cells 
or their remnants are not efﬁciently cleared (e.g. due to mas-
sive cell death or defects in the clearing machinery [167]) 
this may lead to exposure of the citrullinated proteins to 
the immune system. Citrullinated proteins may not be 
recognized as ‘self’, because their posttranslational modi-
ﬁcation changes their charge and structure (described in 
Chapter 5). Many known autoantigens become modiﬁed 
during cell death, in particular during apoptosis (reviewed 
in [162]). Although the presence of citrullinated proteins 
is not speciﬁc for the rheumatoid synovium (Chapter 3), 
the presence of increased amounts of citrullinated proteins 
increases the chance of their exposure to the immune sys-
tem.
B. Although arthritic mice (Chapters 7 and 8) and 
patients with non-rheumatoid joint inﬂammation contain 
citrullinated proteins in the affected tissue (Chapter 3), 
they do not produce anti-citrullinated protein antibod-
ies. This suggests that the presence of these antibodies 
in RA patients most likely is the result of an abnormal, 
though speciﬁc humoral response to citrullinated pro-
Figure 3. Possible links between RA speciﬁc anti-CCP antibodies and RA-associated genetic fac-
tors. A. SNPs in the PAD4 gene may lead to elevated PAD4 expression and, upon cell death, increased 
citrullination of proteins [143]. B. RA associated HLA-DR4 molecules can bind and present citrul-
linated peptides much more efﬁciently than non-citrullinated peptides [159]. C. IL-10 promotor SNPs 
are associated with increased anti-CCP antibody production and severity of the disease [174]. D. 
Various cytokine polymorphisms are associated with RA and may lead to stronger effects of immune 
complex activated cells. Abbreviations: mϕ = macrophage; PMN = polymorphonuclear granulocytes; 
DC = dendritic cell; DR4 = HLA-DR4 molecule; Abs = antibodies; IC = immune complex; Fcγ = Fc 
gamma receptor.
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teins. The anti-citrullinated protein antibody subclass 
distribution (predominantly IgG1 [157,185]) is indicative 
of T cell dependent antibody production and thus sug-
gests HLA involvement [158]. The genetic predisposition 
for RA by certain HLA haplotypes, e.g. HLA-DR4 (HLA-
DRB1*0401 and *0404) is known for over 25 years [11]. 
Recently, it has been shown that citrullinated peptides 
can be bound much more efﬁciently by DR4 molecules 
than the corresponding non-citrullinated peptides [159]. 
This citrulline-dependent interaction might be the basis 
of a citrulline-speciﬁc immune response. In experiments 
with HLA-DR4 transgenic mice, proliferation and activa-
tion of T cells could be induced by citrullinated peptides, 
but not by the corresponding arginine-containing pep-
tides [159]. It is known that there is a strong correlation 
between HLA-DR4 status and anti-CCP positivity in RA 
patients [160]. There is not an absolute requirement for 
HLA-DR4 in order to develop anti-CCP antibodies, but 
this may be attributed to the possibility that other HLA 
genes (e.g. DQ) may have a similar preference for cer-
tain citrullinated peptides [327,328]. It thus appears that 
genetic factors like HLA-DR4 are involved in the process 
of anti-citrullinated protein antibody generation.
C. The presence of anti-CCP antibodies predicts a 
more severe disease outcome (discussed in Chapter 2). 
A speciﬁc SNP in the IL-10 promoter (–2849 (AG/GG)) 
is associated with high IL-10 production [174]. IL-10 is a 
pleiotropic cytokine with many anti-inﬂammatory func-
tions, but it can also stimulate inﬂammation by enhanc-
ing B cell proliferation, differentiation and antibody pro-
duction. Anti-CCP positive RA patients with the “high 
IL-10 haplotype” have signiﬁcantly higher anti-CCP 
titers and more severe erosions than anti-CCP positive 
patients with a “low IL-10 haplotype” [174]. The anti-
CCP antibodies that are locally produced in the inﬂamed 
synovium [88] will form immune complexes with locally 
produced citrullinated proteins. Higher titers of the 
anti-CCP antibodies allow the formation of more immune 
complexes, which can be bound by inﬂammatory cells 
via their Fcγ-receptors. This will activate these cells and 
cause the release of extra pro-inﬂammatory cytokines.
D. Various polymorphisms in pro-inﬂammatory 
cytokines and their receptors ([9,329,330] and refer-
ences therein) are thought to be associated with RA. 
These genetic factors cause the release of larger amounts 
of cytokines upon stimulation or cause cells to be more 
sensitive towards these cytokines. The cytokines are the 
motor of the inﬂammation, causing inﬂux and activation 
of more inﬂammatory cells. These cells will eventually 
die, allowing their PAD enzymes to become activated by 
inﬂux of Ca2+. With this the cycle is complete and will 
continue if not stopped. Ultimately, this will lead to the 
chronic inﬂammatory disease we call RA.
In addition to these genetic factors, other factors asso-
ciated with other susceptibility loci might be involved, 
although their precise nature needs to be clariﬁed in 
order to understand their possible role in the triggering 
or progression of RA.
Now it is time to come back one ﬁnal time to the 
discussion of the possible role of anti-CCP antibodies in 
the pathophysiology of RA. The model that is proposed 
here (Figure 3 and Chapter 2) is based on a combination 
of evidence provided in this thesis and in a variety of 
independent studies. The initial trauma or infection that 
causes death of PAD expressing cells, citrullination of 
proteins and their exposure to the immune system can 
be considered a spark (Figure 4). This spark will only 
have consequences for its environment, when the sur-
rounding weed is dry enough to catch ﬁre. In the case 
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of RA, the dryness of the weed is determined by various 
genetic and by environmental factors, such as the pres-
ence of danger signals, hormonal levels, etc. After this 
initial spark, some unnoticed symptoms may smoulder 
for years until a gust of wind stirs up the inﬂammations 
and the ﬁrst clinical symptoms of this autoimmune dis-
ease appear. The cause of this acceleration may be a sec-
ond small trauma that causes citrullination of proteins. 
But because at this stage anti-CCP antibodies are present, 
Figure 4. Cartoon showing 
how citrullination could be 
the spark that ignites the 
ﬁre in RA. An unknown trau-
ma or infection that causes 
death of PAD-containing 
cells and thereby citrul-
lination of proteins could 
be considered to be a spark. 
Under certain conditions 
(susceptible individual, 
presence of danger signals, 
etc.), this spark may lead 
to an immune response and 
the generation of anti-CCP 
antibodies. Some unnoticed 
symptoms may smoulder for 
years until the development 
of this autoimmune disease 
is accelerated by a gust 
of wind (a second inﬂam-
mation or trauma). The 
anti-CCP antibodies, which 
are present at this stage, 
may cause the formation 
of immunostimulatory im-
mune complexes that may 
cause the inﬂammations to 
persist. Ultimately, this will 
lead to the chronic inﬂam-
matory autoimmune disease 
we call RA. Only when the 
symptoms become more 
severe (above a certain 
personal disease threshold) 
an individual will decide to 
visit a physician. Even then 
it may take several months 
before a deﬁnite diagnosis 
of RA can be made. Because 
of their early presence in 
the development of RA, 
anti-CCP antibodies may 
help to reduce this gap.
they may add to the perpetuation of the joint inﬂamma-
tion by forming immunostimulatory immune complexes 
in the inﬂamed synovium. In such a scheme, anti-CCP 
antibodies contribute to the chronicity and severity of 
RA. Future studies will undoubtedly provide a better 
insight in the role of anti-CCP antibodies in the etiology 
of this enigmatic disease.
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Summary
Antibodies directed to proteins containing the amino 
acid citrulline (e.g. anti-CCP), are extremely speciﬁc for 
rheumatoid arthritis (RA). Since citrulline is a nonstandard 
amino acid, it is not incorporated into proteins during trans-
lation. It can, however, be generated by posttranslational 
deimination of arginine residues. This process, citrullina-
tion, is catalyzed by a group of calcium-dependent pepti-
dylarginine deiminase (PAD) enzymes.
The goals of the research described in this thesis were 
to investigate the presence and nature of citrullinated auto-
antigens in the synovium and to study the expression and 
regulation of relevant PAD enzymes.
Chapter 1, the general introduction to this thesis, pro-
vides some background information about RA. It also dis-
cusses RA in a historical context.
Chapter 2 provides an elaborate review of literature on 
anti-citrullinated protein antibodies. The clinical utility of 
these antibodies as diagnostic and prognostic markers in 
RA is discussed. Furthermore, it is hypothesized that the 
anti-CCP antibodies contribute to the perpetuation and 
severity of the disease by forming immunostimulatory 
immune complexes in the inﬂamed synovium. 
In Chapter 3, the presence of citrullinated autoantigens 
in the rheumatoid synovium is investigated by immunohis-
tochemistry. Citrullinated proteins are detectable not only 
in the RA synovium, but also in synovial tissue of patients 
with other arthropathies. The local presence of these anti-
gens at the site of inﬂammation is thus not speciﬁc for RA. 
The exclusive production of the anti-citrullinated protein 
autoantibodies in RA is, therefore, the result of an abnor-
mal RA-speciﬁc humoral response.
In Chapter 4, the nature of the Sa autoantigen is inves-
tigated. This antigen, which is speciﬁcally recognized by 
autoantibodies from sera of RA patients, can be detected 
in rheumatoid synovial tissue, spleen and placenta. Pep-
tide sequences, that were obtained from highly puriﬁed Sa 
antigen, were unique to the intermediate ﬁlament protein 
vimentin. Recombinant vimentin was, however, not recog-
nized by anti-Sa reference sera. Vimentin is known to be 
subjected to various posttranslational modiﬁcations in vivo, 
including citrullination. Therefore, it was investigated if 
these citrulline residues were present in the Sa antigen and 
if their presence is essential for autoantigenicity. Our data 
show that the Sa antigen indeed is citrullinated vimentin 
and that the presence of citrulline residues is essential for 
the autoantigenicity of vimentin. Anti-Sa antibodies thus 
belong to the family of anti-citrullinated protein/peptide 
antibodies.
In Chapter 5 the ins and outs of PAD enzymes are dis-
cussed. At that time, four human isotypes of PAD enzymes, 
which differ mainly in their tissue distribution, had been 
described. Database analysis revealed the existence of a 
ﬁfth human PAD enzyme as well as the existence of PAD 
enzymes in non-mammalian species. Further bioinformatic 
analyses showed that all ﬁve mammalian PAD genes are 
encoded in a conserved gene cluster and are probably the 
result of a series of gene duplications in a common ancestor. 
The consequences of citrullination (in particular unfolding 
of substrate proteins), the normal physiological functions 
of citrullination, and the involvement of PAD enzymes in 
human disease (RA, multiple sclerosis and psoriasis) are 
also discussed. Based on the data provided in this chapter, 
it can be concluded that PAD2 and PAD4 are the isotypes 
that are most important for RA.
In Chapter 6 the expression of these two isotypes of PAD 
in human monocytes and macrophages is described. During 
monocyte to macrophage differentiation, an upregulation of 
PAD2 expression at the protein level was observed although 
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the PAD2 mRNA levels remained unchanged. In contrast, 
the levels of PAD4 protein remained unchanged during 
differentiation, despite a downregulation of PAD4 mRNA. 
Notwithstanding the presence of PAD enzymes, citrulli-
nated proteins were not detectable, which was most likely 
due to the fact that these enzymes are normally inactive 
in a low calcium environment. Indeed, various proteins 
became citrullinated upon activation of the enzyme(s) by 
raising the intracellular calcium concentration. The data 
presented in this chapter thus show that citrullination 
of proteins by PAD enzymes may be regulated at three 
levels: transcription, translation and activation. The most 
prominent citrullinated protein in macrophages was iden-
tiﬁed as citrullinated vimentin, which in Chapter 4 was 
shown to be the Sa antigen. Citrullinated vimentin can 
therefore be considered a candidate autoantigen in RA.
In Chapter 7 the expression of PAD enzymes and 
the presence of citrullinated proteins in the inﬂamed 
synovium of mice with experimental arthritis is 
described. Two mouse models were investigated: a model 
of chronic joint inﬂammation (collagen induced arthritis), 
and a model of acute joint inﬂammation (streptococcal 
cell wall induced arthritis). PAD4, although absent from 
naive synovia, is expressed by granulocytes inﬁltrating 
the synovial tissue during inﬂammation in both mouse 
models. As a consequence, several synovial proteins are 
citrullinatated, including ﬁbrin, which has been reported 
to be citrullinated also in the synovium of RA patients. 
Although the generation of citrullinated antigens during 
synovial inﬂammation in the mice was eminent, no anti-
citrullinated protein antibodies could be detected. These 
results support the observations reported in Chapter 3 
and it can be concluded that the citrullination of synovial 
antigens is an active process during joint inﬂammation 
both in mouse and man, but that the induction of auto-
antibodies directed to these proteins is a more speciﬁc 
phenomenon only occurring in RA patients.
In Chapter 8, the absence of citrulline-speciﬁc auto-
antibodies in mice with defects in the regulation of 
lymphocyte apoptosis is described. These mice contain 
a spectrum of autoantibodies, including anti-DNA and 
rheumatoid factor, and in a recent publication they were 
reported to contain anti-CCP antibodies as well. However, 
these antibodies appeared to be also reactive with a non-
citrullinated control peptide and are therefore not citrul-
line-speciﬁc. These observations stress the importance of 
performing the proper control experiments when survey-
ing the presence of these antibodies in animals.
Finally, the insights, generated by the studies described 
in this thesis, into the possible role of anti-citrullinated 
protein autoantibodies and citrullinated autoantigens in 
RA are discussed in Chapter 9. In principle every trauma 
or infection that causes death of PAD expressing cells 
could be sufﬁcient to initiate citrullination of proteins. 
Only in a susceptible individual will the presence of these 
citrullinated proteins lead to an immune response and to 
the generation of anti-CCP antibodies. After these initial 
events, some unnoticed symptoms may be smouldering 
for years until they become more severe and appear as 
the ﬁrst clinical symptoms of this autoimmune disease. 
Citrullination may therefore be considered as the spark 
that ignites the ﬁre in RA.
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Samenvatting
Autoantilichamen gericht tegen eiwitten die het amino-
zuur citrulline bevatten (zoals anti-CCP) zijn uiterst spe-
ciﬁek voor reumatoïde artritis (RA). Aangezien citrulline 
geen standaard aminozuur is, wordt het niet in eiwitten 
ingebouwd tijdens translatie. Het kan echter door post-
translationale deïminering van arginine residuen worden 
gegenereerd. Dit proces, citrullinering, wordt gekatalyseerd 
door een groep van calcium-afhankelijke peptidylarginine 
deiminase (PAD) enzymen. 
De doelstellingen van het onderzoek, dat in dit proef-
schrift wordt beschreven, waren: het onderzoeken van de 
aanwezigheid en de aard van gecitrullineerde autoantige-
nen in het synovium en het bestuderen van de expressie en 
regulatie van relevante PAD enzymen.
In Hoofdstuk 1, de algemene inleiding van dit proef-
schrift, wordt de nodige achtergrondinformatie over RA 
verstrekt. Ook wordt RA in een historische context bespro-
ken.
In Hoofdstuk 2 wordt een gedetailleerd overzicht van 
de literatuur over antilichamen tegen gecitrullineerde 
eiwitten gegeven. De klinische toepasbaarheid van deze 
antilichamen als speciﬁeke en voorspellende markers voor 
RA wordt besproken. Voorts wordt er aandacht besteed aan 
de vraag hoe de anti-CCP antilichamen kunnen bijdragen 
aan het chronische karakter van de ontstekingen en aan de 
ernst van de ziekte. De vorming van immuuncomplexen in 
het synovium die het immuunsysteem activeren kan hierbij 
een rol spelen.
In Hoofdstuk 3 wordt de aanwezigheid van gecitrulli-
neerde autoantigenen in het synovium onderzocht middels 
immuunhistochemie. De gecitrullineerde eiwitten blijken 
niet alleen aantoonbaar te zijn in het synovium van RA 
patiënten, maar ook in synoviaal weefsel van patiënten met 
andere vormen van gewrichtsontsteking. De aanwezigheid 
van gecitrullineerde eiwitten op de plaats van de ontstekin-
gen is dus  niet speciﬁek voor RA. De exclusieve productie 
van de antilichamen tegen deze eiwitten in RA is klaarblij-
kelijk het gevolg van een RA-speciﬁeke humorale respons.
In Hoofdstuk 4 wordt de aard van het Sa autoantigeen 
onderzocht. De aanwezigheid van dit antigeen, dat speci-
ﬁek door autoantilichamen in sera van RA patiënten wordt 
herkend, is aangetoond in het ontstoken RA synovium, milt 
en placenta. Peptide sequenties die werden verkregen uit 
gezuiverde Sa preparaten, bleken uniek voor te komen in 
het intermediaire ﬁlament eiwit vimentine. Recombinant 
vimentine wordt echter niet herkend door anti-Sa referen-
tie sera. Het is bekend dat vimentine in vivo aan diverse 
posttranslationale modiﬁcaties (waaronder citrullinering) 
onderworpen wordt. Daarom werd onderzocht of het Sa 
antigeen citrulline residuen bevat en of de aanwezigheid 
daarvan noodzakelijk is voor de autoantigeniciteit. Onze 
resultaten laten zien dat het Sa antigeen inderdaad gecitrul-
lineerd vimentine is en dat de aanwezigheid van citrulline 
residuen essentieel is voor de autoantigeniciteit van vimen-
tine. Anti-Sa antilichamen behoren daarom tot de familie 
van anti-gecitrullineerd eiwit/peptide antilichamen.
In Hoofdstuk 5 worden de ins en outs van de PAD 
enzymen besproken. Tot dusverre waren vier menselijke 
isotypen van PAD enzymen, die hoofdzakelijk in hun weef-
seldistributie verschillen, beschreven. Databank gegevens 
toonden echter aan dat er een vijfde menselijk PAD enzym 
bestaat, evenals diverse PAD enzymen in niet-zoogdieren. 
Via bioinformatische analyses werd eveneens aangetoond 
dat de vijf PAD genen in zoogdieren in een evolutionair 
geconserveerd gencluster zijn gecodeerd en dus logischer-
wijs het resultaat zijn van een reeks genduplicaties in een 
gemeenschappelijke voorouder. De gevolgen van citrulline-
ring (in het bijzonder het ontvouwen van substraateiwit-
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ten), de normale fysiologische functies van citrullinering, 
en de betrokkenheid van de PAD enzymen bij verschillende 
humane ziektes (RA, multiple sclerose en psoriasis) worden 
ook bediscussieerd. Gebaseerd op de gegevens die in dit 
hoofdstuk worden behandeld, kan worden geconcludeerd 
dat PAD2 en PAD4 de belangrijkste PAD isotypen voor RA 
zijn.
Hoofdstuk 6 beschrijft de expressie van deze twee PAD 
isotypen in humane monocyten en macrofagen. Tijdens 
differentiatie van monocyt naar macrofaag, werd er een 
toename van de PAD2 expressie op eiwit niveau waarge-
nomen, terwijl de hoeveelheid PAD2 mRNA gelijk bleef. 
De hoeveelheid PAD4 eiwit bleef onveranderd tijdens dif-
ferentiatie, ondanks een sterke afname in de hoeveelheid 
PAD4 mRNA. Ondanks de aanwezigheid van PAD enzy-
men waren gecitrullineerde eiwitten niet aantoonbaar, 
wat hoogstwaarschijnlijk een gevolg is van het feit dat 
deze enzymen in een laag calcium milieu niet actief zijn. 
Na activering van de PAD enzymen door het verhogen van 
de intracellulaire calcium concentratie werden inderdaad 
verschillende eiwitten gecitrullineerd. De gegevens die in 
dit hoofdstuk worden gepresenteerd laten zien dat citrulli-
nering van eiwitten door PAD enzymen een proces is dat op 
drie niveaus wordt gereguleerd: transcriptie, translatie en 
activering. Het meest prominente gecitrullineerde eiwit in 
macrofagen werd geïdentiﬁceerd als gecitrullineerd vimen-
tine, waarvan  in Hoofdstuk 4 was aangetoond dat dit het 
Sa antigeen is. Gecitrullineerd vimentine kan derhalve als 
kandidaat autoantigen in RA worden beschouwd.
Hoofdstuk 7 beschrijft de expressie van PAD enzymen 
en de aanwezigheid van gecitrullineerde eiwitten in het 
ontstoken synovium van muizen met experimentele artri-
tis. Twee muismodellen werden onderzocht: een model van 
chronische gewrichtsontsteking (collageen geïnduceerde 
artritis) en een model van acute gewrichtsontsteking (strep-
tococcen celwand geïnduceerde artritis). PAD4, hoewel 
afwezig in naïve synovia, werd tot expressie gebracht door 
neutroﬁelen die het synoviale weefsel tijdens de ontsteking 
in beide muismodellen inﬁltreren. Als gevolg daarvan wer-
den diverse synoviale eiwitten gecitrullineerd, waaronder 
ﬁbrine, waarvan eerder beschreven is dat het gecitrulli-
neerd wordt in synoviaal weefsel van RA patiënten. Hoewel 
er eiwitten werden gecitrullineerd tijdens de gewrichtsont-
steking in de muizen, werden er geen antilichamen tegen 
deze eiwitten gevonden. Deze resultaten ondersteunen de 
conclusies die eerder in Hoofdstuk 3 werden getrokken, 
namelijk dat de citrullinering van synoviale eiwitten een 
algemeen voorkomend proces is tijdens gewrichtsontste-
king, zowel in de muis als in de mens en dat het ontstaan 
van antilichamen tegen gecitrullineerde eiwitten een veel 
speciﬁeker fenomeen is dat uitsluitend in RA patiënten 
plaats vindt. 
Hoofdstuk 8 beschrijft de afwezigheid van citrulline-
speciﬁeke autoantilichamen in muizen met een defecte 
regulatie van lymfocyt apoptose. Deze muizen bezitten 
een keur aan autoantilichamen, waaronder  anti-DNA en 
reumafactoren, en mogelijk, zoals in een recent artikel 
beschreven werd, ook anti-CCP antilichamen. Deze antili-
chamen blijken echter in deze muizen ook reactief te zijn 
met een niet-gecitrullineerd controle peptide. De antilicha-
men zijn dus niet citrulline-speciﬁek. Deze bevindingen 
onderschrijven het belang van het gebruik van de juiste 
controles bij onderzoek aan antilichamen tegen gecitrulli-
neerde eiwitten in dieren.
Tenslotte bevat Hoofdstuk 9 een algemene discussie 
over de inzichten die dit proefschrift oplevert over een 
mogelijke rol van gecitrullineerde eiwitten en antilichamen 
daartegen in het ziekteproces van RA. In principe kan elke 
gebeurtenis (zoals een infectie of trauma) die dood van PAD 
bevattende cellen veroorzaakt voldoende zijn om citrulli-
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nering van eiwitten te induceren. Alleen in ontvankelijke 
individuen zal de aanwezigheid van deze gecitrullineerde 
eiwitten leiden tot een immuunreactie en het ontstaan van 
anti-CCP antilichamen. Na deze initiële gebeurtenissen 
kunnen onopgemerkte symptomen jarenlang aanwezig 
zijn om tenslotte te culmineren in de chronische autoim-
muunziekte die wij RA noemen. Wellicht is citrullinering 
de vonk die het vuur van RA ontsteekt.
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